<PAGE>   1

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                    FORM 10-K

              ANNUAL REPORT PURSUANT TO THE SECTION 13 OR 15(d) OF
                     THE SECURITIES AND EXCHANGE ACT OF 1934

                   FOR THE FISCAL YEAR ENDED DECEMBER 31, 2000

                        COMMISSION FILE NUMBER 001-12055

                        PARACELSUS HEALTHCARE CORPORATION
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

         CALIFORNIA                                         95-3565943
(State or other jurisdiction of                           (IRS Employer
incorporation or organization)                          Identification No.)

                  515 W. GREENS ROAD, SUITE 500, HOUSTON, TEXAS
                    (Address of principal executive offices)

        77067                                        (281) 774-5100
     (Zip Code)                       (Registrant's telephone number, including
                                                       area code)

Securities registered pursuant to Section 12(g) of the Act:

   COMMON STOCK, NO STATED VALUE                    NONE
   -----------------------------                    ----
         (Title of Class)           (Name of each exchange on which registered)

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                                  Yes[ ] No[X]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]

The number of shares of Registrant's Common Stock outstanding on May 23, 2001
was 59,143,721. The aggregate market value of voting stock held by
non-affiliates of the Registrant, based upon the closing price of the
Registrant's Common Stock on May 23, 2001 was $65,535.*

----------

*   Excludes 26,376,225 shares deemed to be held by directors and officers, and
    stockholders whose ownership exceeds five percent of the shares of Common
    Stock outstanding at May 23, 2001. Exclusion of shares held by any person
    should not be construed to indicate that such person possesses the power,
    direct or indirect, to direct or cause the direction of the management or
    policies of the Registrant, or that such person is controlled by, or under
    common control with, the Registrant.


<PAGE>   2

                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                             FORM 10-K ANNUAL REPORT
                          YEAR ENDED DECEMBER 31, 2000


                                TABLE OF CONTENTS

<TABLE>
<CAPTION>

                                                                                                      PAGE REFERENCE
                                                                                                        FORM 10-K
                                                                                                      --------------
<S>                                                                                                   <C>
PRELIMINARY STATEMENT

Part I
      Item 1.                   Business                                                                     4
      Item 2.                   Properties                                                                  20
      Item 3.                   Legal Proceedings                                                           20
      Item 4.                   Submission of Matters to a Vote of Security Holders                         22

Part II
      Item 5.                   Market for the Registrant's Common Equity and Related
                                   Stockholder Matters                                                      23
      Item 6.                   Selected Financial Data                                                     24
      Item 7.                   Management's Discussion and Analysis of Financial
                                   Condition and Results of Operations                                      27
      Item 7A.                  Quantitative and Qualitative Disclosures About Market
                                    Risks                                                                   42
      Item 8.                   Financial Statements and Supplementary Data                                 43
      Item 9.                   Changes in and Disagreements with Accountants on
                                   Accounting and Financial Disclosure                                      75

Part III
      Item 10.                  Directors and Executive Officers of the Registrant                          76
      Item 11.                  Executive Compensation                                                      78
      Item 12.                  Security Ownership of Certain Beneficial Owners
                                   and Management                                                           81
      Item 13.                  Certain Relationships and Related Transactions                              83

Part IV
      Item 14.                  Exhibits, Financial Statement Schedule and Reports                          84
                                   on Form 8-K
</TABLE>



                                       2

<PAGE>   3

FORWARD-LOOKING STATEMENTS

         Paracelsus Healthcare Corporation ("PHC") and its subsidiaries,
collectively, are herein referred to as the "Company." Certain statements in
this Form 10-K are "forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve a number of risks and uncertainties. All
statements regarding the Company's expected future financial position, results
of operations, cash flows, liquidity, financing plans, business strategy,
budgets, projected costs and capital expenditures, competitive position, growth
opportunities, plans and objectives of management for future operations and
words such as "anticipate," "believe," "plan," "estimate," "expect," "intend,"
"may" and other similar expressions are forward-looking statements. Such
forward-looking statements are inherently uncertain, and stockholders must
recognize that actual results may differ materially from the Company's
expectations as a result of a variety of factors, including, without limitation,
those discussed below.

         Factors which may cause the Company's actual results in future periods
to differ materially from forecast results include, but are not limited to:

         o        Uncertainties related to PHC's voluntary petition under
                  Chapter 11 of the Bankruptcy Code including, but not limited
                  to, (i) the Company's ability to consummate, in substantial
                  terms, the Plan of Reorganization, as proposed, (ii) actions
                  which may be taken by creditors and the outcome of various
                  administrative matters in the Chapter 11 proceeding and (iii)
                  the possibility of delays in the effective date of the
                  proposed Plan of Reorganization, as amended;

         o        The Company's ability to comply with the terms of the
                  subsidiary level credit facility;

         o        The Company's inability to access capital markets given the
                  Company's current financial condition;

         o        The excessive amount of time and effort that the Company's
                  senior management must devote to dealing with the Company's
                  financial condition, thereby reducing time spent directly on
                  the operations of its businesses;

         o        The Company may be unable to retain top management and other
                  key personnel, including physicians;

         o        Competition, including the impact of a new competing hospital
                  opened in November 2000 in the Fargo, North Dakota market, and
                  general economic, demographic and business conditions, both
                  nationally and in the regions in which the Company operates;

         o        Existing government regulations and changes in legislative
                  proposals for healthcare reform, including changes in Medicare
                  and Medicaid reimbursement levels;

         o        The ability to enter into managed care provider arrangements
                  on acceptable terms;

         o        Liabilities and other claims asserted against the Company;

         o        The loss of any significant customer, including but not
                  limited to managed care contracts;

         o        The Company's ability to achieve profitable operations after
                  the confirmation of the proposed Plan of Reorganization, as
                  amended; and

         o        The Company's ability to generate sufficient cash from
                  operations to meet its obligations.

         o        The Company's ability to comply with the terms of the
                  corporate integrity agreement.

         The Company is generally not required to, and does not undertake to,
update or revise its forward-looking statements.



                                       3
<PAGE>   4



                                     PART I

ITEM 1. BUSINESS

GENERAL

         Paracelsus Healthcare Corporation, a California corporation ("PHC"),
was incorporated in November 1980. PHC, both directly or through its
subsidiaries (collectively, the "Company" or the "Registrant"), owns and
operates acute care and related healthcare businesses in selected markets. In
August 1996, the Company acquired Champion Healthcare Corporation ("Champion")
by exchanging one share of the Company's Common Stock for each share of
Champion's Common Stock and two shares of the Company's Common Stock for each
share of Champion's Preferred Stock (the "Merger"). The Company's hospitals
offer a broad array of general medical and surgical services on an inpatient,
outpatient and emergency basis. In addition, certain hospitals and their related
facilities offer home health, skilled nursing care, rehabilitation and
psychiatric services. As of December 31, 2000, the Company owned or operated 10
acute care hospitals in seven states with 1,287 licensed beds. Of the 10
hospitals, eight hospital facilities are owned and two are leased.

PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE

         On September 15, 2000, PHC filed a voluntary petition for protection
under Chapter 11 of the Bankruptcy Code with the United States Bankruptcy Court
for the Southern District of Texas (Case no. 00-38590-H5-11). The bankruptcy
filing is limited to PHC, the parent company, and does not include any of PHC's
hospital subsidiaries. PHC elected to seek Bankruptcy Court protection in order
to facilitate the restructuring of its debt while continuing to maintain normal
business operations at PHC's hospital subsidiaries. PHC's decision to
restructure its debt was due to its highly leveraged capital structure. Despite
positive earnings before interest, taxes, depreciation, amortization and unusual
charges, the high interest burden severely restricted the Company's reinvestment
opportunities. In an effort to conserve capital and to preserve the normal
operations of the hospital subsidiaries, PHC did not make interest payments of
$33.5 million (including penalty interest) on the 10% Senior Subordinated Notes
(the "Notes") due February 15 and August 15, 2000, nor did PHC make an interest
payment of $468,000 due on the 6.51% subordinated note ("Park Note") on August
30, 2000. Both the Notes and the Park Note are subject to compromise as a result
of PHC's Chapter 11 bankruptcy filing.

         PHC's hospital subsidiaries did not file for bankruptcy protection and
have continued paying, in the ordinary and normal course of business, all wages,
benefits and other employee obligations, all lease and debt obligations, as well
as all outstanding and ongoing accounts payable to their contractors and
vendors. A $62.0 million credit facility (the "Credit Facility"), collateralized
at the subsidiary level, is not directly affected by PHC's bankruptcy filing.
The Company expects cash on hand, cash generated from operations and asset sales
to be sufficient to meet the working capital and capital expenditure needs of
the hospital subsidiaries during the restructuring process.

         On October 2, 2000, PHC received approval from the Bankruptcy Court to
pay pre-petition and post-petition PHC's employee wages, salaries and benefits.
The Bankruptcy Court also approved orders granting authority, among other
things, to pay pre-petition claims of certain utilities. All other PHC
pre-petition liabilities are classified in the consolidated balance sheet as
liabilities subject to compromise. PHC continues to pay post-petition claims of
all vendors and providers in the ordinary course of business.

         Simultaneously with the commencement of its bankruptcy case, PHC filed
an initial plan of reorganization (the "Initial Plan") pursuant to which PHC
proposed to effect its capital restructuring. On




                                       4
<PAGE>   5

November 2, 2000, after notice and a hearing, PHC's Disclosure Statement under
Section 1125 of the Bankruptcy Code with Respect to the Initial Plan was
approved, and PHC was authorized to solicit the acceptance or rejection of the
Initial Plan by creditors entitled to vote. The Initial Plan was accepted by
holders of the Notes, general unsecured claims and common stock prior to
December 8, 2000, the date originally set by the Court for the hearing on
confirmation of the Initial Plan. However, on December 5, 2000, two proofs of
claim aggregating approximately $94.0 million were filed with the Court by a
private person (the "Relator") on behalf of the United States and California for
alleged violations by PHC under the Federal False Claims Act and the California
False Claims Act (the "Claims"). The Claims were based on a partially excised
complaint in a qui tam action filed by the Relator under seal in June 1998 in
the United States District Court for the Central District of California, Western
Division, as Case No. 98-4564 (Shx) (the "Qui Tam Action"). A material condition
to the effectiveness of the Initial Plan was that the aggregate amount of the
allowed and disputed general unsecured claims would not exceed $15.0 million.
The aggregate amount of the Claims, as filed, together with other claims filed
that were not anticipated by PHC, exceeded this cap. Accordingly, at PHC's
request, on December 8, 2000, the Court continued the hearing on confirmation of
the Initial Plan to permit PHC to file, and the Court to consider, an objection
to and a motion to estimate the Claims. On or about March 14, 2001, the United
States and California amended their proof of claims, thereby reducing the
amounts sought under the Claims to approximately $45.0 million in aggregate.

         To avoid the costs of further litigation and to proceed with
confirmation of PHC's plan of reorganization, on April 17, 2001, the Company
signed a settlement agreement with the United States, California and the Relator
to resolve their proofs of claim (the "Qui Tam Claims Settlement"). In general,
the principal settlement terms are the following: the United States, California
and the Relator agreed to grant the Company certain releases and to dismiss the
litigation against the Company pending in another federal court. The Company
agreed that the United States, California and the Relator would have allowed
general unsecured claims in the bankruptcy case in the aggregate amount of $5.5
million (the "Allowed Qui Tam Claims") and that the allowed claims would be
entitled to share with other allowed general unsecured claimants in the
distribution of 11.5% Senior Notes (due on August 15, 2005) (the "New Notes")
and common stock of reorganized PHC and a cash payment to be issued under PHC's
plan of reorganization. In connection therewith, the Company accrued $5.5
million at December 31, 2000, which has been included in "Liabilities Subject to
Compromise." The Company also agreed to enter into a five year Corporate
Integrity Agreement with the Office of Inspector General of the U.S. Department
of Health and Human Services. The Company denied any liability or wrongdoing.
The settlement agreement is the result of extensive, arm's-length negotiations
between PHC, in consultation with the creditors committee, and the Relator and
the government entities. The Court approved the settlement agreement on May 22,
2001.

         On April 23, 2001, PHC filed the First Amended Chapter 11 Plan of
Reorganization (the "Amended Plan") reflecting changes made necessary by (i) the
Allowed Qui Tam Claims, together with other claims filed that were not
anticipated by PHC, and (ii) the downward revisions in the Company's projected
future operating results due to the opening of a competing hospital in the
Company's Fargo, North Dakota market in November 2000, which had a greater than
anticipated negative impact on the Company's results of operations. Upon the
effective date (the "Effective Date") of the Amended Plan, shares of PHC's
common stock held by existing equity holders will be canceled and rendered null
and void, and current equity holders will not receive stock or warrants, as had
previously been provided in the Initial Plan. PHC's current equity holders will
not receive or retain any property under the Amended Plan on account of such
equity interests. Also upon the Effective Date, PHC will merge into a wholly
owned subsidiary incorporated in Delaware and will cease to exist as a separate
company, and the wholly owned subsidiary will emerge from bankruptcy as
reorganized PHC and will be known as Clarent Hospital Corporation. Additionally,
all principal and interest outstanding on the Notes and allowed general
unsecured claims will be exchanged for (i) New Notes in the aggregate principal
amount of $130.0 million (ii) a cash payment, as defined in the Amended



                                       5
<PAGE>   6
 Plan, and (iii) 100.0% of the new common stock issued by the reorganized PHC
under the Amended Plan. Interest on the New Notes shall accrue commencing on the
Effective Date. The Amended Plan incorporates the terms of the Qui Tam Claims
Settlement.

         On May 25, 2001, the Bankruptcy Court approved the Amended Plan. The
effectiveness of the Amended Plan is subject to certain conditions, as defined
in the Amended Plan. Upon the Effective Date, reorganized PHC will take the
steps necessary to cease being subject to the periodic reporting requirements of
the federal securities law. Additionally, reorganized PHC will have a limited
number of stockholders and does not plan to list the New Notes on an exchange.
Therefore, PHC will not be required to file periodic public reports, although
the new board of directors may seek to voluntarily register its new common stock
with the SEC or to list the New Notes on an exchange at a future date and thus
become a publicly reporting company. See Item 7. "Management's Discussion and
Analysis of Financial Condition and Results of Operations - Proceeding Under
Chapter 11 of the Bankruptcy Code," for a more comprehensive discussion of this
matter.


ISSUES AFFECTING LIQUIDITY

         The Company incurred significant operating losses in 2000. Furthermore,
the Company is in a highly leveraged financial position with limited borrowing
capacity available under its Credit Facility in excess of principal currently
outstanding. These matters and certain developments described above have raised
substantial doubt as to the Company's ability to continue operations as a going
concern. The report of the Company's independent auditors,
PricewaterhouseCoopers LLP, includes an explanatory paragraph that refers to
substantial doubt about the Company's ability to continue as a going concern.

         On May 16, 2000, certain subsidiaries of the Company entered into a new
credit agreement with a lending group that provides a $62.0 million revolving
credit and letter of credit guaranty facility (the "Credit Facility"), expiring
May 15, 2003. The Credit Facility was used to refinance obligations outstanding
under the Company's prior off-balance sheet commercial paper financing program,
to replace existing letters of credit outstanding under the previously existing
interim financing arrangement and to fund normal working capital and certain
capital expenditures of the Company's hospitals. The Credit Facility is an
obligation of certain of the Company's subsidiaries and is collateralized by all
of those entities' patient receivables (as defined), certain other assets of the
Company and a first lien on two of its hospitals. Accordingly, the Credit
Facility is not an obligation of PHC. Borrowings under the Credit Facility bear
interest at prime plus 1.5% or LIBOR plus 3.75% per annum and are limited to the
hospitals' eligible patient receivables and certain operating measurements, as
defined.

         The Company has retained an investment banking firm to review its
strategic alternatives following its emergence from Chapter 11 bankruptcy
protection, including, among others, the possible disposition of some or all of
the Company's hospital assets. The investment banking firm is still in the
preliminary stages of its work, and the Board of Directors of the Company has
not approved any strategic recommendations from the firm. The Company cannot
predict the ultimate outcome of this initiative.



                                       6
<PAGE>   7

DIVESTITURES AND CLOSURES OF HOSPITALS

         In December 2000, the Company sold its minority interest in IASIS for
$7.9 million, net of expenses, resulting in a pretax gain of $3.3 million. The
minority interest was retained as part of the Company's 1999 sale of its
hospital operations in the Salt Lake City area, as discussed further below. This
gain was offset by $350,000 in losses due to the write-down of certain notes
received in conjunction with a prior year disposition.

         Pursuant to a recapitalization agreement completed on October 8, 1999,
the Company sold 93.9% of the outstanding common stock of a wholly owned
subsidiary ("HoldCo") to JLL Healthcare, LLC, an affiliate of the private equity
firm of Joseph Littlejohn & Levy, Inc., for $280.0 million in cash, including
net working capital. The Company retained a minority interest in the outstanding
common stock of HoldCo, which owned substantially all of the assets of five
hospitals, with 640 licensed beds, and related facilities located in the Salt
Lake City area (the "Utah Facilities"). Subsequent to the closing of the
recapitalization agreement, IASIS Healthcare Corporation, a Tennessee
corporation, was merged with and into a wholly owned subsidiary of HoldCo, with
the HoldCo subsidiary as the surviving entity. Following the merger, HoldCo
changed its name to IASIS Healthcare Corporation, in which the Company retained
a 5.8% minority interest.

         The recapitalization agreement was arrived at through an arm's length
negotiation. Net cash proceeds were used to eliminate all indebtedness then
outstanding under the Company's senior credit facilities totaling $223.5 million
and to reduce $12.8 million in borrowings under the Company's former commercial
paper program. The Company also eliminated $7.8 million in annual facility
operating lease payments related to one of the Utah Facilities and $7.6 million
in letter of credit obligations.

         On September 30, 1999, the Company completed the sale of the stock of
Paracelsus Senatobia Community, Inc. ("Senatobia"), which owned and operated a
76-bed acute care hospital located in Mississippi. The sales price of
approximately $4.7 million, which included the sale of net working capital, was
paid by a combination of $100,000 in cash, $1.6 million in second lien
promissory notes, and the assumption by the buyer of approximately $3.0 million
in capital lease obligations and related lease guaranty payments.

         Effective June 30, 1999, the Company sold substantially all of the
assets of four skilled nursing facilities (collectively, the "Convalescent
Hospitals"). The facilities had 232 licensed beds. The sales price of
approximately $6.9 million, which excluded net working capital, was paid by a
combination of $3.0 million in cash and a $3.9 million second lien promissory
note, which is subject to prepayment discounts. In connection with the sale, the
Company paid $1.0 million to terminate a lease agreement at one of the
facilities and used the remaining cash proceeds of $2.0 million from the sale to
reduce its outstanding indebtedness under its senior revolving credit facility.

         Effective March 31, 1999, the Company sold the stock of Paracelsus
Bledsoe County Hospital, Inc. ("Bledsoe"), which operated a 32 licensed bed
facility located in Tennessee. The sales price of approximately $2.2 million,
including net working capital, was paid by a combination of $100,000 in cash and
the issuance by the buyer of $2.1 million in promissory notes.




                                       7
<PAGE>   8

BUSINESS STRATEGY

         The Company generally seeks to operate hospitals in small to mid-sized
markets. The Company focuses on increasing its market share by implementing
operating strategies to position each of its hospitals as a preeminent provider
of healthcare services on a quality, cost-effective basis that meets the needs
of the communities that the facilities serve. The Company continually analyzes
whether each of its hospitals fits within its strategic plans and will continue
to evaluate ways in which its assets may be used to maximize shareholder value.
To that end, the Company may from time to time elect to close, sell, exchange or
convert to alternate use certain of its facilities in order to respond to
changing market conditions. When appropriate and to the extent financial
resources permit, the Company will pursue growth opportunities through selective
acquisition of additional hospitals in markets where the Company can develop a
preeminent market position. In light of the uncertainties discussed in "Issues
Affecting Liquidity," the Company is uncertain as to its acquisition and
disposition plan in 2001 and beyond.

HOSPITAL OPERATING STRATEGY

         The Company seeks to provide quality healthcare services on a
cost-effective basis while being responsive to the needs of each community in
which the Company operates. The Company believes that the delivery of healthcare
services is a local business. Accordingly, each hospital's operating strategy
and business plan are designed to meet the healthcare needs of the local market
through local management initiative, responsibility and accountability, combined
with corporate support and oversight. Incentive compensation programs are
offered to reward local managers for accomplishing predetermined goals. The
significant components of the Company's hospital operating strategy are as
follows:

         MARKET PENETRATION - The Company seeks to increase its market share (i)
by offering a full range of hospital and related healthcare services, (ii) by
providing quality services on a cost effective basis and (iii) through
appropriate physician development efforts.

         The Company selectively adds new services such as orthopedic surgery,
cardiology, pain management and industrial medicine programs at its hospitals
and, where appropriate, invests in new technologies. The Company also develops
complementary healthcare businesses such as primary care clinics to augment
service capabilities and create a larger service network for its existing
hospitals, thereby providing care in a cost effective and medically appropriate
setting. In some cases, the Company may also acquire, merge or establish
alliances with other providers through affiliation agreements, joint venture
arrangements or partnerships. Historically, the Company's investment in its
hospitals, primarily through capital expenditures, were financed through
additional borrowings and internally generated funds. Due to the liquidity
issues previously discussed, there can be no assurance that the Company will
have sufficient resources to finance its capital expenditure plan in 2001.

         Various factors, such as technological developments permitting more
procedures to be performed on an outpatient basis, pharmaceutical advances and
pressures to contain healthcare costs, have led to a shift from inpatient care
to ambulatory or outpatient care. The Company has responded to this trend by
restructuring existing surgical and diagnostic capacity to allow a greater
number and range of procedures to be performed on an outpatient basis.

         The Company has a program in each of its hospitals to ensure that
hospital employees are responding to patient needs. This program achieves its
objective through employee training and by focusing management's attention on
areas needing improvement on a timely basis.

         A key element of the Company's hospital operating strategy is to
establish and maintain a cooperative relationship with its physicians. The
Company focuses on supporting and retaining existing




                                       8
<PAGE>   9

physicians and attracting additional qualified physicians in existing or
under-served medical specialties. Furthermore, the Company has implemented a
physician advisory board in each market. The Company's hospitals often provide
newly recruited physicians with various services to assist them in opening and
commencing their practices, including financial support and office rental space.
The Company may affiliate, joint venture or partner with physician practices or,
in selected cases, manage or acquire physician practices through appropriate
subsidiaries and affiliated organizations. While physicians may terminate their
association with a hospital at any time, the Company believes that by improving
the level of care at its hospitals, equipping its hospitals with up-to-date
medical technology and forging strong relationships with physicians, it will
attract and retain qualified physicians.

         COST CONTROLS - The Company seeks to position each of its hospitals as
a cost effective healthcare provider in its market. To achieve this objective,
the Company utilizes a disciplined cost control system to (i) implement staffing
standards and manage resources to optimize staffing efficiency, (ii) utilize
national purchasing contracts and monitor supply usage, (iii) renegotiate or
eliminate purchased service contracts, where appropriate, (iv) evaluate and
eliminate on an ongoing basis underutilized or unprofitable services and (v)
implement utilization management programs to help monitor and manage clinical
resources to render medically appropriate and cost effective care. Corporate
staff support is available for key operating and cost decisions, as well as for
reimbursement, insurance/risk management, purchasing and other significant
accounting and support functions. As healthcare payors seek to reduce their
healthcare expenditures, the ability to reduce and control operating costs will
become more important to the Company's results of operations and future growth.

         STANDARDIZED POLICIES AND PROCEDURES AND MANAGEMENT INFORMATION SYSTEMS
- The Company's hospitals are managed by experienced hospital administrators and
financial personnel. To assist them, the Company has sought to maintain
financial control and to improve operating practices at the hospitals through
standardization. To that end, the Company has developed a comprehensive
financial reporting system and implemented standardized policies and procedures.
The Company uses the financial reporting system to monitor certain key financial
data and operating statistics at each facility, to establish the annual budget
and to measure the hospitals' financial and operational performance. The Company
has also standardized systems for patient billings, general accounting and
payroll, as well as clinical applications and has installed systems to manage
staffing resources and to monitor the profitability of managed care contracts.
In addition, the Company has implemented policies and procedures to guide its
facilities in areas such as quality and customer service, physician relations
and arrangements, human resources, billings and collections, regulatory and
ethical compliance though its corporate compliance program and accounting and
financial reporting.

OPERATIONS

         The Company seeks to create a local healthcare system in each of its
markets that offers a continuum of inpatient, outpatient, emergency and
alternative care options. In many of its markets, the Company will establish its
acute care hospitals as the hub of a local provider system that can include home
health agencies, clinics, physician practices and medical office buildings.

         ACUTE CARE HOSPITALS - The Company owns and operates 10 acute care
hospitals with a total of 1,287 licensed beds in seven states. Each of the
Company's acute care hospitals provides a broad array of general medical and
surgical services on an inpatient, outpatient and emergency basis, including
some or all of the following: intensive and cardiac care, obstetrics,
rehabilitative and skilled nursing services on an inpatient basis and ambulatory
surgery, laboratory and radiology services on an outpatient basis.



                                       9
<PAGE>   10

         HOME HEALTH AGENCIES - The Company provides home health services
through five of its hospitals in four states. These services include home
nursing, infusion therapy, physical therapy, respiratory services and other
rehabilitative services.

         PHYSICIAN PRACTICES - The Company owns and operates a number of
physician practices in rural and urban settings. Most of these practices are
primary care physician offices where the physicians are employed by or are under
contract with one of the Company's hospitals or a related entity. The physician
practices serve to complement the Company's acute care hospitals in their
respective markets by allowing the Company to provide a wider range of services
in optimal settings.

         MEDICAL OFFICE BUILDINGS - The Company owns, leases or manages 16
medical office buildings located adjacent to certain of its hospitals.

COMPETITION

         Competition for patients among hospitals and other healthcare providers
has intensified in recent years. During this period, hospital occupancy rates
have declined as a result of cost containment pressures, changes in technology,
changes in government regulations and reimbursement and a shift from inpatient
to outpatient utilization. Such factors have prompted new competitive strategies
by hospitals and other healthcare providers as well as an increase in the
consolidation of such providers. In certain areas in which the Company operates,
there are other hospitals or facilities that provide services comparable to
those offered by the Company's hospitals. Many of these hospitals may have
greater financial resources and may offer a wider range of services than the
Company's hospitals. In addition, hospitals owned by government agencies or
other tax-exempt entities benefit from endowments, charitable contributions and
tax-exempt financing, none of which are available to the Company.

         On July 1, 1998, the Company completed the purchase from its partner of
the remaining 50% partnership interest in Dakota Heartland Health System
("DHHS") thereby giving the Company 100% ownership of DHHS. DHHS owns and
operates a 218-bed general acute care hospital in Fargo, North Dakota. At the
time of the acquisition, DHHS was one of two primary healthcare providers. In
November 2000, a competing hospital opened in the Company's Fargo, North Dakota
market. This not-for-profit hospital is supported by a physician group who
formerly admitted a significant number of patients to DHHS, and consequently,
DHHS experienced a substantial drop in patient volumes and financial performance
in the fourth quarter of 2000. The Company expects patient volumes and financial
performance at this facility to remain significantly below historical levels,
which will have a material adverse impact on both the hospital's and the
Company's financial performance in the months ahead. For the year ended December
31, 2000, DHHS accounted for 26.4% of total hospital net revenue and 43.8% of
hospital Adjusted EBITDA reported by the Company. The Company is currently
evaluating various business alternatives to preserve DHHS' position in this
market. While management is unable to predict the ultimate impact of this new
facility on the Company's results of operations, it believes that DHHS will
continue to generate positive operating cash flow.

         The competitive position of the Company's hospitals also has been, and
in all likelihood will continue to be, affected by the increased initiatives
undertaken during the past several years by Federal and state governments and
other major purchasers of healthcare, including insurance companies and
employers, to revise payment methodologies and monitor healthcare expenditures
in an effort to contain healthcare costs. As employers, private and government
payors and others turn to the use of managed care in an attempt to control
rising health care costs, the importance of obtaining managed care contracts has
increased over the years and is expected to continue to increase. In many of the
Company's existing markets, the competitive position of its hospital is
dependent on its ability to obtain managed care contracts at reasonable terms.
Under such contracts, health care providers agree to provide services on a



                                       10
<PAGE>   11

discounted-fee or capitated basis in exchange for the payors agreeing to send
some or all of their members/enrollees to those providers. The profitability of
such contracts depends upon the provider's ability to negotiate payments per
patient that, in the aggregate, are adequate to cover the cost of meeting the
health care needs of the covered persons. The Company currently has no contracts
to provide services on a capitated basis.

         The Company's hospitals are dependent upon the physicians practicing in
the communities served by the hospitals. A small number of physicians account
for a significant portion of patient admissions at some of the Company's
hospitals. The competition for physicians in some specialty areas, including
primary care, is intense. While the Company seeks to retain physicians of varied
specialties on its hospitals' medical staffs and to attract other qualified
physicians, there can be no assurance that the Company's hospitals will succeed
in doing so. In addition, certain physicians are affiliated with managed care
providers that may preclude them from utilizing the Company's facilities for
their patients, or referring patients to doctors using the Company's facilities,
if the facility or referred doctors are not currently contracting with such
managed care providers.

         In certain geographic markets, there is a shortage of nurses and other
healthcare professionals in certain specialties, which has resulted in increased
costs at those facilities. The availability of nursing personnel and other
healthcare professionals fluctuates from year to year, and the Company cannot
predict the degree to which it will be affected by the future availability and
cost of nursing and other healthcare personnel.

SOURCES OF REVENUE

         The Company receives payment for services rendered to patients from
private payors (primarily private insurance), managed care providers, the
Federal government under the Medicare and TriCare programs and state governments
under their respective Medicaid programs. See "Hospital Accreditation and
Government Regulation - Medicare, Medicaid."

         The Company's revenue primarily depends on the level of inpatient
census, the volume of outpatient services, the acuity of patients' conditions
and charges for services. Reimbursement rates for inpatient routine services
vary significantly depending on the type of service and the geographic location
of the hospital. The table below sets forth the percentages of acute care gross
patient revenue for each category of payor during each of the periods indicated.


<TABLE>
<CAPTION>

                                                          YEAR ENDED DECEMBER 31,
                                              -----------------------------------------
                                                 2000            1999            1998
                                              ---------       ---------       ---------

<S>                                           <C>             <C>             <C>
Medicare ...............................           42.3%           41.1%           42.6%
Medicaid ...............................            7.5%            7.4%           11.0%
Managed care ...........................           38.8%           33.8%           31.4%
Private insurance and other payors .....           11.4%           17.7%           15.0%
                                              ---------       ---------       ---------
                                                  100.0%          100.0%          100.0%
                                              =========       =========       =========
</TABLE>


         Amounts received from most payors are less than the hospitals'
customary charges for the services provided. All of the Company's hospitals (as
do most acute care hospitals) derive a substantial portion of their revenue from
the Medicare and Medicaid programs, which pay participating health care
providers for covered services rendered and items provided to qualified
beneficiaries. Both of these programs are heavily regulated and use complex
methods for determining payments to providers. These




                                       11
<PAGE>   12

programs are subject to frequent changes and in recent years have made
substantial reductions payments to hospitals for certain services. In light of
the high percentage of Medicare and Medicaid patients, the Company's ability in
the future to operate its business successfully will depend in large measure on
its ability to adapt to changes in these programs. See "Hospital Accreditation
and Governmental Regulation."

         The importance of obtaining managed care contracts has increased over
the years and is expected to continue to increase as employers, private and
government payors and others turn to the use of managed care in an attempt to
control rising health care costs. In recent years, the Company's hospitals have
experienced a shift in payor mix from traditional Medicare/Medicaid to managed
care consistent with industry trends. The revenues and operating results of most
of the Company's hospitals are significantly affected by the hospitals' ability
to negotiate favorable contracts with managed care payors. Inpatient
utilization, average lengths of stay and occupancy rates continue to be
negatively affected by payor-required preadmission authorization and utilization
review and by payor pressure to maximize outpatient and alternative healthcare
delivery services for less acutely ill patients. The Company is responding to
this trend by dedicating resources and managed care professionals to evaluate
and negotiate contracts with these payors and obtain better rates and by
avoiding entering into capitation arrangements. Also, the Company has installed
information systems to improve management's ability to monitor compliance of
hospital billing and collection practices with the negotiated rates. While
management has been successful in negotiating higher rates under its managed
care contracts, the trend toward managed care has and may continue to adversely
affect the Company's ability to grow net operating revenue and improve operating
margins.

HOSPITAL ACCREDITATION AND GOVERNMENT REGULATION

         All hospitals, and the healthcare industry generally, are subject to
compliance with various Federal, state and local regulations relating to
licensure, operations, billing, reimbursement, relationships with physicians,
construction of new facilities, expansion or acquisition of existing facilities,
the offering of new services and Medicare and Medicaid fraud and abuse.
Government action has increased with respect to investigations and/or
allegations concerning possible violations of fraud and abuse and false claims
statutes and/or regulations by healthcare providers. Providers that are found to
have violated these laws and regulations may be excluded from participating in
government healthcare programs, subjected to fines or penalties and/or required
to repay amounts received from government for previously billed patient
services. While management of the Company believes its policies, procedures and
practices comply with governmental regulations, no assurance can be given that
the Company will not be subjected to governmental inquiries or actions.

         All facilities receive periodic inspection by state and local licensing
agencies, as well as by non-governmental organizations acting under contract or
pursuant to Federal law, to review compliance with standards of medical care and
requirements concerning facilities, equipment, staffing, cleanliness and related
matters. Failure to comply with applicable laws and regulations could result in,
among other things, the imposition of fines, temporary suspension of the ability
to admit new patients to the facility or, in extreme circumstances, exclusion
from participation in government healthcare reimbursement programs such as
Medicare and Medicaid (from which the Company derives substantial revenues) or
the revocation of facility licenses. While all of the Company's hospitals have
obtained the licenses that the Company believes are necessary under applicable
law for the operation of the hospitals, there can be no assurance that its
hospitals will be able to comply in the future or that future regulatory changes
will not have an adverse impact on the Company. At December 31, 2000, all of the
Company's hospitals were accredited by the Joint Commission on Accreditation of
Healthcare Organizations ("JCAHO"), allowing them to participate in the
Medicare/Medicaid programs.




                                       12
<PAGE>   13

         CERTIFICATE OF NEED - In four of the states in which the Company's
hospitals operate, certificate of need ("CON") regulations control the
development and expansion of healthcare services and facilities. Those
regulations generally require proper government approval for the expansion or
acquisition of existing facilities, the construction of new facilities, the
addition of new beds, the acquisition of major items of equipment and the
introduction of certain new services. Failure to obtain necessary approval can
result in the inability to complete a project, the imposition of civil and, in
some cases, criminal sanctions, the inability to receive Medicare, Medicaid and
Tricare reimbursement and/or the revocation of a facility's license. Of the
seven states in which the Company operates, a CON is required in Florida,
Georgia, Tennessee and Virginia.

         MEDICARE - The Federal Medicare program provides medical insurance
benefits, including hospitalization, principally to persons 65 and older and to
certain disabled persons. Each of the Company's hospitals is certified as a
provider of services under the Medicare program, and a substantial portion of
the Company's revenue is derived from patients covered by this program. See
"Sources of Revenue" above. The Medicare program has undergone significant
changes during the past several years to reduce overall healthcare costs, which
have resulted in reduced rates of growth in reimbursement payments for a
substantial portion of hospital procedures and charges. In addition, the
requirements for certification in the Medicare program are subject to change. In
order to remain qualified for the program, it may be necessary for the Company
to make changes from time to time in its facilities, equipment, personnel and
services. Although the Company intends to continue its participation in the
Medicare program, there is no assurance that it will continue to qualify for
participation.

         Pursuant to the Social Security Act Amendments of 1983 and subsequent
budget reconciliation and modifications, Congress adopted a prospective payment
system ("PPS"). PPS is a fixed payment system in which illnesses are classified
into Diagnostic Related Groups ("DRGs") which do not consider a specific
hospital's costs, but are adjusted for an area wage differential. Each DRG is
assigned a fixed payment amount that forms the basis for calculating the amount
that the hospital is reimbursed for each Medicare patient. Generally, under PPS,
if the costs of meeting the health care needs of the patient are greater than
the predetermined payment rate, the hospital must absorb the loss. Conversely,
if the cost of the services provided is less than the predetermined payment, the
hospital retains the difference. Since DRG rates are based upon a statistically
normal distribution of severity, a hospital may receive additional payments if a
patient falls outside the normal distribution.

         The DRG rates are updated annually to account for projected inflation.
For several years the annual updates or percentage increases to the DRG rates
have been lower than the actual inflation in the cost of goods and services
purchased by general hospitals. The inflation index used by the Health Care
Financing Administration ("HCFA") to adjust the DRG rates gives consideration to
the cost of goods and services purchased by hospitals as well as non-hospitals
(the "market basket"). The increase in the market basket for the federal fiscal
year ("FY") beginning on October 1, 2000 ("FY 2001") is 3.4%. During the fourth
quarter of 2000, Congress passed the Medicare, Medicaid and SCHIP Benefits
Improvement and Protection Act of 2000 ("BIPA") which, among other things,
increased Medicare and Medicaid payments to health care providers by $35 billion
over 5 years with approximately $12 billion of this amount targeted for
hospitals and $11 billion for managed care payors. These increased
reimbursements to hospitals pursuant to the terms of BIPA commenced in April
2001 and for the period of April 1, 2001 through September 30, 2001, certain
additional reimbursements will be remitted to hospitals. The Balanced Budget Act
of 1997 ("BBA-97") established the annual update for Medicare at market basket
minus 1.1% in both fiscal years 2001 (October 1, 2000 through September 30,
2001) and 2002 and BIPA revised the update at the full market basket in fiscal
year 2001 and market basket minus .55% in fiscal years 2002 and 2003.
Additionally, BIPA increased reimbursement for Medicare bad debts from 55% to
70% with an effective date of January 1, 2001 for most of the Company's
facilities. Although recent


                                       13
<PAGE>   14

regulatory changes have been favorable, the Company cannot predict how future
regulatory adjustments by Congress and HCFA will affect the profitability of its
health care facilities.

         Payments for Medicare outpatient services historically have been paid
based on costs, subject to certain adjustments and limits. BBA-97 required that
payment for those services be converted to PPS, which was implemented on August
1, 2000. Prior to October 1, 1990, Medicare payments for outpatient
hospital-based services were generally the lower of hospital costs or customary
charges. Due to federal budget restraints, the Omnibus Budget Reconciliation Act
of 1993 ("OBRA-1993") reduced Medicare payments for the majority of outpatient
services to the lower of 94.2% of hospital costs, customary charges or a blend
of 94.2% of hospital costs and a fee schedule (such fee schedule generally being
lower than hospital costs) through FY 1998. BBA-97 and the Balanced Budget
Refinement Act of 1999 ("BBRA-99") extended this reduction to the first date
that an outpatient PPS was implemented. On August 1, 2000, as required by BBA-97
and BBRA-99, a Medicare PPS went into effect for hospital outpatient services.
Under the outpatient PPS, all outpatient services are grouped into Ambulatory
Payment Classifications ("APCs"). Services in each APC are clinically similar
and are conceptually similar in terms of the resources they require. A payment
rate has been established by HCFA for each APC, with adjustments provided for
geographic wage differentials. Hospitals may be paid more than one APC per
patient and per encounter, depending upon the services required by and provided
to the Medicare eligible beneficiary. Significantly, the outpatient PPS revises
the way in which beneficiary co-insurance amounts are determined. Initially,
co-insurance amounts will be based on 20% of the national median charge for the
APC. BBRA-99 limits beneficiary liability so that no co-insurance amount can be
greater than the Medicare hospital inpatient deductible for a given year. The
outpatient PPS provides for a transitional adjustment to limit potential payment
reductions experienced as a result of the transition to prospective encounter
payments. For the years 2000 through 2003, providers will receive an adjustment
if their payment-to-cost ratio for outpatient services furnished during the year
is less than a set percentage of their payment-to-cost ratio for those services
in their cost reporting period ending in 1996 (the base year). Rural hospitals
with 100 or fewer beds and cancer hospitals will be held harmless under this
provision. In addition, small rural hospitals, for services furnished before
January 1, 2004, will be maintained at the same payment-to-cost ratio as their
base year cost report, if their PPS payment-to-cost ratio is less. Preliminary
estimates and initial payment amounts have indicated that the outpatient PPS
will not have a material impact on reimbursement to the Company. The Company
anticipates the Medicare outpatient prospective payment system will continue to
be subject to future adjustments. Outpatient laboratory services and certain
physical or occupational therapy services are paid based on a fee schedule which
is substantially lower than customary charges.

         Prior to 1988, Medicare reimbursed hospitals for 100% of their share of
capital related costs, which included depreciation, interest, taxes and
insurance related to plant and equipment for inpatient hospital services. The
reimbursed rate was reduced thereafter to 90% of costs. Federal regulations,
effective October 1, 1991, created a PPS for inpatient capital costs to be
phased in over a ten-year transition period from a hospital-based rate to a
fully Federal payment rate or a per-case rate, which is likely to result in
further reductions in the rate of growth in reimbursement payments. Beginning
with cost reporting periods on or after October 1, 2001, all hospitals are to be
paid at the standard Federal rate. Additionally, pursuant to BBA-97, capital
rates were reduced by an additional 2.1%. For FY 2001, HCFA announced a 1.3%
increase to the Federal rate. The Company anticipates further adjustments in the
future but is unable to predict the amount or impact of future adjustments.

         Psychiatric and rehabilitation hospitals, as well as psychiatric or
rehabilitation units that are distinct parts of a hospital, are exempt from PPS
and continue to be reimbursed on a reasonable cost basis, with limits placed
upon the annual rate of increase in operating costs per discharge. For fiscal
years 1999 through 2002, the annual update factor is dependent upon where the
hospital's costs fall in relation to the limits set by the Tax Equity and Fiscal
Responsibility Act of 1982 ("TEFRA"). The annual



                                       14
<PAGE>   15

update factor will range from 0% to the market basket percentage increase,
depending upon whether the hospital's costs are at, below or above the TEFRA
target limits or the Federal national target limits, whichever are lower.

         On October, 1, 2000, as required by BBA-97 and BBRA-99, Medicare began
paying all home health agencies under a PPS system. Medicare will pay home
health care agencies for each covered 60-day episode of care for each Medicare
beneficiary who continues to remain eligible for home health services. The home
health care PPS system provides payment at a higher rate for the beneficiaries
with greater medical needs, based upon a payment system that relies upon data
collected by caregivers on a patient clinical assessment. PPS rates for FY 2001
range from $1,100 to $5,900, depending upon the intensity of care required by
each beneficiary, with actual rates adjusted by HCFA to reflect the geographic
area wage differentials. Home health care agencies will receive less than the
full PPS amounts in those instances where they provide only a minimal number of
visits to beneficiaries. In addition, the new PPS provides for "outlier"
payments in instances where the costs of care are significantly higher than the
specified rate. In most other instances, they will be paid the full PPS amount.
The Company cannot fully assess the impact of the new PPS system at this time.
The Company anticipates that payments for home health services may be limited or
reduced as a result of this legislation.

         BBA-97 mandated numerous other adjustments and reductions to the
Medicare system that may adversely impact the Company's operations. With respect
to the valuation of capital assets as a result of a change in hospital
ownership, BBA-97 eliminates the allowance for return on equity capital, and
bases reimbursement on the book value of the assets, recognizing no gain or
recapture of depreciation. In addition, BBA-97 mandated the following changes:
(i) a reduction in the bonus payments made to hospitals whose costs are below
the target amounts from 5% of the target amount to 2% and (ii) the transition of
skilled nursing home reimbursement to PPS, based upon 1995 allowable costs, with
a three year transition period beginning on or after July 1, 1998.

         MEDICAID - Medicaid is a Federally mandated medical assistance program
that is administered and funded in part by each state pursuant to which hospital
benefits are available to indigent persons. Each of the Company's hospitals is
certified for participation in the various state Medicaid programs. A
substantial portion of the Company's revenue is derived from patients covered by
this program. See "Sources of Revenue." Medicaid payment methodology varies from
state to state, with most payments being made on a prospective payment system or
under programs that negotiate payment levels with individual hospitals. Many
states have adopted broad-based hospital-specific taxes to help fund the state's
share of its Medicaid program. In addition, certain states have obtained or are
applying for waivers from HCFA to replace their Medicaid programs with managed
care programs.

         BBA-97 repealed the Boren Amendment to the Medicaid Act to give states
greater flexibility in establishing Medicaid payment methods and rates. The
Boren Amendment previously required states to undertake a financial analysis and
provide assurance to the Federal government that the Medicaid rates were
reasonable in meeting the costs incurred by healthcare providers in providing
care to Medicaid patients. In lieu thereof, Congress has mandated that states
employ a rate setting process that requires prior publication and an opportunity
for provider comment on the rates, effective for rates of payment on and after
January 1, 1998.

         Many states have enacted or are considering enacting measures that are
designed to reduce their Medicaid expenditures and to make certain changes to
private health care insurance. California changed the payment system for
participants in its Medicaid program in certain counties from fee-for-service
arrangements to managed care plans. Florida also has legislation, and other
states are considering adopting legislation, imposing a tax on net revenues of
hospitals to help finance or expand the provision




                                       15
<PAGE>   16

of health care to the uninsured and underinsured persons. The Virginia Medicaid
program has contracted with managed care payors and effectively has assigned to
these payors the ability to determine the composition of the provider network.
Texas was denied a waiver under Section 1115 of BBA-97 but is in the process of
implementing regional managed care programs under a more limited waiver. A
number of other states are considering the enactment of managed care initiatives
designed to provide universal low-cost coverage. These proposals also may
attempt to include coverage for some people who currently are uninsured.

         The Medicare and Medicaid programs make additional payments to those
healthcare providers that serve a disproportionate share of low-income patients.
The qualification and funding for disproportionate share payments vary by year
and by state as applicable to Medicaid. Disproportionate share payments for
future years could vary significantly from historical payments.

         Within the statutory framework of the Medicare and Medicaid programs,
there are substantial areas subject to administrative rulings, interpretations
and discretion that may affect payments made under these programs. Funds
received from these programs are subject to audit. These audits can result in
retroactive adjustments of such payments. It often takes many years to make a
final determination about the amounts earned under the programs because of
audits by the program representatives, providers' rights of appeal and the
application of numerous technical reimbursement provisions. Management believes
that adequate provision has been made for such adjustments. There can be no
assurance that future audits will not result in material retroactive
adjustments.

         UTILIZATION REVIEW COMPLIANCE - To ensure efficient utilization of
facilities and services, Federal regulations require that admission to and
utilization of facilities by Medicare and Medicaid patients must be reviewed by
a Peer Review Organization ("PRO"). A PRO may address the appropriateness of
patient admissions and discharges, the quality of care provided, the validity of
DRG classifications and appropriateness of cases with extraordinary length of
stay or cost. The PRO may deny admission or payment. Such review may be
conducted either prospectively or retroactively and is subject to administrative
and judicial appeal.

         ANTI-KICKBACK AND SELF-REFERRAL REGULATIONS - Federal law prohibits the
knowing and willful payment, receipt or offer of remuneration by healthcare
providers to any person, including physicians, to induce referrals of Medicare
and Medicaid patients or in exchange for such referrals (the "Anti-Kickback
Law"). Federal law also prohibits a physician from referring Medicare and
Medicaid patients to certain designated health services in which the physician
has ownership or certain other financial arrangements, unless an exception is
available (the "Stark II Law"). Many states have adopted or are considering
similar legislative proposals to extend the prohibition to referrals of all
patients regardless of payor. Violations of the Anti-Kickback Law and Stark II
Law may result in certain civil sanctions, such as civil monetary penalties, and
exclusion from participating in the Medicare and Medicaid programs. Violations
of the Anti-Kickback Law can also result in the imposition of criminal
sanctions.

         The Office of the Inspector General of Health and Human Services
("OIG") has promulgated regulations that define certain safe harbors to offer
protection to certain common business arrangements under the Anti-Kickback Law.
The failure of an arrangement to meet the requirements of a safe harbor does not
render the arrangement illegal. Those arrangements, however, are subject to
scrutiny by the OIG's office and other enforcement agencies. None of the
Company's joint ventures with physician investors fall within any of the defined
safe harbors. Under the Company's joint venture arrangements, physician
investors are not under any obligation to refer or admit their patients,
including Medicare or Medicaid beneficiaries, to receive services at the
Company's facilities, nor are distributions to those physician investors
contingent upon or calculated with reference to referral by the physician
investors. On the basis thereof, the Company does not believe the ownership of
interests in or receipt of





                                       16
<PAGE>   17

distributions from its joint ventures would be construed to be knowing and
willful payments to the physician investors to induce them to refer patients in
violation of the Anti-Kickback Law. In addition, the Company has entered into
various other relationships and arrangements with physicians, including the
acquisition of physician practices. There can be no assurance that such
arrangements will not be challenged by government enforcement agencies. In
addition, in certain circumstances, private citizens may bring a civil action to
recover sums paid in violation of Federal law. Federal and state government
agencies have announced heightened and coordinated civil and criminal
enforcement efforts. The Company cannot predict the effect on the Company's
financial position, results of operations or liquidity from possible judgments,
if any, that may result from any inquiry, or the impact of new Federal or state
laws and regulations that could require the Company to restructure certain of
its arrangements.

         THE EMERGENCY MEDICAL TREATMENT AND ACTIVE LABOR ACT - Congress adopted
the Federal Emergency Medical Treatment and Active Labor Act ("EMTALA") in
response to reports of a widespread hospital emergency room practice of "patient
dumping." At the time of the enactment, patient dumping was considered to have
occurred when a hospital capable of providing the needed care sent a patient to
another facility or simply turned the patient away based on such patient's
inability to pay for his or her care. The law imposes requirements upon
physicians, hospitals and other facilities that provide emergency medical
services. These requirements pertain to what care must be provided to anyone who
comes to such facilities seeking care before they may be transferred to another
facility or otherwise denied care. Sanctions, which may be imposed on a
physician, hospital or other facility failing to fulfill these requirements,
include termination of a hospital's Medicare provider agreement, exclusion of a
physician from participation in Medicare and Medicaid programs and civil
monetary penalties. In addition, the law creates private civil remedies that
enable (i) an individual who suffers personal harm as a direct result of a
violation of the law and (ii) a medical facility that suffers a financial loss
as a direct result of another participating hospital's violation of the law to
sue the offending hospital for damages and equitable relief. The Company
believes that hospital practices are in compliance with EMTALA.

         HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996 - The
Administrative Simplification Provisions of the Health Insurance Portability and
Accountability Act of 1996 ("HIPAA") mandates the adoption of standards for the
exchange of electronic health information in an effort to encourage overall
administrative simplification and enhance effectiveness and efficiency of the
health care industry. On August 17, 2000, the Department of Health and Human
Services ("HHS") published final regulations establishing electronic data
interchange ("EDI") and code set standards that all health care providers must
use when submitting or receiving certain health care transactions
electronically. Compliance with these regulations is required by October 16,
2002. The Administrative Simplification Provisions of HIPAA also mandates the
adoption of national standards to protect the security and privacy of
health-related information. HHS proposed security standards on August 12, 1998.
The proposed security standards have not been finalized, but as proposed would
require health care providers to implement organizational and technical
practices to protect the security of health-related information. In addition,
HHS released final privacy regulations on December 28, 2000. These privacy rules
extensively regulate the use and disclosure of individually identifiable
health-related information, whether communicated electronically, orally or on
paper. The final privacy regulations provide patients with significant new
rights related to understanding and controlling how their health information is
used or disclosed. Compliance with these privacy standards is required by April
14, 2003. However, these privacy regulations could be further amended prior to
the compliance date. Violations of HIPAA could result in civil penalties of up
to $25,000 per type of violation in each calendar year and criminal penalties of
up to $250,000 per violation. The Company has begun the assessment phase of its
organizational policies, procedures and technical infrastructure for HIPAA
compliance. At this time, the Company anticipates that it will be able to fully
comply with the HIPAA requirements that have been adopted. However, the Company
cannot currently estimate the cost of implementing the required modifications.



                                       17
<PAGE>   18

ENVIRONMENTAL MATTERS

         The Company is subject to various Federal, state and local statutes and
ordinances regulating the discharge of materials into the environment. The
Company's management does not believe that the Company will be required to
expend any material amounts in order to comply with these laws and regulations
or that compliance will materially affect its capital expenditures, earnings or
competitive position.

SEASONALITY

         The hospital industry is seasonal, with the strongest demand for
hospital services generally occurring during January through April and the
weakest during the summer months. Accordingly, the Company's revenues and
earnings are generally highest during the first quarter and lowest during the
third quarter. Seasonal variations are caused by a number of factors, including,
but not necessarily limited to, seasonal cycles of illness, climate and weather
conditions, vacation patterns of both patients and physicians and other factors
relating to the timing of elective procedures.

MEDICAL STAFF AND EMPLOYEES

         At December 31, 2000, the Company had approximately 3,800 full-time and
part-time employees. The Company also had 870 licensed physicians who were
members of the medical staffs of the Company's hospitals. Physician staff
members may also serve on the medical staffs of other hospitals and each may
terminate his or her affiliation with the Company's hospitals at any time. The
Company is subject to Federal and state employment laws and the Federal minimum
wage and hour labor laws. The Company also maintains employee benefit plans,
which are subject to reporting and operational compliance with the Internal
Revenue Code and the U.S. Department of Labor. Labor relations at the Company's
hospitals have been satisfactory.

LIABILITY INSURANCE

         The Company is subject to claims and suits in the ordinary course of
business, including those arising from care and treatment provided at its
facilities. The Company maintains insurance and, where appropriate, reserves for
possible liabilities arising from such claims. The Company is self-insured for
the first $1.0 million per occurrence of general and professional liability
claims. Excess insurance amounts up to $50.0 million are covered by third party
insurance carriers. The Company records an estimated liability for its uninsured
exposure and self-insured retention based on historical loss patterns and
actuarial projections. Although the Company believes that its insurance and loss
reserves are adequate, there can be no assurance that such insurance and loss
reserves will cover all potential claims that may be asserted.




                                       18
<PAGE>   19




ITEM 1A. EXECUTIVE OFFICERS OF THE REGISTRANT

         The following is certain information regarding the executive officers
of the Company.

         ROBERT L. SMITH, age 49, joined the Company as Chief Executive Officer
and director effective March 27, 2000. Since March 1999, Mr. Smith was
Divisional Vice President of Christus Health, a Dallas-based not-for-profit
healthcare system. Prior to Christus Health, he was Chief Executive Officer and
Regional President of the Southeast Texas Operating Division of the Sisters of
Charity of the Incarnate Word Health Care System since 1995. Prior thereto, Mr.
Smith spent 14 years with National Medical Enterprises, Inc. ("NME"),
predecessor company to Tenet Healthcare Corporation, where he held a number of
divisional senior management positions.

         LAWRENCE A. HUMPHREY, age 45, Chief Financial Officer since August 1999
and has served as Executive Vice President - Finance since June 1997, and as
Senior Vice President, Corporate Finance since August 1996. Effective February
1996, Mr. Humphrey was promoted to Senior Vice President - Corporate Finance.
From 1993 to 1994, he was Operations Controller, and from September 1994 to
1996, he was Vice President - Operations Finance of Champion. Prior thereto, he
was employed in various management positions for 12 years by NME. Mr. Humphrey
is a Certified Public Accountant.

         DEBORAH H. FRANKOVICH, age 54, Senior Vice President and Treasurer
since June 1997, has served as Vice President and Treasurer since August 1996.
From 1994 to 1996, she was Vice President and Treasurer of Champion. From 1990
to 1994, she was a healthcare financing consultant. Prior thereto, she was Vice
President and Treasurer of Healthcare International, Inc. from 1985 to 1989, and
Vice President and Treasurer of HealthVest, which she co-founded, from 1986 to
1990. Prior to joining Healthcare International, she worked in the New York
healthcare lending group of Citibank for seven years.

         ROBERT M. STARLING, age 41, a Senior Vice President and Controller
since June 1997, has served as Vice President and Controller since August 1996.
From 1995 to 1996, he was Vice President and Controller of Champion. Prior
thereto, he was Director of Finance for Columbia/HCA Healthcare Corporation from
July 1994 to December 1994 and an Audit Manager with Coopers and Lybrand LLP
(now PricewaterhouseCoopers LLP) from 1986 to 1994. Mr. Starling is a Certified
Public Accountant.

         During 2000, the following executive officers resigned from the
Company: James G. VanDevender, Interim Chief Executive Officer and director; and
Michael M. Brooks, Senior Vice President - Development. The following executive
officers resigned from the Company in February 2001: Tod B. Mitchell, Senior
Vice President, Operations Finance; Steven D. Porter, Senior Vice President,
Operations.




                                       19
<PAGE>   20




ITEM 2. PROPERTIES

         The following table sets forth the name and location of facility, date
of acquisition and number of licensed beds for each of the hospitals operated by
the Company as of December 31, 2000. Unless otherwise indicated, all hospitals
are owned by the Company.

<TABLE>
<CAPTION>

                                                                                     DATE OF       LICENSED
                   LICENSED FACILITY                    LOCATION                   ACQUISITION       BEDS
                   -----------------                    --------                   -----------     --------
<S>                                                     <C>                        <C>             <C>
CALIFORNIA
Lancaster Community Hospital                            Lancaster                    2/01/81          117

FLORIDA
Santa Rosa Medical Center (1)                           Milton                       5/17/96          129

GEORGIA
Flint River Community Hospital (1)                      Montezuma                    1/01/86           49

NORTH DAKOTA
Dakota Heartland Health System                          Fargo                        8/16/96          218

TENNESSEE
Cumberland River Hospital                               Celina                      10/01/85           36
Fentress County General Hospital                        Jamestown                   10/01/85           85

TEXAS
BayCoast Medical Center                                 Baytown                      8/16/96          191
The Medical Center of Mesquite                          Mesquite                    10/01/90          176
Westwood Medical Center                                 Midland                      8/16/96          107

VIRGINIA
Capitol Medical Center (2)                              Richmond                     8/16/96          179
                                                                                                    -----

     Total Licensed Beds                                                                            1,287
                                                                                                    =====
</TABLE>

----------

(1)      Hospital facility is leased.

(2)      The Company owns an 89.7% general partnership interest in a limited
         partnership that owns the hospital.

         The Company owns, leases or manages medical office buildings located
adjacent to certain of its hospitals. Most of the space in each medical office
building is leased or subleased, primarily to local physicians. The remaining
space is used by the Company for hospital administration and clinical purposes
or held for future development.

         The Company leases its corporate offices in Houston, Texas.

         The Company believes that its existing facilities are adequate to carry
on its business as presently conducted.

ITEM 3. LEGAL PROCEEDINGS

         On September 15, 2000, PHC filed a voluntary petition for protection
under Chapter 11 of the Bankruptcy Code with the United States Bankruptcy Court
for the Southern District of Texas (Case no. 00-38590-H5-11). The bankruptcy
filing is limited to PHC, the parent company, and does not include any of PHC's
hospital subsidiaries. See Item 7. "Management's Discussion and Analysis of
Financial Condition and Results of Operations - Proceedings under Chapter 11 of
the Bankruptcy Code," for a more comprehensive discussion of this matter.




                                       20
<PAGE>   21
 On December 5, 2000, two proofs of claim aggregating approximately $94.0
million were filed with the Bankruptcy Court by a private person (the "Relator")
on behalf of the United States and California for alleged violations by PHC
under the Federal False Claims Act and the California False Claims Act (the
"Claims"). The Claims were based on a partially excised complaint in a qui tam
action filed by the Relator under seal in June 1998 in the United States
District Court for the Central District of California, Western Division, as Case
No. 98-4564 (Shx). On or about March 14, 2001, the United States and California
amended their proof of claims, thereby reducing the amounts sought under the
Claims to approximately $45.0 million in aggregate. To avoid the costs of
further litigation and to proceed with confirmation of PHC's plan of
reorganization, on April 17, 2001, the Company signed a settlement agreement
with the United States, California and the Relator to resolve their proofs of
claim (the "Qui Tam Claims Settlement"). In general, the principal settlement
terms are the following: the United States, California and the Relator agreed to
grant the Company certain releases and to dismiss the litigation against the
Company pending in another federal court. The Company agreed that the United
States, California and the Relator would have allowed general unsecured claims
in the bankruptcy case in the aggregate amount of $5.5 million and that the
allowed claims would be entitled to share with other allowed general unsecured
claimants in a distribution of New Notes and common stock of reorganized PHC and
a cash payment to be issued under the Plan. The Company also agreed to enter
into a five year Corporate Integrity Agreement with the Office of Inspector
General of the U.S. Department of Health and Human Services. The Company denied
any liability or wrongdoing. The settlement agreement is the result of
extensive, arm's-length negotiations between PHC, in consultation with the
creditors committee, and the Relator and the government entities. See Item 7.
"Management's Discussion and Analysis of Financial Condition and Results of
Operations - Proceedings under Chapter 11 of the Bankruptcy Code," for a more
comprehensive discussion of this matter.

         A subsidiary of the Company is a defendant in two law suits alleging
certain violations of Federal and North Dakota wage and hour laws for the period
1994 through 1998 at the Fargo, North Dakota hospital. The actions currently
pending are Sister Colette Werlinger, et al., vs. Champion Healthcare
Corporation, et al., Civ. NO. 97-2466 (District Court, County of Cass, State of
North Dakota) and Sister Juliana Wisnewski, et al., vs Champion Healthcare
Corporation, et al., Civil No. A3-96-72 in the United States District Court for
the District of North Dakota, Southeastern Division, on appeal as Shelly Reimer,
et al. vs. Champion Healthcare Corporation, et al., Case No. 00-2413 in the
United States 8th Circuit Court of Appeals. See Item 7. "Management's Discussion
and Analysis of Financial Condition and Results of Operations - Litigation," for
a more comprehensive discussion of these matters.

         On April 26, 2001, the Company learned that a private person acting on
behalf of the United States had filed a civil damages action under seal in
February 1996 against many defendants throughout the United States, including a
subsidiary of the Company, Paracelsus Fentress County General Hospital, Inc.
("Fentress"), in the United States District Court for the Eastern District of
Pennsylvania. The complaint alleged that Fentress and the other defendants
committed violations of the federal civil False Claims Act by using inaccurate
codes to obtain higher reimbursement from Medicare for treating certain types of
pneumonia. The complaint seeks an unspecified amount of money damages,
penalties, costs and reasonable attorney's fees and other unspecified relief.
The United States has not intervened in the case, and Fentress has not been
formally served with the complaint. Before learning of the complaint, Fentress
had been involved in discussions with the Federal government regarding a review
of pneumonia claims filed with the Medicare program by Fentress for years
1992-1997 with a view to a possible settlement of the issue. See Item 7.
"Management's Discussion and Analysis of Financial Condition and Results of
Operations - Litigation," for a more comprehensive discussion of these matters.

         Also on April 26, 2001, the Company learned that an unidentified
private person acting on behalf of the United States had filed a civil damages
action under seal in July 2000 against the Company and Fentress in the United
States District Court for the Middle District of Tennessee. The complaint
alleged that




                                       21
<PAGE>   22

Fentress committed violations of the federal civil False Claims Act by using
inaccurate codes to obtain higher reimbursement from Medicare for treating
certain medical conditions and that the Company assisted Fentress. The complaint
seeks money damages of not less than $5 million, treble the amount of damages,
penalties and other unspecified relief. The Company is in the preliminary stages
of its review of this matter and is unable to predict at this time what impact,
if any, this action will have on the Company's financial condition, results of
operations or liquidity.

         The United States has not intervened in the case, and neither the
Company nor Fentress have been formally served with the complaint. If the
Company or Fentress is served and made a defendant in the case, it will
vigorously defend.

         OTHER LITIGATION - The Company is subject to claims and legal actions
by patients and others in the ordinary course of business. The Company believes
that all such claims and actions are either adequately covered by insurance or
will not have a material adverse effect on the Company's financial condition,
results of operations or liquidity.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         On November 2, 2000, after notice and a hearing, PHC's Disclosure
Statement under Section 1125 of the Bankruptcy Code with Respect to the Initial
Plan was approved, and PHC was authorized to solicit the acceptance or rejection
of the Initial Plan by creditors and other parties entitled to vote. Pursuant to
such solicitation, approximately 98.2% of the shares of PHC's common stock were
voted in favor of the Initial Plan. However, pursuant to the Amended Plan
submitted on April 23, 2001, shares of PHC's common stock held by existing
equity holders will be canceled and rendered null and void upon the Effective
Date, and current equity holders will not receive stock or warrants, as had
previously been provided in the Initial Plan. Accordingly, PHC's current equity
holders will not receive or retain any property under the Amended Plan on
account of such equity interests; therefore, such holders will be deemed to have
rejected the Amended Plan under the Bankruptcy Code. See Item 7. "Management's
Discussion and Analysis of Financial Condition and Results of Operations -
Proceedings under Chapter 11 of the Bankruptcy Code," for a more comprehensive
discussion of this matter.




                                       22
<PAGE>   23
                                     PART II

ITEM 5.  MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
                                    MATTERS

         The Company's common stock trades on the Over the Counter Bulletin
Board Service ("OTCBB") under ticker symbol "PLHCQ." Under the Amended Plan, all
shares of the Company's common stock held by existing equity holders will be
canceled and rendered null and void, and PHC's current equity holders will
neither receive nor retain any property on account of such equity interests. At
May 25, 2001, there were approximately 1,606 holders of record of the Company's
common stock. The following table sets forth the high and low sale prices per
share of the Company's common stock for the periods indicated:

<TABLE>
<CAPTION>

                                                  HIGH            LOW
                                                ---------      ---------
<S>                                             <C>            <C>
Fiscal Year Ended December 31, 2000
  First Quarter ..........................      $    0.63      $    0.19
  Second Quarter .........................           0.25           0.03
  Third Quarter ..........................           0.11           0.03
  Fourth Quarter .........................           0.03           0.01


Fiscal Year Ended December 31, 1999
  First Quarter ..........................      $    1.56      $    1.00
  Second Quarter .........................           1.38           1.00
  Third Quarter ..........................           1.38           0.75
  Fourth Quarter .........................           0.94           0.25
</TABLE>


         The Company did not declare a cash dividend in 2000 and 1999 and does
not anticipate the payment of any cash dividends in the foreseeable future.
Restrictions imposed by the Company's existing debt obligations also limit the
Company's ability to pay dividends.

         The Company did not issue any unregistered securities during 2000. In
connection with the settlement of the Shareholder Litigation in 1999 (the
"Shareholder Litigation"- see Item 8, Note 3), the Company issued 1.5 million
shares of common stock for purposes of distribution to class members and 1.0
million shares of common stock to terminate a service and advisory contract with
a former chairman of the Board of Directors. The securities issued were exempt
from registration with the U.S. Securities and Exchange Commission (the "SEC")
pursuant to Section 3(a)(10) of the Securities Act of 1933.

         On May 23, 2000, the New York Stock Exchange (the "Exchange") suspended
trading of the Company's common stock and shortly thereafter applied to the SEC
to delist the issue. Among the reasons cited by the Exchange were an abnormally
low trading price, and that the Company had fallen below certain of the
Exchange's continued listing criteria. On June 5, 2000, the Company's common
stock began trading on the OTCBB under ticker symbol "PLHCQ." On July 13, 2000,
the SEC granted the Exchange's application to remove the Company's common stock
from listing and registration on the Exchange under the Securities Act of 1934.
The removal from listing and registration was effective on July 14, 2000.



                                       23
<PAGE>   24




ITEM 6. SELECTED FINANCIAL DATA

         The following table summarizes certain selected financial data of the
Company and should be read in conjunction with the related Consolidated
Financial Statements and accompanying Notes to Consolidated Financial Statements
(See Item 8).

         The 2000 Consolidated Financial Statements have been prepared on the
basis of accounting principles applicable to going concerns and contemplate the
realization of assets and the settlement of liabilities and commitments in the
normal course of business. The consolidated financial statements do not include
any adjustments that might result from the resolution of the Chapter 11 case or
other matters discussed herein. The report of the Company's independent
auditors, PricewaterhouseCoopers LLP, includes an explanatory paragraph that
refers to substantial doubt about the Company's ability to continue as a going
concern.

<TABLE>
<CAPTION>

                                                           ($ IN 000'S, EXCEPT PER SHARE DATA AND RATIOS)


YEARS ENDED DECEMBER 31,                              2000             1999             1998             1997              1996
                                                   ----------       ----------       ----------       ----------       ----------
<S>                                                <C>              <C>              <C>              <C>              <C>
INCOME STATEMENT DATA
Net revenue .................................      $  369,151       $  516,537       $  664,058       $  659,219       $  493,106
Operating expenses ..........................        (341,250)        (474,108)        (584,594)        (587,559)        (496,782)
Capital costs (a) ...........................         (60,686)         (89,830)         (90,189)         (77,551)         (54,761)
Equity in earnings of Dakota Heartland
   Health System ............................              --               --               --            9,794            3,207
Impairment charges (b) ......................         (29,673)              --           (1,417)          (7,782)         (72,322)
Merger costs ................................          (8,233)              --               --               --          (40,804)
Unusual items (c) ...........................           2,955           (4,248)           6,637            6,531          (60,521)
Gain on sale of facilities ..................          (7,734)          77,454            6,825               --               --
Reorganization costs ........................              --               --               --               --               --
Minority interests ..........................              --              (54)          (3,180)          (1,996)          (1,806)
                                                   ----------       ----------       ----------       ----------       ----------
Income (loss) from continuing
   operations before income
   taxes and extraordinary loss .............         (75,470)          25,751           (1,860)             656         (230,683)
Provision (benefit) for income taxes (d) ....              --           54,207              693            1,812          (76,186)
                                                   ----------       ----------       ----------       ----------       ----------
Income (loss) from continuing
   operations before extraordinary loss .....         (75,470)         (28,456)          (2,553)          (1,156)        (154,497)
Loss from discontinued operations (d) .......              --           (1,019)          (2,424)          (5,243)         (70,995)
                                                   ----------       ----------       ----------       ----------       ----------
Income (loss) before extraordinary loss .....         (75,470)         (29,475)          (4,977)          (6,399)        (225,492)
Extraordinary loss (d) (e) ..................              --           (4,168)          (1,175)              --           (7,724)
                                                   ----------       ----------       ----------       ----------       ----------
Net income (loss) ...........................      $  (75,470)      $  (33,643)      $   (6,152)      $   (6,399)      $ (233,216)
                                                   ==========       ==========       ==========       ==========       ==========
Income (loss) per share - basic and
    assuming dilution:
    Continuing operations ...................      $    (1.29)      $    (0.51)      $    (0.05)      $    (0.02)      $    (3.94)
    Net income (loss) .......................      $    (1.29)      $    (0.60)      $    (0.11)      $    (0.12)      $    (5.95)

Weighted average common shares
   outstanding (f) ..........................          58,718           55,957           55,108           54,946           39,213
</TABLE>

                                   Continued.



                                       24
<PAGE>   25

ITEM 6. SELECTED FINANCIAL DATA, CONTINUED


<TABLE>
<CAPTION>

YEARS AT DECEMBER 31,                              2000           1999            1998            1997           1996
                                                ---------       ---------       ---------      ---------      ---------
<S>                                             <C>             <C>             <C>            <C>            <C>
BALANCE SHEET DATA
Cash and cash equivalents .................     $  17,140       $  22,723       $  11,944      $  28,173      $  17,771
Net working capital (deficit) (g) .........        57,715        (309,157)         22,526         37,378         33,762
Total assets ..............................       406,499         437,058         716,102        734,824        772,832
Long-term debt (h) ........................        33,537           3,685         533,048        491,914        491,057
Liabilities subject to compromise .........       373,012              --              --             --             --
Long-term debt in default classified as
   current liabilities ....................         3,085         335,445              --             --             --
Stockholders' equity (deficit) ............       (70,200)          5,197          34,341         42,003         48,487
Book value per share ......................           N/A            0.09            0.62           0.76           0.88

RATIOS
Adjusted EBITDA  (i) ......................     $  27,901       $  42,375       $  76,284      $  79,458      $  (2,275)
Adjusted EBITDA margin ....................           7.6%            8.2%           11.5%          12.1%          (0.5)%
Debt to total debt and equity .............           N/A            98.5%           93.9%          92.1%          91.0%
</TABLE>

----------

a)    Includes interest, depreciation and amortization.

b)    Consists of (i) a $29.7 million ($0.51 per share) write-down of the
      Richmond, VA facility, certain clinic assets and home health operations of
      another facility in 2000 to estimated fair value (ii) a $1.4 million
      ($0.02 per share) write-down of certain Tennessee facilities in 1998,
      (iii) a $7.8 million ($0.09 per share) write-down of certain of the
      Company's Los Angeles Metropolitan hospitals ("LA Metro") in 1997 and (iv)
      in 1996, the write-down of PHC Regional Medical Center ("PHC Regional")
      for $52.5 million ($0.90 per share), certain LA Metro hospitals for $11.9
      million ($0.20 per share) and two other facilities and estimated disposal
      costs of $7.9 million ($0.13 per share).

c)    In 2000, a $8.2 million charge, which included a (i) $5.5 million charge
      to accrue for Allowed Qui Tam Claims, (ii) a $3.4 million charge to
      reflect legal fees incurred and estimated liability under a class action
      lawsuit brought against the Company's Fargo, North Dakota facility and
      (iii) a gain of $622,000 on insurance proceeds received as a result of
      flood damage sustained at the Fargo, North Dakota facility during 2000.
      The unusual charge in 1999 consists of (i) a $5.5 million corporate
      restructuring charge ($0.10 per share), (ii) a $2.2 million charge ($0.04
      per share) associated with the execution of an executive agreement (the
      "Executive Agreement"), (iii) a $2.0 million charge ($0.04 per share) in
      the fourth quarter associated with litigation expenses and the write-down
      to net realizable value of a note receivable and other assets, all of
      which were related to sold facilities, offset by (iv) a $5.5 million gain
      ($0.10 per share) from the settlement of the Shareholder Litigation.
      Unusual items in 1998 consist of (i) a $7.5 million gain ($0.08 per share)
      from the settlement of a 1996 capitation agreement offset by (ii) a net
      charge of $863,000 ($0.01 per share) resulting from the execution of the
      Executive Agreement, the restructuring of certain home health operations,
      severances and the settlement of a contract dispute and litigation.
      Unusual items in 1997 consist of (i) a reversal of a loss contract accrual
      of $15.5 million ($0.17 per share), (ii) a charge of $3.5 million ($0.03
      per share) relating to the closure of PHC Regional, (iii) a charge of $2.5
      million ($0.03 per share) for a corporate reorganization and (iv) a charge
      of $3.0 million ($0.04 per share) for the settlement of certain
      litigation. Unusual items in 1996 consist of charges of $38.1 million
      ($0.65 per share) for a loss contract and $22.4 million ($0.38 per share)
      for expenses relating to certain investigation and other litigation
      matters.

d)    The Company reserved all tax benefits generated in 2000. The provision for
      income taxes in 1999 includes an increase in income tax provision of $26.8
      million ($0.48 per share) from the recording of




                                       25
<PAGE>   26

      a valuation allowance, which offsets the Company's net deferred tax
      assets. Of this amount, $24.7 million was applied to increase income tax
      provision on income from continuing operations and $2.1 million was
      applied to eliminate income tax benefits on losses from discontinued
      operations and an extraordinary loss. The benefit for income taxes in 1996
      includes a reduction in income tax benefits of $50.0 million ($1.27 per
      share) from the recording of a valuation allowance. Of this amount, $17.7
      million was applied to reduce income tax benefits on losses from
      continuing operations and the remaining $32.3 million to reduce income tax
      benefits on losses from discontinued operations and an extraordinary loss.
      As a result, no income tax benefits have been recognized on the losses
      from discontinued operations and the extraordinary losses recorded in 1999
      and 1996.

e)    Reflects loss associated with the early extinguishment of debt.

f)    Reflects the effect of the 66,159.426-for-one stock split in conjunction
      with the Merger.

g)    If the PHC Chapter 11 proceeding had not been filed, the Company would
      have reported a net working capital deficit of approximately $315.3
      million at December 31, 2000.

h)    Excludes long-term debt due within one year and long-term debt in default
      classified as current liabilities.

i)    Adjusted EBITDA represents income (loss) from continuing operations before
      income taxes and extraordinary loss, depreciation and amortization,
      interest, impairment charges, merger costs, unusual items and gain from
      sale of facilities. While EBITDA is not a substitute for operating cash
      flows determined in accordance with generally accepted accounting
      principles, it is a commonly used tool for measuring a company's ability
      to service debt. Adjusted EBITDA is not an acceptable measure of
      liquidity, cash flow or operating income under generally accepted
      accounting principles and may not be comparable to similarly titled
      measures of other companies.




                                       26
<PAGE>   27

SELECTED OPERATING STATISTICS

         The following table sets forth selected operating statistics for the
Company's consolidated hospitals for the periods and dates indicated.

<TABLE>
<CAPTION>

                                                               YEAR ENDED DECEMBER 31,
                                                  ------------------------------------------------
                                                     2000               1999             1998
                                                  ------------      ------------      ------------
<S>                                               <C>               <C>               <C>
ACUTE CARE HOSPITALS(1):
 Total number of hospitals ..................               10                10                16
 Licensed beds at end of period .............            1,287             1,287             1,916
 Patient days ...............................          187,387           246,203           311,144
 Inpatient admissions .......................           39,245            53,655            65,746
 Average length of stay (days) ..............              4.8               4.6               4.7
 Outpatient visits (excluding home health) ..          319,689           572,593           689,192
 Home health visits .........................          236,593           274,758           503,944
 Deliveries .................................            3,269             7,652             9,602
 Surgery cases ..............................           20,433            34,431            46,902
 Occupancy rate .............................             39.9%             38.6%             35.8%
 Outpatient utilization (2) .................             35.2%             38.5%             37.6%

PSYCHIATRIC HOSPITALS(3):
 Total number of hospitals ..................               --                --                --
 Licensed beds at end of period .............               --                --                --
 Patient days ...............................               --                --             4,099
 Inpatient admissions .......................               --                --               322
 Average length of stay (days) ..............               --                --              12.7
 Outpatient visits ..........................               --                --             4,736
 Occupancy rate .............................               --                --              25.0%
 Outpatient utilization (2) .................               --                --              18.3%
</TABLE>

----------

(1)   Includes the sold facilities through their respective dates of disposition
      and DHHS from January 1, 1998.

(2)   Gross Outpatient Revenue as a percentage of Total Gross Patient Revenue.

(3)   Includes the LA Metro psychiatric facilities though their disposition
      date.


ITEM 7.     MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
            CONDITION AND RESULTS OF OPERATIONS

           The Consolidated Financial Statements in Item 8 set forth certain
data with respect to the financial position, results of operations and cash
flows of the Company and should be read in conjunction with the following
discussion and analysis.

           The 2000 Consolidated Financial Statements have been prepared on the
basis of accounting principles applicable to going concerns and contemplate the
realization of assets and the settlement of liabilities and commitments in the
normal course of business. The consolidated financial statements do not include
any adjustments that might result from the resolution of the Chapter 11 case or
other matters discussed herein. The report of the Company's independent
auditors, PricewaterhouseCoopers, LLP, includes an explanatory paragraph that
refers to substantial doubt about the Company's ability to continue as a going
concern.


                                       27
<PAGE>   28
FORWARD-LOOKING STATEMENTS

         Certain statements in this Form 10-K are "forward-looking statements"
made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements involve a number of risks and
uncertainties. All statements regarding the Company's expected future financial
position, results of operations, cash flows, liquidity, financing plans,
business strategy, budgets, projected costs and capital expenditures,
competitive position, growth opportunities, plans and objectives of management
for future operations and words such as "anticipate," "believe," "plan,"
"estimate," "expect," "intend," "may" and other similar expressions are
forward-looking statements. Such forward-looking statements are inherently
uncertain, and stockholders must recognize that actual results may differ
materially from the Company's expectations as a result of a variety of factors,
including, without limitation, those discussed below.

         Factors which may cause the Company's actual results in future periods
to differ materially from forecast results include, but are not limited to:

         o        Uncertainties related to PHC's voluntary petition under
                  Chapter 11 of the Bankruptcy Code including, but not limited
                  to, (i) the Company's ability to consummate, in substantial
                  terms, the Amended Plan, as proposed, (ii) actions which may
                  be taken by creditors and the outcome of various
                  administrative matters in the Chapter 11 proceeding and (iii)
                  the possibility of delays in the effective date of the Amended
                  Plan;

         o        The Company's ability to comply with the terms of the
                  subsidiary level credit facility;

         o        The Company's inability to access capital markets given the
                  Company's current financial condition;

         o        The excessive amount of time and effort that the Company's
                  senior management must devote to dealing with the Company's
                  financial condition, thereby reducing time spent directly on
                  the operations of its businesses;

         o        The Company may be unable to retain top management and other
                  key personnel, including physicians;

         o        Competition, including the impact of a new competing hospital
                  opened in November 2000 in the Fargo, North Dakota market, and
                  general economic, demographic and business conditions, both
                  nationally and in the regions in which the Company operates;

         o        Existing government regulations and changes in legislative
                  proposals for healthcare reform, including changes in Medicare
                  and Medicaid reimbursement levels;

         o        The ability to enter into managed care provider arrangements
                  on acceptable terms;

         o        Liabilities and other claims asserted against the Company;

         o        The loss of any significant customer, including but not
                  limited to managed care contracts;

         o        The Company's ability to achieve profitable operations after
                  the confirmation of the Amended Plan; and

         o        The Company's ability to generate sufficient cash from
                  operations to meet its obligations.

         o        The Company's ability to comply with the terms of the
                  corporate integrity agreement.

         The Company is generally not required to, and does not undertake to,
update or revise its forward-looking statements.



                                       28
<PAGE>   29

PROCEEDINGS UNDER CHAPTER 11 OF THE BANKRUPTCY CODE

         On September 15, 2000, PHC filed a voluntary petition for protection
under Chapter 11 of the Bankruptcy Code with the United States Bankruptcy Court
for the Southern District of Texas (Case no. 00-38590-H5-11). The bankruptcy
filing is limited to PHC, the parent company, and does not include any of PHC's
hospital subsidiaries. PHC elected to seek Bankruptcy Court protection in order
to facilitate the restructuring of its debt while continuing to maintain normal
business operations at PHC's hospital subsidiaries. PHC's decision to
restructure its debt was due to its highly leveraged capital structure. Despite
positive earnings before interest, taxes, depreciation, amortization and unusual
charges, the high interest burden severely impacted the Company's reinvestment
opportunities. In an effort to conserve capital and to preserve the normal
operations of the hospital subsidiaries, PHC did not make interest payments of
$33.5 million (including penalty interest) on the 10% Senior Subordinated Notes
(the "Notes") due February 15 and August 15, 2000, nor did PHC make an interest
payment of $468,000 due on the 6.51% subordinated note ("Park Note") on August
30, 2000. Both the Notes and the Park Note are subject to compromise as a result
of PHC's Chapter 11 bankruptcy filing.

         PHC's hospital subsidiaries did not file for bankruptcy protection and
have continued paying, in the ordinary and normal course of business, all wages,
benefits and other employee obligations, all debt and lease obligations, as well
as all outstanding and ongoing accounts payable to their contractors and
vendors. A $62.0 million credit facility (the "Credit Facility"), collateralized
at the subsidiary level, is not directly affected by PHC's bankruptcy filing.
The Company expects cash on hand, cash generated from operations and asset sales
to be sufficient to meet the net working capital and capital expenditure needs
of the hospital subsidiaries during the restructuring process.

         On October 2, 2000, PHC received approval from the Bankruptcy Court to
pay pre-petition and post-petition PHC's employee wages, salaries and benefits.
The Bankruptcy Court also approved orders granting authority, among other
things, to pay pre-petition claims of certain utilities. All other PHC
pre-petition liabilities are classified in the consolidated balance sheet as
liabilities subject to compromise. PHC continues to pay post-petition claims of
all vendors and providers in the ordinary course of business.

         Simultaneously with the commencement of its bankruptcy case, PHC filed
the initial plan of reorganization (the "Initial Plan") pursuant to which PHC
proposed to effect its capital restructuring. On November 2, 2000, after notice
and a hearing, PHC's Disclosure Statement under Section 1125 of the Bankruptcy
Code with Respect to the Initial Plan was approved, and PHC was authorized to
solicit the acceptance or rejection of the Initial Plan by creditors entitled to
vote. The Initial Plan was accepted by holders of the Notes, general unsecured
claims and common stock prior to December 8, 2000, the date originally set by
the Court for the hearing on confirmation of the Initial Plan. However, on
December 5, 2000, two proofs of claim aggregating approximately $94.0 million
were filed with the Court by a private person (the "Relator") on behalf of the
United States and California for alleged violations by PHC under the Federal
False Claims Act and the California False Claims Act (the "Claims"). The Claims
were based on a partially excised complaint in a qui tam action filed by the
Relator under seal in June 1998 in the United States District Court for the
Central District of California, Western Division, as Case No. 98-4564 (Shx) (the
"Qui Tam Action"). A material condition to the effectiveness of the Initial Plan
was that the aggregate amount of the allowed and disputed general unsecured
claims would not exceed $15.0 million. The aggregate amount of the Claims, as
filed, together with other claims filed that were not anticipated by PHC,
exceeded this cap. Accordingly, at PHC's request, on December 8, 2000, the Court
continued the hearing on confirmation of the Initial Plan to permit PHC to file,
and the Court to consider, an objection to and a motion to estimate the Claims.
On or about March 14, 2001, the United States and




                                       29
<PAGE>   30

California amended their proof of claims, thereby reducing the amounts sought
under the Claims to approximately $45.0 million in aggregate.

         To avoid the costs of further litigation and to proceed with
confirmation of PHC's plan of reorganization, on April 17, 2001, the Company
signed a settlement agreement with the United States, California and the Relator
to resolve their proofs of claim. In general, the principal settlement terms are
the following: the United States, California and the Relator agreed to grant the
Company certain releases and to dismiss the litigation against the Company
pending in another federal court. The Company agreed that the United States,
California and the Relator would have allowed general unsecured claims in the
bankruptcy case in the aggregate amount of $5.5 million (the "Allowed Qui Tam
Claims") and that the allowed claims would be entitled to share with other
allowed general unsecured claimants in the distribution of 11.5% Senior Notes
(due on August 15, 2005) (the "New Notes") and common stock of reorganized PHC
and a cash payment to be issued under the Initial Plan. In connection therewith,
the Company accrued $5.5 million at December 31, 2000, which has been included
in "Liabilities Subject to Compromise." The Company also agreed to enter into a
five year Corporate Integrity Agreement with the Office of Inspector General of
the U.S. Department of Health and Human Services. The Company denied any
liability or wrongdoing. The settlement agreement is the result of extensive,
arm's-length negotiations between PHC, in consultation with the creditors
committee, and the Relator and the government entities. The Court approved the
settlement agreement on May 22, 2001.

         On April 23, 2001, PHC filed the First Amended Chapter 11 Plan of
Reorganization (the "Amended Plan") reflecting changes made necessary by (i) the
Allowed Qui Tam Claims, together with other claims filed that were not
anticipated by PHC, and (ii) the downward revisions in the Company's projected
future operating results due to the opening of a competing hospital in the
Company's Fargo, North Dakota market in November 2000, which had a greater than
anticipated negative impact on the Company's results of operations. Upon the
effective date (the "Effective Date") of the Amended Plan, shares of PHC's
common stock held by existing equity holders will be canceled and rendered null
and void, and current equity holders will not receive stock or warrants, as had
previously been provided in the Initial Plan. PHC's current equity holders will
not receive or retain any property under the Amended Plan on account of such
equity interests. Also upon the Effective Date, PHC will merge into a wholly
owned subsidiary incorporated in Delaware and will cease to exist as a separate
company, and the wholly owned subsidiary will emerge from bankruptcy as
reorganized PHC and will be known as Clarent Hospital Corporation. Additionally,
all principal and interest outstanding on the Notes and allowed general
unsecured claims will be exchanged for (i) New Notes in the aggregate principal
amount of $130.0 million (ii) a cash payment, as defined in the Amended Plan,
and (iii) 100.0% of the new common stock issued by the reorganized PHC under the
Amended Plan. Interest on the New Notes shall accrue commencing on the Effective
Date. The Amended Plan incorporates the terms of the Qui Tam Claims Settlement.

         On May 25, 2001, the Bankruptcy Court approved the Amended Plan. The
effectiveness of the Amended Plan is subject to certain conditions, as defined
in the Amended Plan. Upon the Effective Date, reorganized PHC will take the
steps necessary to cease being subject to the periodic reporting requirements of
the federal securities law. Additionally, reorganized PHC will have a limited
number of stockholders and does not plan to list the New Notes on an exchange.
Therefore, PHC will not be required to file periodic public reports, although
the new board of directors may seek to voluntarily register its new common stock
with the SEC or to list the New Notes on an exchange at a future date and thus
become a publicly reporting company.


                                       30
<PAGE>   31

         Pursuant to the terms of a settlement agreement executed in connection
with the global settlement of shareholder litigation that became effective in
September 1999, the Park Note and accrued interest must convert to PHC's common
stock in the event PHC files a voluntary petition in bankruptcy. No shares of
common stock have been issued to Park at this time. See "Liabilities Subject to
Compromise" discussed below. Under the Amended Plan (i) the Park Note will be
deemed to have been converted to approximately 1.9 million shares of PHC's
common stock upon the filing of the Bankruptcy, (ii) the Park Note holder (Park
Hospital GmbH or "Park") will be deemed to have been issued the common stock in
accordance with the terms of the settlement and (iii) the Park Note will be
deemed to be cancelled. On the Effective Date, the 1.9 million shares of PHC
common stock will be deemed canceled and rendered null and void, and Park will
neither receive nor retain any property on account of such equity interests.

         The Amended Plan also contains a management retention plan (the
"Retention Plan") to enhance the ability of the Company to retain key management
employees during the restructuring period. Under the Retention Plan, bonuses
aggregating $1.0 million will be awarded, subject to certain conditions, to
certain key management employees. The Retention Plan provides that the retention
bonuses will be awarded in two equal amounts upon: (i) the Effective Date and
(ii) ninety days following the Effective Date. The Amended Plan and PHC's
Disclosure Statement are on file with the Bankruptcy Court and are available for
review and copying during the Bankruptcy Court's normal business hours.

         Under the Bankruptcy Code, actions to collect pre-petition indebtedness
from PHC are subject to an automatic stay and other contractual obligations
against PHC may not be enforced. In addition, PHC may assume or reject executory
contracts, including lease obligations, under the Bankruptcy Code. Parties
affected by the lease or contract rejections may file claims with the Bankruptcy
Court in accordance with procedures set forth in the Bankruptcy Code.

         "Liabilities Subject to Compromise" on the Company's consolidated
balance sheet reflect PHC liabilities incurred prior to the commencement of the
Chapter 11 proceeding and do not reflect liabilities of any of PHC's
subsidiaries. These liabilities, consisting primarily of long-term debt,
including the principal amounts of the Notes and the Park Note and accrued
interest through September 15, 2000, certain accounts payable, accrued
liabilities and post-termination benefit obligations to former officers and key
employees, represent the Company's estimate of known or potential claims to be
resolved in connection with the Chapter 11 proceedings. Such claims remain
subject to future adjustments based on negotiations, actions of the Bankruptcy
Court, further developments with respect to disputed claims, future rejection of
executory contracts or unexpired leases, determination as to the value of any
collateral for claims, treatment under the Amended Plan and other events.
Payment terms for these amounts as proposed in the Amended Plan are discussed
above.




                                       31
<PAGE>   32




         A summary of the principal categories of claims classified as
"Liabilities Subject to Compromise" as a result of the Chapter 11 proceeding
follows (in thousands):

<TABLE>

<S>                                                  <C>
10% Senior Subordinated Notes ..................     $    325,000
Unamortized deferred financing costs ...........           (5,544)
Accrued interest through September 15, 2000 ....           36,833
6.51% Subordinated Note ........................            7,185
Post-termination benefit obligations ...........            3,255
Vendor accounts payable ........................              183
Accrued litigation liabilities .................            6,100
                                                     ------------
    Total liabilities subject to compromise ....     $    373,012
                                                     ============
</TABLE>

         The financial statements do not include further adjustments, if any,
reflecting the possible future effects on the recoverability and classification
of assets or the amount and classification of liabilities that may result from
the outcome of the uncertainties associated with the Chapter 11 proceeding. If
the Chapter 11 proceeding had not been filed, the Company would have reported a
net working capital deficit of approximately $315.3 million at December 31,
2000. During the pendency of the Chapter 11 proceeding, the Company is not
recording the contractual amount of interest expense related to the Notes and
the Park Note after September 15, 2000. Contractual interest obligations
excluded from interest expense reported on the accompanying consolidated
statements of operations were $10.8 million for the year ended December 31,
2000.

         Due to cross default provisions, a hospital subsidiary's capital lease
obligation has been included in current liabilities in the Company's
consolidated balance sheet at December 31, 2000.

         At the Company's request, on October 26, 2000, the Bankruptcy Court
dismissed PHC Finance, Inc.'s Chapter 11 proceeding, which was filed on March
15, 2000.

RESULTS OF OPERATIONS

         The comparison of operating results to prior years is difficult given
the numbers of divestitures, closures and acquisition by the Company in the
affected periods. "Same Hospitals" as used in the following discussion, where
appropriate, consist of acute care hospitals owned throughout both periods for
which comparative operating results are presented.



                                       32
<PAGE>   33




OPERATIONS DATA

         The following table summarizes, for the periods indicated, changes in
selected operating percentages for the Company's facilities. The discussion that
follows should be read in conjunction with the Company's Consolidated Financial
Statements and the notes thereto included elsewhere herein.

<TABLE>
<CAPTION>

                                                                 YEAR ENDED DECEMBER 31,
                                                     --------------------------------------------------
                                                        2000               1999               1998
                                                     ------------       ------------       ------------
<S>                                                  <C>                <C>                <C>
Percentage of Net Revenue

Net revenue ....................................            100.0%             100.0%             100.0%
                                                     ------------       ------------       ------------

Salaries and benefits ..........................            (44.1)             (42.4)             (41.6)
Other operating expenses .......................            (38.5)             (41.3)             (40.0)
Provision for bad debts ........................             (9.8)              (8.1)              (6.4)
                                                     ------------       ------------       ------------

Operating costs ................................            (92.4)             (91.8)             (88.0)
                                                     ------------       ------------       ------------

Operating margin ...............................              7.6                8.2               12.0

Capital costs (a) ..............................            (16.5)             (17.4)             (13.6)
Impairment charges .............................             (8.0)                --               (0.2)
Unusual items ..................................             (2.2)              (0.8)               1.0
Gain on sale of facilities .....................              0.8               15.0                1.0
Reorganization costs ...........................             (2.1)                --                 --
Minority interests .............................               --                 --               (0.5)
                                                     ------------       ------------       ------------
 Income (loss) from continuing operations before
    income taxes, discontinued operations and
     extraordinary loss ........................            (20.4)%              5.0%              (0.3)%
                                                     ============       ============       ============
</TABLE>


----------

(a)      Includes interest, depreciation and amortization.


YEAR ENDED DECEMBER 31, 2000
COMPARED WITH YEAR ENDED DECEMBER 31, 1999

         Net revenue for year ended December 31, 2000, was $369.2 million
compared to $516.5 million for 1999, a decrease of $147.3 million, or 28.5%.
The decline in net revenue was due to the sale of ten hospitals in 1999.

         Net revenue at "Same Hospitals" increased by $9.9 million, or 2.7%, to
$367.5 million for the year ended December 31, 2000, compared to $357.6 million
in 1999, due primarily to a combination of increased patient volumes in certain
markets and improved reimbursement/pricing for certain hospital services.
Improvements in patient volumes were offset, in part, by the continuing shift in
payor mix from traditional Medicare, Medicaid and indemnity coverage to managed
care, from which the Company generally receives lower reimbursement. The Company
has responded to this shift by renegotiating managed care contracts to obtain
better rates and by increasing its emphasis on collecting under payments,
reducing denials and restricting silent preferred provider organizations as part
of its recently implemented revenue cycle management program, as discussed
further below. As a result of these efforts, the Company is beginning to realize
improved reimbursement from managed care and expects to see continued
improvements in future periods; however, the continuing shift of business toward
managed care plans has and may continue to adversely affect the Company's
ability to grow net operating revenue and improve operating margins.




                                       33

<PAGE>   34

         Inpatient admissions at the Company's "Same Hospitals" increased from
38,435 in 1999 to 39,245 in 2000, or 2.1%, while same Hospital patient days
decreased from 190,117 in 1999 to 187,387 in 2000, or 1.4%. Consequently,
average length of stay declined from 4.95 in 1999 to 4.77 in 2000, a trend that
is generally positive in a fixed reimbursement environment. Excluding home
health visits, outpatient visits at "Same Hospitals" increased 4.0% from 307,314
in 1999 to 319,689 in 2000. Home health visits in "Same Hospitals" decreased
9.2% from 260,689 in 1999 to 236,593 in 2000. The decrease in home health visits
was due in part to a de-emphasis of services, as well as a restructuring of the
mix of services, in response to changes in reimbursement methodologies. The
Company expects the decline in home health visits to continue.

         In November 2000, a competing hospital opened in the Company's Fargo,
North Dakota market. This not-for-profit hospital is supported by a physician
group who formerly admitted a significant number of patients to DHHS, and
consequently, DHHS experienced a substantial drop in patient volumes and
financial performance in the fourth quarter 2000. The Company expects patient
volumes and financial performance at this facility to remain significantly below
historical levels, which will have a material adverse impact on both the
hospital's and the Company's financial performance in the months ahead. For the
year ended December 31, 2000, DHHS accounted for 26.4% of total hospital net
revenue and 43.8% of hospital Adjusted EBITDA reported by the Company. While
management is unable to predict the ultimate impact of this new facility on the
Company's results of operations, it believes that DHHS will continue to generate
positive operating cash flow.

         Operating expenses (salaries and benefits, other operating expenses and
provision for bad debts) increased to 92.4% of net revenue in 2000 compared to
91.8% in 1999. Operating margins were 7.6% and 8.2%, respectively. On a Same
Hospital basis, operating expenses were 88.9% of net revenue in 2000 compared to
87.2% in 1999, and operating margins were 11.1% and 12.8%, respectively. The
decline in Same Hospital operating margins is primarily due to a $5.4 million
increase in the provision for bad debts, or 18.0%, compared to 1999.
Approximately 93% of the increase in bad debt expense occurred at one hospital
and was due largely to poor accounts receivable management as well as an
increase in emergency room visits and an overall increase in self-pay patients,
both of which generally result in higher bad debt charges. Additionally, this
hospital and certain other of the Company's hospitals have experienced
significant turnover in business office personnel, which has had an adverse
impact on collections. The Company has filled all but one of its business office
manager vacancies and has implemented business office incentive programs with
the duel objectives of rewarding positive operating performance on a more timely
basis and improving staff continuity. Consequently, the Company expects to see
improved business office performance in the months ahead. The Company is also
implementing a comprehensive revenue cycle management initiative in all of its
hospitals, a significant component of which is aimed at reducing bad debt
expense through improved business office processes. This initiative involves the
implementation of systems and processes to track, benchmark and improve the
hospitals' admission, billing and collection cycles. While this initiative has
shown positive results to date, a full revenue cycle is generally required
before substantial improvements are realized. Accordingly, the full impact of
the Company's efforts will not be realized until the latter half of 2001.
Operating margins were also adversely impacted by higher salaries and benefits
cost due to a combination of market related wage increases and increased volumes
at certain hospitals.

         Interest expense decreased $21.0 million from $50.2 million in 1999 to
$29.2 million in 2000, primarily as a consequence of PHC's Chapter 11 bankruptcy
filing. The Company ceased accruing interest on the Notes and other debt
obligations subject to compromise on September 15, 2000, the date of the
bankruptcy filing. Consequently, interest expense excludes contractual interest
obligations of $10.8 million on debt subject to compromise, $10.6 million of
which is attributable to the Notes. Interest expense also declined due to the
repayment of all amounts outstanding under a senior credit facility in




                                       34
<PAGE>   35

October 1999 following the disposition of the Utah Facilities, partially offset
by an increase in interest rates in 2000. Interest rates increased due to a
combination of an overall market increase in interest rates and additional
interest incurred on the defaulted interest payments on the Notes.

         Depreciation and amortization expense decreased from $39.6 million in
1999 to $31.5 million in 2000, or $8.1 million, due primarily to the sale of the
Utah Facilities, partially offset by an increase in depreciation and
amortization at Same Hospital facilities attributable to current year capital
expenditures.

           Loss before income taxes, discontinued operations and extraordinary
charge for the year ended December 31, 2000, was $75.5 million and reflected (i)
an impairment charge of $29.7 million to write-down the Richmond, VA facility,
certain clinic assets and home health operations to fair value, (ii)
reorganization costs of approximately $7.7 million for professional fees
incurred in connection with the Company's reorganization efforts, (iii) a net
unusual charge of $8.2 million and (iv) a net $3.0 million gain on the sale of
facilities. The net unusual charge of $8.2 million was comprised of (i) a $5.5
million charge to accrue for Allowed Qui Tam Claims, (ii) a $3.4 million charge
to reflect legal fees incurred and estimated liability under a class action
lawsuit brought against the Company's Fargo, North Dakota facility alleging
certain violations of Federal and North Dakota wage and hour laws for the period
1994 through 1998 offset by (iii) a gain of $622,000 on insurance proceeds
received as a result of flood damage sustained at the Fargo, North Dakota
facility during 2000. The gain on the sale of facilities was comprised of a $3.3
million gain on the disposition of the Company's equity interest in IASIS, which
the Company retained pursuant to the 1999 sale of the Utah Facilities, offset by
$350,000 in losses attributable to certain notes received in conjunction with a
prior year disposition.

         Income before income taxes, discontinued operations and extraordinary
charge was $25.8 million for the year ended December 31, 1999 and included a
$77.5 million net gain on the sale of facilities and a net unusual charge of
$4.2 million. The gain on sale of facilities resulted from the sale of the Utah
Facilities, Senatobia and the Convalescent Hospitals, which was partially offset
by a loss on the final net working capital adjustment and the recognition of a
prepayment discount on notes receivable related to the 1998 sale of the
Company's LA Metro hospitals (see Item 8. Note 4). The net unusual charge, as
more fully discussed in Item 8. Note 3, consisted of (i) a $5.5 million
corporate restructuring charge relating to employee termination costs, service
contract cancellation and the write-down of certain deferred costs, leasehold
improvements and redundant equipment, (ii) a $2.2 million charge associated with
the execution of the Executive Agreement, (iii) a $2.0 million charge associated
with litigation expenses and the write-down to net realizable value of a note
receivable and other assets, all of which were related to sold facilities,
offset by (iv) a $5.5 million gain from the settlement of the Shareholder
Litigation.

         All net deferred tax assets resulting from the Company's 2000 net
operating losses were offset by the recognition of additional valuation
allowances due to issues affecting liquidity and related uncertainties discussed
herein, which, if unfavorably resolved, will adversely affect the Company's
future operations. Consequently, the Company did not recognize an income tax
benefit in 2000. In 1999, the Company recorded an income tax provision for
income from continuing operations of $54.2 million, $26.8 million of which was
recorded to reserve all remaining net deferred tax assets as of December 31,
1999. Of the $26.8 million, $24.7 million was applied to increase the income tax
provision on income from continuing operations and $2.1 million was applied to
eliminate income tax benefits on losses from discontinued operations and an
extraordinary loss. As a result, no income tax benefits were recognized on the
losses from discontinued operations and the extraordinary loss recorded in 1999.

         In 1999, the Company recorded a loss from discontinued operations of
$1.0 million (no tax benefits), or $0.02 per share, resulting from certain
Medicare contractual adjustments related to the discontinued psychiatric
operations sold in 1998.




                                       35
<PAGE>   36

         Net loss was $75.5 million, or $1.29 per diluted share, in 2000,
compared to $33.6 million, or $0.60 per diluted share, in 1999. Net loss for
1999 included an extraordinary charge for the write-off of deferred loan costs
of $4.2 million (no tax benefits), or $0.07 per share. Weighted average common
and common equivalent shares outstanding were 58.7 million and 56.0 million in
2000 and 1999, respectively. The increase in weighted average common and common
equivalent shares was due to the 1999 issuance of common stock in connection
with the settlement of the Shareholder Litigation, a restricted stock grant of
1.3 million shares to the Company's Chief Executive Officer in 2000 and the
exercise of employee stock options in 2000.

YEAR ENDED DECEMBER 31, 1999
COMPARED WITH YEAR ENDED DECEMBER 31, 1998

         Net revenue for year ended December 31, 1999, was $516.6 million, a
decrease of $147.5 million, or 22.2%, from $664.1 million for the same period in
1998. The decline in net revenue is largely due to the sale of eight acute care
hospitals in 1998 and the sale of Bledsoe, the Convalescent Hospitals, Senatobia
and the Utah Facilities in 1999.

         Net revenue at "Same Hospitals" decreased by $8.4 million, or 2.3%, to
$357.6 million for the year ended December 31, 1999, compared to $366.0 million
in 1998. This decrease resulted primarily from an $8.0 million charge to net
revenue in the fourth quarter to revise estimates of amounts due to the Company
from managed care payors ($7.0 million) and from the Medicare/Medicaid programs
($1.0 million). The increase in managed care allowances reflects the impact of
increased managed care penetration at several of the Company's hospitals, the
effect of the increasing discounted fee structures demanded by the managed care
payors and the improvement in information available which has allowed the
Company to better estimate amounts due under managed care contracts. In
response, management is currently reviewing all material managed care contracts
and when permitted, either renegotiating or canceling contracts it deems
unfavorable to the Company. The Company has installed information systems at
certain of it hospitals to improve management's ability to ensure that billing
and collection practices accurately reflect negotiated rates. The trend of
payors shifting to managed care plans has and may continue to adversely affect
the Company's ability to grow net operating revenue and improve operating
margins.

         The Company's "Same Hospitals" experienced a 3.1% increase in inpatient
admissions from 37,288 in the year ended December 31, 1998 to 38,435 in the
comparable period in 1999. Same Hospital patient days increased 0.7% from
188,889 in 1998 to 190,117 in 1999. The increase in admissions and patient days
resulted from (i) an increase in the number of physicians and services at
several of the Company's hospitals and (ii) increased volume generated from
certain hospital benchmarking and service awareness programs implemented in
1998. Excluding home health visits, outpatient visits at "Same Hospitals"
declined 2.9% from 316,397 in 1998 to 307,314 in 1999 due primarily to the
consolidation and/or selective reduction of services at certain hospitals. Home
health visits in "Same Hospitals" decreased 29.6% from 370,223 in 1998 to
260,689 in 1999 primarily due to the 1998 closure or sale of home health
operations in response to the 1997 Budget Act.

         Operating expenses (salaries and benefits, other operating expenses and
provision for bad debts), expressed as a percentage of net revenue, were 91.8%
of net revenue in 1999 and 88.0% in 1998, and operating margins were 8.2% and
12.0%, respectively. Operating expenses in 1998 were favorably impacted by a
$5.5 million reduction in general and medical professional liability costs.
Additionally, operating expenses in 1999 were unfavorably impacted by a $2.9
million increase in bad debt expense at the Company's Same Hospitals, as
discussed below, and a $4.7 million increase in workers compensation reserves.
The increased charges for workers compensation were the result of revised
actuarial estimates,




                                       36
<PAGE>   37

which were negatively impacted by unfavorable claims experience. Substantially
all of these charges related to prior years and approximately half of the
charges were incurred at the sold/closed facilities.

           The aforementioned factors ($2.3 million of the workers compensation
charge and all of the increase in bad debt expense) contributed to the decline
in Same Hospitals operating margins. Operating expenses at the Company's Same
Hospitals were 87.2% of net revenue in 1999 as compared to 84.2% in 1998, and
operating margins were 12.8% and 15.8%, respectively. The Company believes that
the increase in bad debt expense resulted from (i) the shift in payor mix from
traditional Medicare, which has minimal bad debts, to managed care and self-pay
patients, (ii) a general trend in payment delays and denial of claims by managed
care payors, which increased the allowance for doubtful accounts, (iii) the
residual effect of the computer system conversion at certain facilities in the
early part of the year and (iv) business office turnover at certain facilities.
While the Company is unable to predict whether the current trend in bad debt
expense will continue, the Company has undertaken a number of actions to
mitigate the increase in bad debts. These actions include strengthening hospital
business office operations, pursuing litigation on past due accounts,
particularly with respect to certain managed care payors, and modifying
admittance policies at selected hospitals.

         Interest expense decreased $1.6 million from $51.8 million in 1998 to
$50.2 million in 1999, due to the repayment of all amounts outstanding under the
senior credit facilities in October 1999 and reductions in amounts outstanding
under the commercial paper program, offset by increased borrowings under such
facilities during the year. The increased borrowings were used primarily to fund
facility expansion, Year 2000 expenditures and working capital.

         Depreciation and amortization expense increased $1.3 million from $38.3
million in 1998 to $39.6 million in 1999, primarily due to the acquisition of
DHHS on July 1, 1998 and additions to property and equipment. This increase was
partially offset by a decrease in depreciation and amortization from facilities
sold in 1999.

         Income before income taxes, discontinued operations and extraordinary
charge was $25.8 million for the year ended December 31, 1999 and included a net
gain on sale of facilities of $77.5 million and a net unusual charge of $4.2
million. The gain on sale of facilities resulted from the sale of the Utah
Facilities, Senatobia and the Convalescent Hospitals, which was partially offset
by a loss from the final net working capital adjustment and prepayment discount
on notes receivable related to the sale in 1998 of LA Metro (see Item 8. Note
4). The net unusual charge, as more fully discussed in Item 8. Note 3, consisted
of (i) a $5.5 million corporate restructuring charge relating to employee
termination costs, service contract cancellation and the write-down of certain
deferred costs, leasehold improvements and redundant equipment, (ii) a $2.2
million charge associated with the execution of the Executive Agreement, (iii) a
$2.0 million charge in the fourth quarter associated with litigation expenses
and the write-down to net realizable value of a note receivable and other
assets, all of which were related to sold facilities, offset by (iv) a $5.5
million gain from the settlement of the Shareholder Litigation.

         Loss before income taxes, discontinued operations and extraordinary
charge for the year ended December 31, 1998, was $1.9 million and reflected (i)
an impairment charge of $1.4 million to write-down certain long lived assets to
fair value, (ii) minority interest of $4.1 million, attributable to DHHS offset
by (iii) a net unusual gain of $6.6 million primarily from the settlement of a
capitation contract ($7.5 million) offset by net charges from the execution of
the Executive Agreement, the restructuring of home health operations, severances
and the settlement of litigation ($863,000) and (iv) a net gain of $6.8 million
on sale of facilities.

         The Company recorded an income tax provision for income from continuing
operations of $54.2 million in 1999 and $693,000 in 1998. The total provision
for income taxes in 1999 includes an increase




                                       37
<PAGE>   38

in income tax provision of $26.8 million from providing an additional valuation
allowance to reserve all remaining net deferred tax assets as of December 31,
1999. See more discussion in "Valuation Allowance on Deferred Tax Assets." Of
the $26.8 million, $24.7 million was applied to increase the income tax
provision on income from continuing operations and $2.1 million was applied to
eliminate income tax benefits on losses from discontinued operations and an
extraordinary loss. As a result, no income tax benefits have been recognized on
the losses from discontinued operations and the extraordinary loss recorded in
1999. The income tax provision in 1999 differed from the statutory rate due to
(i) the aforementioned increase in the valuation allowance (ii) nondeductible
goodwill associated with the sale of the Utah Facilities, (iii) nondeductible
expenses from the settlement of Shareholder Litigation and from goodwill
amortization, which were partially offset by (iv) a non-taxable gain related to
the execution of the Executive Agreement. Income tax expense in 1998 differed
from the statutory rate due to nondeductible goodwill amortization and expenses
related to the Shareholder Litigation, partially offset by a decrease in
valuation allowance.

         In 1999, the Company recorded a loss from discontinued operations of
$1.0 million (no tax benefits), or $0.02 per share, resulting from certain
Medicare contractual adjustments related to the discontinued psychiatric
operations sold in 1998. In 1998, the Company recorded a loss from discontinued
operations of $2.4 million (net of tax of $1.7 million), or $0.04 per share, to
reflect the settlement of litigation concerning alleged violations of certain
Medicare rules.

         Net loss was $33.6 million, or $0.60 per diluted share, in 1999,
compared to $6.2 million, or $0.11 per diluted share, in 1998. Net loss included
an extraordinary charge for the write-off of deferred loan costs of $4.2 million
(no tax benefits), or $0.07 per share, in 1999 and $1.2 million (net of tax
benefits of $816,000), or $0.02 per share, in 1998, relating to the early
extinguishment of debt in those respective years. Weighted average common and
common equivalent shares outstanding were 56.0 million and 55.1 million in 1999
and 1998, respectively. The increase in common and common equivalent shares
reflects the weighted average effect of shares of common stock issued in
connection with the settlement of the Shareholder Litigation.

LIQUIDITY AND CAPITAL RESOURCES

         Net cash provided by operating activities before reorganization costs
was $11.5 million for the year ended December 31, 2000, compared to cash used in
operations of $43.5 million for the same period in 1999. The $55.0 million
increase in cash provided by operating activities before payment of
reorganization costs resulted primarily from the suspension of interest payments
on the Notes in 2000 and unique or significantly higher cash outflows in 1999 to
(i) pay down amounts outstanding under the former commercial paper program in
conjunction with the sale of the Utah Facilities, (ii) provide cash collateral
to secure letters of credit outstanding under an interim credit facility, (iii)
fund Executive Agreements with certain former senior officers and (iv) repay
amounts due under the Medicare/Medicaid programs. Including reorganization
costs, net cash provided by operating activities was $4.6 million in 2000. The
Company expects to pay future reorganization costs from internally generated
cash from operations and existing cash balances. Net cash used in investing
activities was $5.2 million during 2000 compared to net cash provided by
investing activities of $253.3 million during 1999. The $258.5 million decrease
was primarily attributable to net cash received from the disposition of
hospitals in 1999 of $282.1 million compared to $7.9 million in 2000. Cash
attributable to investing activities also reflected a $19.0 million decline in
capital expenditures, primarily as a result of hospital divestitures in 1999,
and to a lessor extent, liquidity constraints resulting from the Company's
restructuring process. Net cash used in financing activities during 2000 was
$5.0 million compared to net cash used in financing activities of $199.1 million
during 1999. This decrease resulted primarily from the repayment of all amounts
outstanding under the senior credit facilities in 1999 in conjunction with the
sale of the Utah facilities




                                       38
<PAGE>   39

and other dispositions. In 2000, the Company also incurred $2.4 million in
deferred financing cost associated with the Credit Facility.

         The Company has retained an investment banking firm to review its
strategic alternatives following its emergence from Chapter 11 bankruptcy
protection, including, among others, the possible disposition of some or all of
the Company's hospital assets. The investment banking firm is still in the
preliminary stages of its work, and the Board of Directors of the Company has
not approved any strategic recommendations from the firm. The Company cannot
predict the ultimate outcome of this initiative.

         On May 16, 2000, certain subsidiaries of the Company entered into the
Credit Facility with a lending group that provides a $62.0 million revolving
credit and letter of credit guaranty facility expiring May 15, 2003. The Credit
Facility was used to refinance obligations outstanding under the Company's prior
off-balance sheet commercial paper financing program, to replace existing
letters of credit outstanding under the previously existing interim financing
arrangement and to fund normal working capital and certain capital expenditures
of the Company's hospitals. The Credit Facility is an obligation of certain of
the Company's subsidiaries and is collateralized by all of those entities'
patient receivables (as defined), certain other assets of the Company and a
first lien on two of its hospitals. Accordingly, the Credit Facility is not an
obligation of PHC. Borrowings under the Credit Facility bear interest at prime
plus 1.5% or LIBOR plus 3.75% per annum and are limited to the hospitals'
eligible patient receivables and certain operating measurements, as defined. The
Company is obligated to pay certain commitment fees based upon amounts borrowed
and available for borrowing during the terms of the Credit Facility. The Company
also is subject to certain default provisions and a covenant on certain minimum
levels of cash generated from operations. The Company was not in compliance with
certain covenants under the Credit Facility for the month ending December 31,
2000. The Company subsequently received waivers for all such violations. The
weighted average borrowing rate under the Credit Facility was 10.4% for the year
ended December 31, 2000.

         The termination of the off-balance sheet commercial paper program
effectively resulted in the Company's reacquisition of $32.0 million in accounts
receivable previously sold to an unaffiliated trust on a non-recourse basis,
which was financed with borrowings under the Credit Facility. At December 31,
2000, the Company had $30.0 million in outstanding borrowings under the Credit
Facility and $7.7 million in outstanding letters of credit, which are fully
secured by cash collateral held by a collateral agent for the benefit of the
lenders.

         As of May 30, 2001, the Company had $4.5 million in borrowing capacity
under the Credit Facility. The Company anticipates that internally generated
cash from operations and existing cash balances will be sufficient to fund the
hospitals' working capital requirements through 2001. Capital expenditures
during the last three years were financed primarily through additional
borrowings, asset sales and internally generated funds. Due to the liquidity
issues previously discussed, there can be no assurance that the Company will
have sufficient resources to finance its capital expenditure program in 2001.

         On October 12, 1999, the Company repaid all borrowings outstanding
under its senior credit facilities in conjunction with the sale of the Utah
Facilities, or $223.5 million, and repaid borrowings of $12.8 million under its
commercial paper program.

LITIGATION

           A subsidiary of the Company is a defendant in two law suits alleging
certain violations of Federal and North Dakota wage and hour laws for the period
1994 through 1998 at the Fargo, North Dakota hospital. The actions currently
pending are Sister Colette Werlinger, et al., vs. Champion




                                       39
<PAGE>   40

Healthcare Corporation, et al., Civ. NO. 97-2466 (District Court, County of
Cass, State of North Dakota) and Sister Juliana Wisnewski, et al., vs. Champion
Healthcare Corporation, et al., Civil No. A3-96-72 in the United States District
Court for the District of North Dakota, Southeastern Division, on appeal as
Shelly Reimer, et al. vs. Champion Healthcare Corporation, et al., Case No.
00-2413 in the United States 8th Circuit Court of Appeals. The federal case was
certified as a Fair Labor Standards Act collective action in 1999, and the state
case was granted class action status in 1998. In January 2000, the federal court
granted the Company's motion for summary judgment for all but one of the federal
claims. The federal issue not dismissed involved a computation error on the part
of the Company that had been voluntarily corrected. Related liquidated damages
were subsequently settled with the payment of an immaterial amount. The parties
have appealed the federal trail court's summary judgment rulings to the 8th
Circuit Court of Appeals. In November 2000, the state court issued a ruling that
increased the number of individuals covered under the class action and the scope
of the potential damages to which the Company might be subject in the event of
an adverse jury verdict. Attempts to settle this matter have been unsuccessful
to date, although discussions are ongoing. In the fourth quarter of 2000, the
Company recorded an unusual charge of $2.7 million to accrue for its estimated
liability with respect to this matter. The Company has also incurred an
additional $655,000 in legal fees related to this matter.

         On April 26, 2001, the Company learned that a private person acting on
behalf of the United States had filed a civil damages action under seal in
February 1996 against many defendants throughout the United States, including a
subsidiary of the Company, Paracelsus Fentress County General Hospital, Inc.
("Fentress"), in the United States District Court for the Eastern District of
Pennsylvania. The complaint alleged that Fentress and the other defendants
committed violations of the federal civil False Claims Act by using inaccurate
codes to obtain higher reimbursement from Medicare for treating certain types of
pneumonia. The complaint seeks an unspecified amount of money damages,
penalties, costs and reasonable attorney's fees and other unspecified relief.

         The United States has not intervened in the case, and Fentress has not
been formally served with the complaint. Before learning of the complaint,
Fentress had been involved in discussions with the Federal government regarding
a review of pneumonia claims filed with the Medicare program by Fentress for
years 1992-1997 with a view to a possible settlement of the issue. Based on the
results of the Company's independent review, the Company has accrued $800,000
for potential settlement costs associated with this matter.

         Also on April 26, 2001, the Company learned that an unidentified
private person acting on behalf of the United States had filed a civil damages
action under seal in July 2000 against the Company and Fentress in the United
States District Court for the Middle District of Tennessee. The complaint
alleged that Fentress committed violations of the federal civil False Claims Act
by using inaccurate codes to obtain higher reimbursement from Medicare for
treating certain medical conditions and that the Company assisted Fentress. The
complaint seeks money damages of not less than $5 million, treble the amount of
damages, penalties and other unspecified relief. The Company is in the
preliminary stages of its review of this matter and is unable to predict at this
time what impact, if any, this action will have on the Company's financial
condition, results of operations or liquidity.

         The Company is subject to claims and legal actions by patients and
others in the ordinary course of business. The Company believes that all such
claims and actions are either adequately covered by insurance or will not have a
material adverse effect on the Company's financial condition, results of
operations or liquidity.



                                       40
<PAGE>   41

VALUATION ALLOWANCE ON DEFERRED TAX ASSETS

         The Company considers prudent and feasible tax planning strategies in
assessing the need for a valuation allowance. As of December 31, 2000, a
valuation allowance for the full amount of the net deferred tax asset was
recorded due to issues affecting liquidity and related uncertainties discussed
herein, which, if unfavorably resolved, will adversely affect the Company's
future operations on a continuing basis. As a result of PHC's Chapter 11
bankruptcy filing, the realization of the tax assets may be substantially and
permanently impaired. The future realization of the deductible temporary
differences and net operating loss carryforwards depends, among other things, on
the Company's ability to develop and consummate an acceptable and sustainable
financial structure and the existence of sufficient taxable income within the
carryforward period.

         At December 31, 2000, the Company had net operating loss carryforwards
of $197.6 million for U.S. Federal income tax purposes that will expire in
varying amounts from 2010 to 2020, if not utilized. As a result of the Company's
Chapter 11 Bankruptcy filing, upon the Effective Date the Company expects to
realize a material amount of cancellation of indebtedness ("COD") income.
However, because PHC is in bankruptcy, it will not be required to include COD
income in taxable income but rather will be required to reduce its NOLs and
possibly certain other tax attributes, including the tax basis of assets by the
amount of the COD income. Furthermore, the issuance of common stock under the
Amended Plan will result in an ownership change and thus, subject to certain
exceptions applicable to Chapter 11 Bankruptcy proceedings, the Company's
utilization of its remaining NOLs may be subject to an annual limitation. The
Company is currently reviewing its options under the Tax Code. Accordingly,
future limitation on NOLs can not be determined at this time.

INDUSTRY OUTLOOK

         The general hospital industry in the United States and the Company's
hospitals continue to have significant unused capacity, and thus there is
substantial competition for patients. Inpatient utilization continues to be
negatively affected by payor-required pre-admission authorization and by payor
pressure to maximize outpatient and alternative healthcare delivery services for
less acutely ill patients. Increased competition, admission constraints and
payor pressure are expected to continue.

         In some markets nurse and medical support personnel availability has
become a significant operating issue to health care providers. This shortage may
require the Company to enhance wages and benefits to recruit and retain nurses
and other medical personnel or to hire more expensive temporary personnel. There
can be no assurance as to future availability and cost of qualified medical
personnel.

          The ongoing challenge facing the Company and the healthcare industry
as a whole is to continue to provide quality patient care in an environment of
rising costs, strong competition for patients and a general reduction of
reimbursement rates by both private and government payors. Because of national,
state and private industry efforts to reform healthcare delivery and payment
systems, the healthcare industry as a whole faces increased uncertainty. The
Company is unable to predict whether any new healthcare legislation at the
federal and/or state level will be passed in the future and what action it may
take in response to such legislation, but it continues to monitor all proposed
legislation and analyze its potential impact in order to formulate the Company's
future business strategies.

OTHER REGULATORY MATTER

         On March 9, 1998, the SEC entered a formal order authorizing a private
investigation, In re Paracelsus Healthcare Corp., FW-2067. Pursuant to the
formal order, the staff of the SEC's Fort Worth District Office is investigating
the accounting and financial reporting issues that were the subject of the


                                       41
<PAGE>   42

internal inquiry described in the Company's 1996 Form 10-K filed in April 1997.
The Company is cooperating with the staff of the SEC.

IMPACT OF INFLATION

         The healthcare industry is labor intensive. Wages and other expenses
increase during periods of inflation and when shortages of qualified personnel
in the marketplace occur. The Company has attempted to abate increases in other
operating costs by increasing charges, expanding services and implementing cost
control measures to curb increases in operating costs. The Company's ability to
increase prices is limited by various Federal and state laws that establish
payment limitations for hospital services rendered to Medicare and Medicaid
patients and by other factors. The Company's ability to increase prices may also
be affected by its need to remain competitive. There can be no assurance that
the Company will be able to continue to offset such future cost increases.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

        As previously discussed, PHC filed a voluntary petition for protection
under Chapter 11 of the Bankruptcy Code on September 15, 2000. Consequently,
principal and interest due under the Notes and the Park Note are subject to
compromise. While the fair values of the Company's debt obligations have
declined significantly in 2000 as a result of the Chapter 11 proceedings, such
amounts do not reflect any adjustments that might result from resolutions of the
Chapter 11 proceedings. Under the Bankruptcy Code, actions to collect
pre-petition indebtedness against the PHC are subject to an automatic stay and
other contractual obligations against the PHC may not be enforced.

        The Company's only exposure to market risk is changes in the general
level of U.S. interest rates. To mitigate the impact of fluctuations in US
interest rates, the Company generally maintains in excess of 90% of the
borrowings under its Credit Facility at a fixed rate by borrowing on a fixed
term basis. As of December 31, 2000, the Company's remaining debt obligations
(see Item 8. Notes 7 and 8) had fixed interest rates ranging from 6.51% to 10.5%
and have no earnings exposure to changes in interest rates. The Company does not
hold or issue derivative instruments for trading purposes and is not a party to
any instruments with leverage features.





                                       42
<PAGE>   43





ITEM 8.     FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

                          INDEX TO FINANCIAL STATEMENTS

<TABLE>
<CAPTION>

                                                                                                           PAGE
                                                                                                           ----
<S>                                                                                                         <C>
   Paracelsus Healthcare Corporation Consolidated Financial Statements:
   Report of Independent Accountants..................................................................      44
   Report of Independent Auditors.....................................................................      45
   Consolidated Balance Sheets - December 31, 2000 and 1999...........................................      46
   Consolidated Statements of Operations - for the years ended December 31, 2000, 1999
        And 1998......................................................................................      48
   Consolidated Statements of Stockholders' Equity (Deficit) - for the years ended
         December 31, 2000, 1999 and 1998.............................................................      49
   Consolidated Statements of Cash Flows - for the  years ended December 31, 2000,
        1999 and 1998.................................................................................      50
   Notes to Consolidated Financial Statements.........................................................      52
</TABLE>





                                       43
<PAGE>   44


                        REPORT OF INDEPENDENT ACCOUNTANTS




To the Board of Directors and
Stockholders of Paracelsus Healthcare Corporation


In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of operations, stockholders' equity (deficit) and cash
flows present fairly, in all material respects, the financial position of
Paracelsus Healthcare Corporation at December 31, 2000, and the results of its
operations and its cash flows for the year ended December 31, 2000, in
conformity with accounting principles generally accepted in the United States of
America. In addition, in our opinion, the financial statement schedule listed in
the index appearing under Item 14(a)(2) on page 84, presents fairly in all
material respects the information set forth therein when read in conjunction
with the related consolidated financial statements. These financial statements
and financial statement schedule are the responsibility of the Company's
management; our responsibility is to express an opinion on these financial
statements and financial statement schedule based on our audits. We conducted
our audits of these statements in accordance with auditing standards generally
accepted in the United States of America, which require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for our opinion. The
financial statements and the related financial statement schedule listed in the
index appearing under Item 14(a)(2) of the Company as of December 31, 1999 and
for the years ended December 31, 1999 and 1998 were audited by other independent
accountants whose report dated March 30, 2000, expressed an unqualified opinion
on those statements but included an explanatory paragraph that referred to
substantial doubt about the Company's ability to continue as a going concern.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 2 to the
consolidated financial statements, the Company has suffered recurring losses
from operations, negative working capital, and defaults under the Company's
senior subordinated indenture agreement and certain other financing agreements.
Management's plans concerning these matters are also discussed in Note 2. The
uncertainties associated with these matters raise substantial doubt about the
Company's ability to continue as a going concern. The consolidated financial
statements do not include adjustments that might result from the outcome of
these uncertainties.



/s/  PricewaterhouseCoopers LLP


May 11, 2001, except for the second
paragraph in Note 7, as to which
the date is June 5, 2001
Houston, Texas


                                       44
<PAGE>   45





                         REPORT OF INDEPENDENT AUDITORS


Board of Directors and Stockholders
Paracelsus Healthcare Corporation

We have audited the accompanying consolidated balance sheet of Paracelsus
Healthcare Corporation as of December 31, 1999, and the related consolidated
statements of operations, stockholders' equity and cash flows for each of the
two years in the period ended December 31, 1999. Our audits also included the
financial statement schedule listed in the index at Item 14(a)(2). These
financial statements and schedule are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements and schedule based on our audits.

We conducted our audits in accordance with auditing standards generally accepted
in the United States. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated financial position of Paracelsus
Healthcare Corporation at December 31, 1999, and the consolidated results of its
operations and its cash flows for each of the two years in the period ended
December 31, 1999, in conformity with accounting principles generally accepted
in the United States. Also, in our opinion, the related financial statement
schedule, when considered in relation to the basic financial statements taken as
a whole, presents fairly in all material respects the information set forth
therein.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As more fully described in
Note 2 to the consolidated financial statements, the Company incurred
significant operating losses in 1999 and had a working capital deficiency at
December 31, 1999. In addition, the Company is in default under its senior
subordinated indenture agreement and certain other financing agreements. These
conditions raise substantial doubt about the Company's ability to continue as a
going concern. (Management's plans in regard to these matters are also described
in Note 2.) The consolidated financial statements do not include adjustments, if
any, to reflect the possible future effects on the recoverability and
classification of assets or the amounts and classification of liabilities that
may result from the outcome of these uncertainties.




/s/ Ernst & Young LLP

Houston, Texas
March 30, 2000



                                       45
<PAGE>   46





                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                           CONSOLIDATED BALANCE SHEETS
                                  ($ in 000's)


<TABLE>
<CAPTION>

                                                                             DECEMBER 31,
                                                                      ------------------------
                                                                        2000            1999
                                                                      ---------      ---------
<S>                                                                   <C>            <C>
ASSETS
Current assets:
 Cash and cash equivalents ......................................     $  17,140      $  22,723
 Restricted cash ................................................         8,807         12,991
 Accounts receivable, net of allowance for doubtful
         accounts: 2000- $29,281; 1999- $27,553 .................        66,165         30,796
 Supplies .......................................................         8,735          8,655
 Refundable income taxes ........................................         6,321          6,152
 Prepaid expenses and other current assets ......................         8,171         14,212
                                                                      ---------      ---------
        Total current assets ....................................       115,339         95,529

Property and equipment (Note 8):
 Land and improvements ..........................................        14,575         14,704
 Buildings and improvements .....................................       192,526        189,544
 Equipment ......................................................       132,685        132,901
 Construction in progress .......................................         2,962          2,379
                                                                      ---------      ---------
                                                                        342,748        339,528
Less: Accumulated depreciation and amortization .................      (142,551)      (113,052)
                                                                      ---------      ---------
                                                                        200,197        226,476
Goodwill, net of accumulated amortization : 2000 - $13,332;
  1999 - $9,828 (Notes 3 and 4) .................................        71,068         87,684
Other assets ....................................................        19,895         27,369
                                                                      ---------      ---------

Total Assets ....................................................     $ 406,499      $ 437,058
                                                                      =========      =========
</TABLE>


                                   Continued.




                                       46
<PAGE>   47

                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                     CONSOLIDATED BALANCE SHEETS, CONTINUED
                                  ($ in 000's)

<TABLE>
<CAPTION>

                                                                              DECEMBER 31,
                                                                        ------------------------
                                                                          2000           1999
                                                                        ---------      ---------
<S>                                                                     <C>            <C>
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
 Accounts payable .................................................     $  34,113      $  35,563
 Accrued liabilities:
     Accrued salaries and benefits ................................         9,569          8,877
     Accrued interest .............................................           581         12,598
     Other ........................................................         9,805         11,549
 Long-term debt due within one year ...............................           471            654
 Long-term debt in default classified as current (Notes 2 and 7) ..         3,085        335,445
                                                                        ---------      ---------
     Total current liabilities ....................................        57,624        404,686

Long-term debt (Note 7) ...........................................        33,537          3,685
Liabilities subject to compromise (Note 2) ........................       373,012             --
Other long-term liabilities (Note 13) .............................        12,526         23,490
Commitments and contingencies (Note 13) ...........................            --             --

Stockholders' equity (deficit) (Notes 2 and 11):
 Preferred stock, $.01 par value per share, 25,000,000 shares
  authorized, none outstanding ....................................            --             --
 Common stock, no stated value, 150,000,000 shares
  authorized, 59,143,721 shares outstanding in 2000 and
  57,667,721 in 1999 ..............................................       216,047        215,761
 Additional paid-in capital .......................................        11,892         12,105
 Accumulated deficit ..............................................      (298,139)      (222,669)
                                                                        ---------      ---------
     Total stockholders' equity (deficit) .........................       (70,200)         5,197
                                                                        ---------      ---------

Total Liabilities and Stockholders' Equity (Deficit) ..............     $ 406,499      $ 437,058
                                                                        =========      =========
</TABLE>



                             See accompanying notes.




                                       47
<PAGE>   48
                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                       ($ in 000's, except per share data)

<TABLE>
<CAPTION>

                                                                          YEAR ENDED DECEMBER 31,
                                                               ------------------------------------------------
                                                                   2000             1999               1998
                                                               ------------      ------------      ------------
<S>                                                            <C>               <C>               <C>
Net Revenue ..............................................     $    369,151      $    516,537      $    664,058
Costs and expenses:
   Salaries and benefits .................................          162,834           219,012           276,200
   Other operating expenses ..............................          142,386           213,404           265,735
   Provision for bad debts ...............................           36,030            41,692            42,659
   Interest ..............................................           29,166            50,235            51,859
   Depreciation and amortization .........................           31,520            39,595            38,330
   Impairment charges (Note 3) ...........................           29,673                --             1,417
   Unusual items (Note 3) ................................            8,233             4,248            (6,637)
                                                               ------------      ------------      ------------
Total costs and expenses .................................          439,842           568,186           669,563
                                                               ------------      ------------      ------------
Loss before minority interests, reorganization costs,
   income taxes, discontinued operations, gain on the
   sale of healthcare operations and extraordinary loss ..          (70,691)          (51,649)           (5,505)
Gain on sale of healthcare operations (Note 4) ...........            2,955            77,454             6,825
Minority interests .......................................               --               (54)           (3,180)
                                                               ------------      ------------      ------------
Income (loss) before reorganization costs, income taxes,
   discontinued operations and extraordinary loss ........          (67,736)           25,751            (1,860)
Reorganization costs .....................................           (7,734)               --                --
                                                               ------------      ------------      ------------
Income (loss) before income taxes, discontinued
   operations and extraordinary loss .....................          (75,470)           25,751            (1,860)
Provision for income taxes (Note 6) ......................               --           (54,207)             (693)
                                                               ------------      ------------      ------------
Loss before discontinued operations
   and extraordinary loss ................................          (75,470)          (28,456)           (2,553)
Loss on discontinued operations (Note 5) .................               --            (1,019)           (2,424)
                                                               ------------      ------------      ------------
Loss before extraordinary loss ...........................          (75,470)          (29,475)           (4,977)
Extraordinary loss from early extinguishment of
   debt (Note 7) .........................................               --            (4,168)           (1,175)
                                                               ------------      ------------      ------------
Net loss .................................................     $    (75,470)     $    (33,643)     $     (6,152)
                                                               ============      ============      ============

Net loss per share - basic and assuming dilution:
   Continuing operations .................................     $      (1.29)     $      (0.51)     $      (0.05)
   Discontinued operations ...............................               --             (0.02)            (0.04)
   Extraordinary loss ....................................               --             (0.07)            (0.02)
                                                               ------------      ------------      ------------
Net loss per share .......................................     $      (1.29)     $      (0.60)     $      (0.11)
                                                               ============      ============      ============
</TABLE>


                             See accompanying notes.


                                       48




<PAGE>   49


                       PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
           CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
                  YEARS ENDED DECEMBER 31, 2000, 1999 AND 1998
                            ($ and shares in 000's)




<TABLE>
<CAPTION>

                                                                                      OTHER
                                             COMMON STOCK             ADDITIONAL    COMPREHEN-
                                     ----------------------------      PAID-IN        SIVE           ACCUMULATED
                                         SHARES         AMOUNT         CAPITAL        LOSS             DEFICIT          TOTAL
                                     ------------    ------------    ------------  ------------      ------------   ------------
<S>                                  <C>             <C>             <C>           <C>               <C>            <C>
Balance at January 1, 1998 .....           55,094    $    224,475    $        390  $         12      $   (182,874)  $     42,003
Exercise of stock options ......               17              61              --            --                --             61
Exercise of warrants ...........                7               7              --            --                --              7
Forfeiture of value options
 (Note 14) .....................               --          (1,566)             --            --                --         (1,566)
Change in unrealized gains on
 marketable securities, net of
 taxes .........................               --              --              --           (12)               --            (12)
Net loss .......................               --              --              --            --            (6,152)        (6,152)
                                                                                   ------------      ------------   ------------
Comprehensive loss .............                                                            (12)           (6,152)        (6,164)
                                     ------------    ------------    ------------  ------------      ------------   ------------
Balance at December 31, 1998 ...           55,118         222,977             390            --          (189,026)        34,341
Common stock issued/
 transferred in connection with
 the settlement of Shareholder
 Litigation (Notes 3 and 11) ...            1,549           1,840          11,715            --                --         13,555
Issuance of common stock in
 connection with termination
 of certain advisory and service
 agreements (Notes 3 and 11) ...            1,000           1,188              --            --                --          1,188
Forfeiture of value options
 (Notes 3 and 11) ..............               --         (10,244)             --            --                --        (10,244)
Net loss .......................               --              --              --            --           (33,643)       (33,643)
                                     ------------    ------------    ------------  ------------      ------------   ------------
Balance at December 31, 1999 ...           57,667         215,761          12,105            --          (222,669)         5,197
Exercise of stock options ......              177               2              --                                              2
Stock grant ....................            1,300             284            (284)           --                               --
Amortization of stock grant ....               --              --              71            --                --             71
Net loss .......................               --              --              --            --           (75,470)       (75,470)
                                     ------------    ------------    ------------  ------------      ------------   ------------
Balance at December 31, 2000 ...           59,144    $    216,047    $     11,892  $         --      $   (298,139)  $    (70,200)
                                     ============    ============    ============  ============      ============   ============
</TABLE>





                             See accompanying notes.



                                       49
<PAGE>   50




                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  ($ in 000's)

<TABLE>
<CAPTION>

                                                                                     YEAR ENDED DECEMBER 31,
                                                                       ------------------------------------------------
                                                                          2000               1999              1998
                                                                       ------------      ------------      ------------
<S>                                                                    <C>               <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss .........................................................     $    (75,470)     $    (33,643)     $     (6,152)
Adjustments to reconcile net loss to net cash provided by
 (used in) operating activities:
 Extraordinary loss ..............................................               --             4,168             1,175
 Disposal loss on discontinued operations ........................               --             1,019             2,424
 Minority interests ..............................................               --                54             3,180
 Gain on sale of facilities ......................................           (2,955)          (77,454)           (6,825)
 Reorganization costs ............................................            7,734                --                --
 Unusual items ...................................................            8,233             4,248            (6,637)
 Impairment charges ..............................................           29,673                --             1,417
 Depreciation and amortization ...................................           31,520            39,595            38,330
 Deferred income taxes ...........................................               --            52,737               609
 Changes in operating assets and liabilities, net of effects of
    acquisitions and divestitures:
     Accounts receivable .........................................           (3,369)            1,274            17,363
     Refundable income taxes, net ................................             (169)            1,213               333
     Supplies, prepaid expenses and other current assets .........            4,877            (5,834)            1,928
     Accounts payable and other accrued liabilities ..............           11,394           (30,846)          (52,402)
                                                                       ------------      ------------      ------------
Net cash provided by (used in) operating activities
    before reorganization costs ..................................           11,468           (43,469)           (5,257)
Reorganization costs paid to date ................................           (6,878)               --                --
                                                                       ------------      ------------      ------------
Net cash provided by (used in) operating activities ..............            4,590           (43,469)           (5,257)
                                                                       ------------      ------------      ------------

CASH FLOWS FROM INVESTING ACTIVITIES:
Sale of marketable securities ....................................               --                --             2,145
Acquisitions of facilities, net of cash acquired .................               --                --           (59,278)
Proceeds from disposal of facilities .............................            7,940           282,050            38,219
Additions to property and equipment, net .........................          (10,236)          (29,203)          (21,965)
Increase (decrease) in minority interests ........................               --               509            (4,355)
Increase in other assets .........................................           (2,879)              (49)           (5,106)
                                                                       ------------      ------------      ------------
Net cash provided by (used in) investing activities ..............           (5,175)          253,307           (50,340)
                                                                       ------------      ------------      ------------
</TABLE>

                                   Continued.


                                       50
<PAGE>   51

                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                CONSOLIDATED STATEMENTS OF CASH FLOWS, CONTINUED
                                  ($ in 000's)


<TABLE>
<CAPTION>
                                                                                  YEAR ENDED DECEMBER 31,
                                                                      ------------------------------------------------
                                                                         2000               1999              1998
                                                                      ------------      ------------      ------------
<S>                                                                   <C>               <C>               <C>
CASH FLOWS FROM FINANCING ACTIVITIES:
Borrowings (repayments) under Revolving Credit Facility, net .....          30,000           (83,282)           49,043
Termination of the commercial paper
 program .........................................................         (32,000)               --                --
Repayments of debt ...............................................            (647)         (115,777)           (5,759)
Deferred financing costs .........................................          (2,351)               --            (3,984)
Sale of common stock, net ........................................              --                --                68
                                                                      ------------      ------------      ------------
Net cash provided by (used in) financing activities ..............          (4,998)         (199,059)           39,368
                                                                      ------------      ------------      ------------

Increase (decrease) in cash and cash equivalents .................          (5,583)           10,779           (16,229)
Cash and cash equivalents at beginning of year ...................          22,723            11,944            28,173
                                                                      ------------      ------------      ------------
Cash and cash equivalents at end of year .........................    $     17,140      $     22,723      $     11,944
                                                                      ============      ============      ============
</TABLE>



Supplemental schedule of noncash investing and financing activities:



<TABLE>
<CAPTION>

                                                                                   YEAR ENDED DECEMBER 31,
                                                                      -----------------------------------------------
                                                                          2000             1999              1998
                                                                      ------------     ------------      ------------
<S>                                                                   <C>              <C>               <C>
Settlement of Shareholder Litigation (Note 3):
  Issuance of common stock .......................................    $         --     $      3,028      $         --
  Forfeitures of Value Options ...................................              --          (10,244)               --
  Common stock contributed by the Former Majority Shareholder ....              --           11,715                --
                                                                      ------------     ------------      ------------
                                                                      $         --     $      4,499      $         --
                                                                      ============     ============      ============
Details of businesses acquired in purchase transactions:
  Fair value of assets acquired ..................................    $         --     $         --      $     71,217
  Liabilities assumed ............................................              --               --           (11,939)
                                                                      ------------     ------------      ------------

Cash paid for acquisitions .......................................    $         --     $         --      $     59,278
                                                                      ============     ============      ============
Grant of common stock ............................................    $        284     $         --      $         --
                                                                      ============     ============      ============
Notes receivable from sale of hospitals ..........................    $         --     $      7,304      $     13,698
                                                                      ============     ============      ============
Debt assumed by purchaser of hospitals ...........................    $         --     $      2,952      $      3,239
                                                                      ============     ============      ============
Capital lease obligations ........................................    $        141     $      4,018      $      1,653
                                                                      ============     ============      ============
</TABLE>


                             See accompanying notes.



                                       51
<PAGE>   52




                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                DECEMBER 31, 2000

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

         ORGANIZATION - Paracelsus Healthcare Corporation ("PHC") was
incorporated in November 1980 for the principal purpose of owning and operating
acute care and related healthcare businesses in selected markets. PHC and its
subsidiaries are collectively referred to herein as the "Company." Prior to
August 16, 1996, the Company was wholly owned by Park Hospital GmbH (the "Former
Majority Shareholder"), a German Corporation wholly owned by Dr. Manfred G.
Krukemeyer, the Company's former Chairman of the Board of Directors (the "Former
Chairman"). On August 16, 1996, the Company acquired Champion Healthcare
Corporation ("Champion") (the "Merger") and completed an initial public equity
offering. As of December 31, 2000, the Company operated 10 hospitals with 1,287
licensed beds in seven states.

         PRINCIPLES OF CONSOLIDATION - The consolidated financial statements
include the accounts of the Company and its wholly-owned or majority-owned
subsidiaries and partnerships. All significant intercompany accounts and
transactions have been eliminated in consolidation. Investments in affiliates,
of which the Company owns more than 20% but not in excess of 50%, are recorded
on the equity method. Minority interests represent income allocated to the
minority partners' investment.

         USE OF ESTIMATES - The preparation of financial statements in
conformity with generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.

         CASH EQUIVALENTS - The Company considers highly liquid investments with
original maturities of three months or less to be cash equivalents.

         RESTRICTED CASH - The Company had restricted cash of $8.8 million and
$13.0 million at December 31, 2000 and 1999, respectively, as collateral for
outstanding letters of credit and in 1999 for payments of fees and interest
related to the commercial paper financing program and as collateral for
outstanding letters of credit.

         SUPPLIES - Supplies, principally medical supplies, are stated at the
lower of cost (first-in, first-out basis) or market.

         PROPERTY AND EQUIPMENT - Property and equipment are recorded at cost.
Depreciation is computed using the straight-line method over the estimated
useful lives of the land improvements (5-25 years), buildings and improvements
(5-40 years) and equipment (3-20 years). Leaseholds are amortized on a
straight-line basis over the lesser of the terms of the respective leases or
their estimated useful lives. Expenditures for renovations and other significant
improvements are capitalized; however, maintenance and repairs, which do not
improve or extend the useful lives of the respective assets, are charged to
operations as incurred. Depreciation expense was $21.7 million, $28.9 million
and $27.7 million for the years ended December 31, 2000, 1999 and 1998,
respectively.

         GOODWILL AND OTHER LONG-TERM ASSETS - Goodwill, representing costs in
excess of net assets acquired, is amortized on a straight-line basis over a
period of 20 to 35 years. Other long term assets



                                       52
<PAGE>   53

consist primarily of debt issue cost, deferred physician costs and notes
receivable from hospital dispositions. Debt issuance costs are amortized on a
straight-line basis (which approximates the interest method) over the term of
the related debt. Deferred physician costs are amortized on a straight line
basis over the applicable contractual period. Amortization expense was $9.8
million, $10.7 million and $10.6 million for the years ended December 31, 2000,
1999 and 1998, respectively. The Company regularly reviews the carrying value of
goodwill and other long-term assets in relation to the operating performance and
future undiscounted cash flows of the underlying hospitals. The Company records
to expense on a current basis any diminution in values of goodwill and other
long-term assets based on the difference between the sum of the future
discounted cash flows and net book value.

         NET REVENUE - Net revenue includes amounts estimated by management to
be reimbursable by Medicare under the Prospective Payment System and by Medicare
and Medicaid programs under the provisions of cost-reimbursement and other
payment formulas. Payments for services rendered to patients covered by such
programs are generally less than billed charges. Deductions from revenue are
made to reduce the charges to these patients to estimated receipts based on each
program's principles of payment/reimbursement. Final settlements under these
programs are subject to administrative review and audit by third parties.
Settlements under reimbursement agreements with third-party payers are estimated
and recorded in the period the related services are rendered. Laws and
regulations governing the Medicare and Medicaid programs are complex and subject
to interpretation. As a result, there is at least a reasonable possibility that
recorded estimates will change by a material amount. The estimated reimbursement
amounts are adjusted in subsequent periods as cost reports are prepared and
filed and as final settlements are determined (in relation to certain government
programs, primarily Medicare, this is generally referred to as the "cost report"
filing and settlement process). The adjustments to estimated reimbursement
amounts resulted in decreases to revenues of $3.2 million, $5.7 million and $1.3
million in 2000, 1999 and 1998, respectively. Approximately 49.8%, 48.5% and
53.6% of gross patient revenue for the years ended December 31, 2000, 1999 and
1998, respectively, related to services rendered to patients covered by Medicare
and Medicaid programs.

         The Company believes that it is in compliance with all applicable laws
and regulations and is not aware of any material pending or threatened
investigations involving allegations of potential wrongdoing other than those
items noted in Note 13. Compliance with such laws and regulations can be subject
to future government review and interpretation as well as significant regulatory
action including fines, penalties and exclusion from the Medicare, Medicaid and
Tricare programs.

         In the ordinary course of business, the Company renders services free
of charge to patients who are financially unable to pay for hospital care. The
value of these services rendered is not material to the Company's consolidated
results of operations.

         INCOME TAXES - The Company records its income taxes under the liability
method. Under this method, deferred income tax assets and liabilities are
recognized for the tax consequences of temporary differences by applying enacted
statutory tax rates applicable to future years to differences between the
financial statement carrying amounts and the tax bases of existing assets and
liabilities.




                                       53
<PAGE>   54




         NET LOSS PER SHARE - The following table (in 000's except per share
data) sets forth the computation of basic and diluted loss per share from
continuing operations as required by Statement of Financial Accounting Standards
("SFAS") No. 128, "Earnings per Share."

<TABLE>
<CAPTION>
                                                          2000            1999            1998
                                                        --------        --------        --------

<S>                                                     <C>             <C>             <C>
Numerator (a):
   Loss from continuing operations
      before extraordinary loss .................       $(75,470)       $(28,456)       $ (2,553)
   Loss on discontinued operations ..............             --          (1,019)         (2,424)
   Extraordinary charge .........................             --          (4,168)         (1,175)
                                                        --------        --------        --------
   Net loss .....................................       $(75,470)       $(33,643)       $ (6,152)
                                                        ========        ========        ========

Denominator:
   Weighted average shares used for basic
      earnings per share ........................         58,718          55,957          55,108
   Effect of dilutive securities:
      Employee stock options ....................             --              --              --
                                                        --------        --------        --------
   Dilutive potential common shares .............             --              --              --
                                                        --------        --------        --------
Shares used for diluted earnings per share ......         58,718          55,957          55,108
                                                        ========        ========        ========

Loss per share - basic and assuming dilution:
   Loss from continuing operations
      before extraordinary loss .................       $  (1.29)       $  (0.51)       $  (0.05)
   Loss on discontinued operations ..............             --           (0.02)          (0.04)
   Extraordinary charge .........................             --           (0.07)          (0.02)
                                                        --------        --------        --------
   Net loss .....................................       $  (1.29)       $  (0.60)       $  (0.11)
                                                        ========        ========        ========
</TABLE>

----------

(a) Amount is used for both basic and diluted earnings per share computations
since there is no earnings effect related to dilutive securities.

         Options to purchase 1,220,403 shares of the Company's common stock at a
weighted average exercise price of $3.95 per share and warrants to purchase
414,690 shares at the exercise price of $9.00 per share were outstanding during
the year ended December 31, 2000, but were not included in the computation of
diluted EPS because the options' exercise price was greater than the average
market price of the common shares. Under PHC's Amended Plan, all of the
Company's warrants, stock option plans and all options outstanding thereunder
will be canceled and rendered null and void upon the Effective Date, and the
holders of such options will neither receive nor retain any property on account
of such interests. (See Note 2).

         COMPREHENSIVE LOSS - Comprehensive loss for the year ended December 31,
1998 included a $12,000 loss related to unrealized losses on marketable
securities. Comprehensive loss for the years ended December 31, 2000 and 1999
was equal to reported net loss for those years.

         EMPLOYEE STOCK OPTIONS - The Company does not recognize stock option
compensation costs for its stock option plans. See Note 11 for pro forma
disclosures reflecting stock option compensation costs based on the fair value
of options.


                                       54
<PAGE>   55



NOTE 2. PROCEEDING UNDER CHAPTER 11 OF THE BANKRUPTCY CODE


         On September 15, 2000, PHC filed a voluntary petition for protection
under Chapter 11 of the Bankruptcy Code with the United States Bankruptcy Court
for the Southern District of Texas (Case no. 00-38590-H5-11). The bankruptcy
filing is limited to PHC, the parent company, and does not include any of PHC's
hospital subsidiaries. PHC elected to seek Bankruptcy Court protection in order
to facilitate the restructuring of its debt while continuing to maintain normal
business operations at PHC's hospital subsidiaries. PHC's decision to
restructure its debt was due to its highly leveraged capital structure. Despite
positive earnings before interest, taxes, depreciation, amortization and unusual
charges, the high interest burden severely restricted the Company's reinvestment
opportunities. In an effort to conserve capital and to preserve the normal
operations of the hospital subsidiaries, PHC did not make interest payments of
$33.5 million (including penalty interest) on the 10% Senior Subordinated Notes
(the "Notes") due February 15 and August 15, 2000, nor did PHC make an interest
payment of $468,000 due on the 6.51% subordinated note ("Park Note") on August
30, 2000. Both the Notes and the Park Note are subject to compromise as a result
of PHC's Chapter 11 bankruptcy filing.

         PHC's hospital subsidiaries did not file for bankruptcy protection and
have continued paying, in the ordinary and normal course of business, all wages,
benefits and other employee obligations, all debt and lease obligations, as well
as all outstanding and ongoing accounts payable to their contractors and
vendors. A $62.0 million credit facility (the "Credit Facility"), collateralized
at the subsidiary level, is not directly affected by PHC's bankruptcy filing.
The Company expects cash on hand, cash generated from operations and asset sales
to be sufficient to meet the net working capital and capital expenditure needs
of the hospital subsidiaries during the restructuring process.

         On October 2, 2000, PHC received approval from the Bankruptcy Court to
pay pre-petition and post-petition PHC's employee wages, salaries and benefits.
The Bankruptcy Court also approved orders granting authority, among other
things, to pay pre-petition claims of certain utilities. All other PHC
pre-petition liabilities are classified in the consolidated balance sheet as
liabilities subject to compromise. PHC continues to pay post-petition claims of
all vendors and providers in the ordinary course of business.

         Simultaneously with the commencement of its bankruptcy case, PHC filed
the initial plan of reorganization (the "Initial Plan") pursuant to which PHC
proposed to effect its capital restructuring. On November 2, 2000, after notice
and a hearing, PHC's Disclosure Statement under Section 1125 of the Bankruptcy
Code with Respect to the Initial Plan was approved, and PHC was authorized to
solicit the acceptance or rejection of the Initial Plan by creditors entitled to
vote. The Initial Plan was accepted by holders of the Notes, general unsecured
claims and common stock prior to December 8, 2000, the date originally set by
the Court for the hearing on confirmation of the Initial Plan. However, on
December 5, 2000, two proofs of claim aggregating approximately $94.0 million
were filed with the Court by a private person (the "Relator") on behalf of the
United States and California for alleged violations by PHC under the Federal
False Claims Act and the California False Claims Act (the "Claims"). The Claims
were based on a partially excised complaint in a qui tam action filed by the
Relator under seal in June 1998 in the United States District Court for the
Central District of California, Western Division, as Case No. 98-4564 (Shx) (the
"Qui Tam Action"). A material condition to the effectiveness of the Initial Plan
was that the aggregate amount of the allowed and disputed general unsecured
claims would not exceed $15.0 million. The aggregate amount of the Claims, as
filed, together with other claims filed that were not anticipated by PHC,
exceeded this cap. Accordingly, at PHC's request, on December 8, 2000, the Court
continued the hearing on confirmation of the Initial Plan to permit PHC to file,
and the Court to consider, an objection to and a motion to estimate the Claims.
On or about March 14, 2001, the United States and



                                       55
<PAGE>   56

California amended their proof of claims, thereby reducing the amounts sought
under the Claims to approximately $45.0 million in aggregate.

         To avoid the costs of further litigation and to proceed with
confirmation of PHC's plan of reorganization, on April 17, 2001, the Company
signed a settlement agreement with the United States, California and the Relator
to resolve their proofs of claim (the "Qui Tam Claims Settlement"). In general,
the principal settlement terms are the following: the United States, California
and the Relator agreed to grant the Company certain releases and to dismiss the
litigation against the Company pending in another federal court. The Company
agreed that the United States, California and the Relator would have allowed
general unsecured claims in the bankruptcy case in the aggregate amount of $5.5
million (the "Allowed Qui Tam Claims") and that the allowed claims would be
entitled to share with other allowed general unsecured claimants in the
distribution of 11.5% Senior Notes (due on August 15, 2005) (the "New Notes")
and common stock of reorganized PHC and a cash payment to be issued under the
Initial Plan. In connection therewith, the Company accrued $5.5 million at
December 31, 2000, which is included in "Liabilities Subject to Compromise." The
Company also agreed to enter into a five year Corporate Integrity Agreement with
the Office of Inspector General of the U.S. Department of Health and Human
Services. The Company denied any liability or wrongdoing. The settlement
agreement is the result of extensive, arm's-length negotiations between PHC, in
consultation with the creditors committee, and the Relator and the government
entities. The Court approved the settlement on May 22, 2001.

         On April 23, 2001, PHC filed the First Amended Chapter 11 Plan of
Reorganization (the "Amended Plan") reflecting changes made necessary by (i) the
Allowed Qui Tam Claims, together with other claims filed that were not
anticipated by PHC, and (ii) the downward revisions in the Company's projected
future operating results due to the opening of a competing hospital in the
Company's Fargo, North Dakota market in November 2000, which had a greater than
anticipated negative impact on the Company's results of operations. Upon the
effective date (the "Effective Date") of the Amended Plan, shares of PHC's
common stock held by existing equity holders will be canceled and rendered null
and void, and current equity holders will not receive stock or warrants, as had
previously been provided in the Initial Plan. PHC's current equity holders will
not receive or retain any property under the Amended Plan on account of such
equity interests. Also upon the Effective Date, PHC will merge into a wholly
owned subsidiary incorporated in Delaware and will cease to exist as a separate
company, and the wholly owned subsidiary will emerge from bankruptcy as
reorganized PHC and will be known as Clarent Hospital Corporation. Additionally,
all principal and interest outstanding on the Notes and allowed general
unsecured claims will be exchanged for (i) New Notes in the aggregate principal
amount of $130.0 million (ii) a cash payment, as defined in the Amended Plan,
and (iii) 100.0% of the new common stock issued by the reorganized PHC under the
Amended Plan. Interest on the New Notes shall accrue commencing on the Effective
Date. The Amended Plan incorporates the terms of the Qui Tam Claims Settlement.

         On May 25, 2001, the Bankruptcy Court approved the Amended Plan. The
effectiveness of the Amended Plan is subject to certain conditions, as defined
in the Amended Plan. Upon the Effective Date, reorganized PHC will take the
steps necessary to cease being subject to the periodic reporting requirements of
the federal securities law. Additionally, reorganized PHC will have a limited
number of stockholders and does not plan to list the New Notes on an exchange.
Therefore, PHC will not be required to file periodic public reports, although
the new board of directors may seek to voluntarily register its new common stock
with the SEC or to list the New Notes on an exchange at a future date and thus
become a publicly reporting company.


                                       56
<PAGE>   57

         Pursuant to the terms of a settlement agreement executed in connection
with the global settlement of shareholder litigation that became effective in
September 1999, the Park Note and accrued interest must convert to PHC's common
stock in the event PHC files a voluntary petition in bankruptcy. No shares of
common stock have been issued to Park at this time. See "Liabilities Subject to
Compromise" discussed below. Under the Amended Plan (i) the Park Note will be
deemed to have been converted to approximately 1.9 million shares of PHC's
common stock upon the filing of the Bankruptcy, (ii) the Park Note holder (Park
Hospital GmbH or "Park") will be deemed to have been issued the common stock in
accordance with the terms of the settlement and (iii) the Park Note will be
deemed to be cancelled. On the Effective Date, the 1.9 million shares of PHC
common stock will be deemed canceled and rendered null and void, and Park will
neither receive nor retain any property on account of such equity interests.

         The Amended Plan also contains a management retention plan (the
"Retention Plan") to enhance the ability of the Company to retain key management
employees during the restructuring period. Under the Retention Plan, bonuses
aggregating $1.0 million will be awarded, subject to certain conditions, to
certain key management employees. The Retention Plan provides that the retention
bonuses will be awarded in two equal amounts upon: (i) the Effective Date and
(ii) ninety days following the Effective Date. The Amended Plan and PHC's
Disclosure Statement are on file with the Bankruptcy Court and are available for
review and copying during the Bankruptcy Court's normal business hours.

         Under the Bankruptcy Code, actions to collect pre-petition indebtedness
from PHC are subject to an automatic stay and other contractual obligations
against PHC may not be enforced. In addition, PHC may assume or reject executory
contracts, including lease obligations, under the Bankruptcy Code. Parties
affected by the lease or contract rejections may file claims with the Bankruptcy
Court in accordance with procedures set forth in the Bankruptcy Code.

         "Liabilities Subject to Compromise" on the Company's consolidated
balance sheet reflect PHC liabilities incurred prior to the commencement of the
Chapter 11 proceeding and do not reflect liabilities of any of PHC's
subsidiaries. These liabilities, consisting primarily of long-term debt,
including the principal amounts of the Notes and the Park Note and accrued
interest through September 15, 2000, certain accounts payable, accrued
liabilities and post-termination benefit obligations to former officers and key
employees, represent the Company's estimate of known or potential claims to be
resolved in connection with the Chapter 11 proceedings. Such claims remain
subject to future adjustments based on negotiations, actions of the Bankruptcy
Court, further developments with respect to disputed claims, future rejection of
executory contracts or unexpired leases, determination as to the value of any
collateral for claims, treatment under the Amended Plan and other events.
Payment terms for these amounts as proposed in the Amended Plan are discussed
above.




                                       57
<PAGE>   58




         A summary of the principal categories of claims classified as
"Liabilities Subject to Compromise" as a result of the Chapter 11 proceeding
follows (in thousands):

<TABLE>

<S>                                                  <C>
10% Senior Subordinated Notes ..................     $    325,000
Unamortized deferred financing costs ...........           (5,544)
Accrued interest through September 15, 2000 ....           36,833
6.51% Subordinated Note ........................            7,185
Post-termination benefit obligations ...........            3,255
Vendor accounts payable ........................              183
Accrued litigation liabilities .................            6,100
                                                     ------------
    Total liabilities subject to compromise ....     $    373,012
                                                     ============
</TABLE>

         The financial statements do not include further adjustments, if any,
reflecting the possible future effects on the recoverability and classification
of assets or the amount and classification of liabilities that may result from
the outcome of the uncertainties associated with the Chapter 11 proceeding. If
the Chapter 11 proceeding had not been filed, the Company would have reported a
net working capital deficit of approximately $315.3 million at December 31,
2000. During the pendency of the Chapter 11 proceeding, the Company is not
recording the contractual amount of interest expense related to the Notes and
the Park Note after September 15, 2000. Contractual interest obligations
excluded from interest expense reported on the accompanying consolidated
statements of operations were $10.8 million for the year ended December 31,
2000.

         Due to cross default provisions, a hospital subsidiary's capital lease
obligation has been included in current liabilities in the Company's
consolidated balance sheet at December 31, 2000.

         At the Company's request, on October 26, 2000, the Bankruptcy Court
dismissed PHC Finance, Inc.'s Chapter 11 proceeding, which was filed on March
15, 2000.

NOTE 3. IMPAIRMENT CHARGES AND UNUSUAL ITEMS

         UNUSUAL ITEMS - In 2000, the Company recorded net unusual charges of
$8.2 million, which included (i) a $5.5 million charge to accrue for Allowed Qui
Tam Claims, (ii) a $3.4 million charge to reflect legal fees incurred and
estimated liability under a class action lawsuit brought against the Company's
Fargo, North Dakota facility alleging certain violations of Federal and North
Dakota wage and hour laws for the period 1994 through 1998 offset by (iii) a
gain of $622,000 on insurance proceeds received as a result of flood damage
sustained at the Fargo, North Dakota facility during 2000.

         In 1999, the Company recorded a net unusual charge of $4.2 million,
which included (i) a $2.2 million net charge associated with the execution of a
senior executive agreement (the "Executive Agreement") with certain former
officers (the "Senior Executives") of the Company, see Note 14, (ii) a $5.5
million corporate restructuring charge, discussed below, (iii) a $2.0 million
charge associated with litigation expenses and the write-down to net realizable
value of a note receivable and other assets, all of which were related to sold
facilities offset by (iv) a net gain of $5.5 million related to the settlement
of litigation (the "Shareholder Litigation") as discussed below.

         The restructuring charge was recorded in June 1999 as a result of the
Company's efforts to further reduce corporate overhead through the consolidation
and/or elimination of various corporate functions and contracts and a reduction
of corporate office space under lease. Such charge included $2.2 million for
employee termination costs, $1.3 million for the cancellation of certain lease
and maintenance contracts and $2.0 million for the write-down of certain
deferred costs, leasehold improvements and




                                       58
<PAGE>   59

redundant equipment. Costs totaling $185,000, which primarily related to the
cancellation of a service contract, remained in accrued expenses in the
accompanying Consolidated Balance Sheet as of December 31, 2000.

         In September 1999, the global settlement of the putative class and
derivative actions, collectively the Shareholder Litigation, arising out of the
Merger and two related public offerings became effective. In accordance with the
terms of the global settlement, the Company paid $14.0 million, which was funded
from insurance proceeds, to the class settlement fund for distribution to class
members and issued 1.5 million shares of common stock for purposes of
distribution to class members. The Former Majority Shareholder also transferred
8.7 million shares of the Company's common stock to certain former Champion
shareholders and 1.2 million shares of the Company's common stock for purposes
of distribution to class members. In addition, the Company made a payment of
$1.0 million in cash and issued 1.0 million shares of common stock to the Former
Chairman to terminate a service and advisory contract with him. With respect to
the issuance/transfer of the Company's common stock, the values assigned to the
shares issued/transferred were determined based on the quoted market value at
the time global settlement was executed.

         The settlement reduced the Company's existing and future obligations to
certain former officers and directors and terminated options, granted in
connection with the Merger, to purchase the Company's common stock of
approximately 1.4 million shares at $0.01 per share ("Value Options") and 2.8
million shares at $8.50 per share ("Market Options"). The Company, all class
members, the derivative plaintiffs, the separately represented former Champion
shareholders, the Former Majority Shareholder, the underwriter, and the affected
current and former officers and directors provided mutual releases of all claims
arising out of or related to the Merger and the related public offerings.

         During 1998, the Company recorded unusual items of $6.6 million
consisting primarily of (i) a gain of $7.5 million resulting from the settlement
with PacifiCare of Utah ("PacifiCare") regarding a dispute over administration
of a 1996 capitation agreement offset by (ii) a net charge of $863,000 resulting
from the execution of the Executive Agreement, the restructuring of certain home
health operations, severances and the settlement of a contract dispute and
litigation.

         IMPAIRMENT CHARGES - The Company recorded $29.7 million in impairment
charges during the fourth quarter of 2000 to write-down the book value of
certain assets to their estimated fair value. Approximately $25.8 million of
this charge was attributable to the Richmond, Virginia facility and was recorded
as a result of a decline in operating performance. The remaining impairment
charges consisted of (i) $1.9 million charge to write-down home health
operations at one facility, which were sold in January 2001 at no material gain
or loss to the Company, (ii) a $1.7 million charge to write-down certain clinic
assets at one facility, which are no longer in operation and (iii) a $268,000
charge to write-down certain other non hospital assets. Assets impaired included
$13.1 million of goodwill.

         During the fourth quarter of 1998, the Company recorded an impairment
charge of $1.4 million on two of its facilities to reduce the book value of
these facilities to their estimated fair value. The charge occurred as the
result of the deterioration of the home health operations at these facilities.


NOTE 4. ACQUISITIONS, DISPOSITIONS AND CLOSURES OF HOSPITALS

         ACQUISITIONS - On July 1, 1998, the Company completed the purchase of
Dakota Medical Foundation's 50% partnership interest in a general partnership
operating as DHHS for $64.5 million, including net working capital, thereby
giving the Company 100% ownership of DHHS. Prior to the purchase, the Company
owned 50% of DHHS and accounted for its investment under the equity method.




                                       59
<PAGE>   60

The transaction was accounted for as a step purchase acquisition. As the result
of the change in control of DHHS, the Company has recast its Consolidated
Statements of Operations to account for DHHS under the consolidated method of
accounting as though the transaction had occurred at the beginning of the year.
The Company's results of operations for the year ended December 31, 1998,
reflect minority interest of $4.1 million for the six-month period prior to the
change in control. The accompanying financial statements reflect the allocation
of purchase price based on the results of a third-party appraisal. Based on this
appraisal, the Company recorded goodwill of $24.7 million, which is being
amortized on a straight-line basis over an estimated useful life of 20 years.

         DISPOSITIONS AND CLOSURES - In December 2000, the Company sold its
minority interest in IASIS for $7.9 million, net of expenses, resulting in a
pretax gain of $3.3 million. The minority interest was acquired in 1999 in
conjunction with the sale of the Company's former operations in the Salt Lake
City area, as discussed further below. This gain was offset by $350,000 in
losses attributable to the write-down of certain notes received in conjunction
with a prior year disposition.

         Pursuant to a recapitalization agreement completed on October 8, 1999,
the Company sold 93.9% of the outstanding common stock of a wholly owned
subsidiary ("HoldCo") to JLL Healthcare, LLC, an affiliate of the private equity
firm of Joseph Littlejohn & Levy, Inc., for $280.0 million in cash, including
net working capital. The Company retained a minority interest in the outstanding
common stock of HoldCo, which owned substantially all of the assets of five
hospitals, with 640 licensed beds, and related facilities located in the Salt
Lake City area (the "Utah Facilities"). Subsequent to the closing of the
recapitalization agreement, IASIS Healthcare Corporation, a Tennessee
corporation, was merged with and into a wholly owned subsidiary of HoldCo, with
the HoldCo subsidiary as the surviving entity. Following the Merger, HoldCo
changed its name to IASIS Healthcare Corporation, in which the Company retained
a 5.8% minority interest.

         The recapitalization agreement was arrived at through an arm's length
negotiation. Net cash proceeds were used to eliminate all indebtedness then
outstanding under the Company's senior credit facilities totaling $223.5 million
and to reduce borrowings under the Commercial Paper program by $12.8 million.
The Company also eliminated $7.8 million in annual facility operating lease
payments at one of the Utah Facilities and $7.6 million in letter of credit
obligations. The Company recorded a pretax gain of $77.8 million, net of
allocated goodwill of $43.1 million, on the sale of the Utah Facilities.

         On September 30, 1999, the Company completed the sale of the stock of
Paracelsus Senatobia Community, Inc. ("Senatobia"), which owned and operated a
76-bed acute care hospital located in Mississippi. The sales price of
approximately $4.7 million, which included the sale of net working capital, was
paid by a combination of $100,000 in cash, $1.6 million in second lien
promissory notes, and the assumption by the buyer of approximately $3.0 million
in capital lease obligations and related lease guaranty payments. The Company
recorded a pretax gain of approximately $2.0 million on the sale of Senatobia.

         Effective June 30, 1999, the Company sold substantially all of the
assets of four skilled nursing facilities (collectively, the "Convalescent
Hospitals"). The facilities had 232 licensed beds. The sales price of
approximately $6.9 million, which excluded net working capital, was paid by a
combination of $3.0 million in cash and a $3.9 million second lien promissory
note. In connection with the sale, the Company paid $1.0 million to terminate a
lease agreement at one of the facilities. The Company recorded a pretax gain of
approximately $1.3 million on the disposition.

         Effective March 31, 1999, the Company sold the stock of Paracelsus
Bledsoe County Hospital, Inc. ("Bledsoe"), which operated a 32 licensed bed
facility located in Tennessee. The sales price of approximately $2.2 million,
including net working capital, was paid by a combination of $100,000 in




                                       60
<PAGE>   61

cash and the issuance by the buyer of $2.1 million in promissory notes. The
notes are collateralized by all outstanding common stock and assets of Bledsoe.
The Company recorded no material gain or loss on the Bledsoe disposition.

         On December 29, 1998, the Company terminated the lease and closed
Cumberland River Hospital South, a 41-bed acute care facility in Gainesboro,
Tennessee. The closure had no significant impact on the Company's financial
position or results of operations.

          On September 30, 1998, the Company completed the sale of substantially
all of the assets of the eight LA Metro hospitals (527 licensed beds and one
previously closed hospital). The purchase price of approximately $33.7 million,
which included the purchase of net working capital, was paid by a combination of
$16.5 million in cash, the assumption of approximately $3.2 million in debt, and
issuance by the purchaser of $9.9 million of secured promissory notes and an
additional secured second lien subordinated note in the principal amount of $3.8
million. In June 1999, the Company recorded a loss of $3.6 million in connection
with the sale of LA Metro. The charge resulted from the final settlement of net
working capital and the recognition of a prepayment discount on certain
promissory notes, which were repaid in full during the second quarter of 1999.

         On June 30, 1998, the Company completed the sale of substantially all
of the assets of Chico Community Hospital, Inc., which included a 123-bed acute
care hospital and a 60-bed rehabilitation hospital, both located in Chico,
California, (collectively, the "Chico Hospitals") for $25.0 million in cash plus
net working capital and the termination of a facility operating lease and
related letter of credit. The Company recorded a pretax gain of $7.1 million on
the disposition.

NOTE 5. DISCONTINUED OPERATIONS

         With the sale of the LA Metro facilities in September 1998, the Company
completed its previously announced plan to exit the psychiatric hospital
business. Such operations had been reported as discontinued operations since
September 1996. During 1998, losses of $4.4 million from operations of the
discontinued psychiatric hospitals were charged to the disposal loss accrual
previously established in September 1996. Accordingly, such losses were not
reflected in the Consolidated Statement of Operations.

         Loss from discontinued operations for the year ended December 31, 1999
reflected a charge of $1.0 million (no tax benefits) from certain Medicare
contractual adjustments related to the completion of prior year cost reports for
the discontinued psychiatric operations.

         Loss from discontinued operations of $2.4 million (net of tax benefit
of $1.7 million) for the year ended December 31, 1998 reflected the settlement
of litigation concerning alleged violations of certain Medicare rules at the
discontinued psychiatric facilities.




                                       61
<PAGE>   62




NOTE 6. INCOME TAXES

 The provision for income taxes consisted of the following ($ in 000's):

<TABLE>
<CAPTION>

                                                                      YEAR ENDED DECEMBER 31,
                                                             ----------------------------------------
                                                                2000         1999 (a)         1998
                                                             ----------     ----------     ----------
<S>                                                          <C>            <C>            <C>
Continuing operations:
Current:
   Federal .............................................     $       --     $    1,437     $       --
   State ...............................................             --             33             84
Deferred:
   Federal .............................................             --         45,603            520
   State ...............................................             --          7,134             89
                                                             ----------     ----------     ----------
Total income tax provision from continuing operations ..             --         54,207            693
Discontinued operations ................................             --             --         (1,685)
Benefit for extraordinary losses .......................             --             --           (816)
                                                             ----------     ----------     ----------
Total income tax provision (benefit) ...................     $       --     $   54,207     $   (1,808)
                                                             ==========     ==========     ==========
</TABLE>



----------

(a)  The provision for income taxes in 1999 included a charge of $26.8 million
     to establish a valuation allowance that offsets the Company's net deferred
     tax assets. Of this amount, $24.7 million was applied to increase the
     income tax provision on income from continuing operations and $2.1 million
     was applied to eliminate income tax benefits on losses from discontinued
     operations and an extraordinary loss. As a result, no income tax benefits
     have been recognized on the losses from discontinued operations and the
     extraordinary loss recorded in 1999.

         The following table reconciles the differences between the statutory
Federal income tax rate and the effective tax rate for continuing operations ($
in 000's):


<TABLE>
<CAPTION>

                                                                           YEAR ENDED DECEMBER 31,
                                                   ------------------------------------------------------------------------
                                                      2000          %          1999          %         1998           %
                                                   ---------    ---------    ---------   ---------   ---------    ---------

<S>                                                <C>          <C>          <C>         <C>         <C>          <C>
Federal statutory rate ........................    $ (26,415)       (35.0)   $   9,013        35.0   $    (651)       (35.0)
State income taxes, net of Federal income tax
  benefit .....................................       (4,528)        (6.0)       1,545         6.0        (112)        (6.0)
Non-deductible merger and litigation settlement
  costs(a) ....................................           --                        14          --       5,068        272.5
Non-deductible goodwill amortization ..........          801          1.1        1,278         5.0       1,488         80.0
Non-deductible impairment of
  goodwill(b) .................................        4,561          6.0           --          --          --           --
Non-deductible goodwill related to the sale of
  the Utah facilities(c) ......................           --           --       17,657        68.6          --           --
Adjustment to valuation allowance(d) ..........       25,581         33.9       24,700        95.9      (5,100)      (274.2)
                                                   ---------    ---------    ---------   ---------   ---------    ---------
Effective income tax rate .....................    $      --           --    $  54,207       210.5   $     693         37.3
                                                   =========    =========    =========   =========   =========    =========
</TABLE>

----------
(a)   Certain liabilities relating to the Shareholder Litigation were
      recharacterized as non-deductible for federal income tax purposes as a
      result of the global settlement.

(b)   Non-deductible impairment of goodwill related to a facility acquired in
      connection with the Merger.



                                       62
<PAGE>   63

(c)   Non-deductible goodwill related to certain sold Utah facilities that were
      acquired in connection with the Merger.

(d)   See discussion of valuation allowance below.

         The tax effects of temporary differences that give rise to significant
portions of the Federal and state deferred tax assets and liabilities are
comprised of the following ($ in 000's):


<TABLE>
<CAPTION>

                                                       DECEMBER 31,
                                                   ----------------------
                                                     2000          1999
                                                   ---------    ---------
<S>                                                <C>          <C>
DEFERRED TAX LIABILITIES:
 Accelerated depreciation ......................   $   6,428    $  21,249
                                                   ---------    ---------
  Total deferred tax liabilities ...............       6,428       21,249
                                                   ---------    ---------

DEFERRED TAX ASSETS:
 Allowance for bad debts .......................      (3,660)      (7,109)
 Accrued liabilities ...........................           8      (11,699)
 Net operating losses ..........................     (81,025)     (56,063)
 Other - net ...................................     (21,669)     (21,386)
                                                   ---------    ---------
  Total deferred tax assets ....................    (106,346)     (96,257)
 Valuation allowance for deferred tax assets ...      99,918       75,008
                                                   ---------    ---------
  Net deferred tax assets ......................      (6,428)     (21,249)
                                                   ---------    ---------

Net deferred tax assets ........................          --           --
Less: Current deferred tax assets ..............          --           --
                                                   ---------    ---------
Long-term deferred tax assets ..................   $      --    $      --
                                                   =========    =========
</TABLE>

         The Company considers prudent and feasible tax planning strategies in
assessing the need for a valuation allowance. As of December 31, 1999, a
valuation allowance for the full amount of the net deferred tax asset was
recorded due to issues affecting liquidity and related uncertainties discussed
in Note 2, which, if unfavorably resolved, will adversely affect the Company's
future operations on a continuing basis. The provision for income taxes in 1999
includes a charge of $26.8 million to establish a valuation allowance that
offsets the Company's net deferred tax assets. The benefit for income taxes
recorded in 2000 was offset in full by the recognition of a valuation allowance
to fully reserve net deferred tax assets resulting from 2000 operating losses.
As a result of the Company's Chapter 11 bankruptcy, the realization of the tax
assets may be substantially and permanently impaired. The future realization of
the deductible temporary differences and net operating loss carryforwards
depends on the Company's ability to develop and consummate an acceptable and
sustainable financial structure and the existence of sufficient taxable income
within the carryforward period.

         At December 31, 2000, the Company had net operating loss carryforwards
of $197.6 million for U.S. Federal income tax purposes that will expire in
varying amounts from 2010 to 2020, if not utilized. Additionally, U.S. Federal
income tax law limits a corporation's ability to utilize net operating losses if
it experiences an ownership change of greater than 50% over a three-year period.
As a result of the Company's Chapter 11 Bankruptcy filing, upon the Effective
Date the Company expects to realize a material amount of cancellation of
indebtedness ("COD") income. However, because PHC is in bankruptcy, it will not
be required to include COD income in taxable income but rather will be required
to reduce its NOLs and possibly certain other tax attributes, including the tax
basis of assets by the amount of the COD income. Furthermore, the issuance of
common stock under the Amended Plan will result in an ownership change and thus,
subject to certain exceptions applicable to Chapter 11 Bankruptcy proceedings,
the Company's utilization of its remaining NOLs may be subject to an annual
limitation. The Company is currently reviewing its options under the Tax Code.
Accordingly, future limitation on NOLs can not be determined at this time.



                                       63

<PAGE>   64

         The Company made income tax payments, net of refunds, of $714,000 in
2000 and received income tax refunds, net of payments, $492,000 and $333,000 in
1999 and 1998 respectively.

NOTE 7. LONG TERM DEBT

         The 10% Senior Subordinated Notes and the 6.51% Subordinated Note
summarized below have been classified as liabilities subject to compromise as a
result of PHC's Chapter 11 bankruptcy filing on September 15, 2000. The
Company's long-term debt consisted of the following ($ in 000's):

<TABLE>
<CAPTION>

                                                                             DECEMBER 31,
                                                                       -----------------------
                                                                          2000          1999
                                                                       ---------     ---------

<S>                                                                    <C>           <C>
Revolving Credit Facility .........................................    $  30,000     $      --
10% Senior Subordinated Notes .....................................      325,000       325,000
6.51% Subordinated Note ...........................................        7,185         7,185
Capital lease obligations (See Note 8) ............................        7,093         7,599
                                                                       ---------     ---------
                                                                         369,278       339,784
Less long-term debt in default classified as current liabilities ..       (3,085)     (335,445)
Less long-term debt subject to compromise .........................     (332,185)           --
Less long-term debt due within one year ...........................         (471)         (654)
                                                                       ---------     ---------
Total long-term debt ..............................................    $  33,537     $   3,685
                                                                       =========     =========
</TABLE>


         SENIOR CREDIT FACILITIES - On May 16, 2000, certain subsidiaries of the
Company entered into a new credit agreement with a lending group that provides a
$62.0 million revolving credit and letter of credit guaranty facility expiring
May 15, 2003. The Credit Facility was used to refinance obligations outstanding
under the Company's prior off-balance sheet commercial paper financing program,
to replace existing letters of credit outstanding under the previously existing
interim financing arrangement and to fund normal working capital and certain
capital expenditures of the Company's hospitals. The Credit Facility is an
obligation of certain of the Company's subsidiaries and is collateralized by all
of those entities' patient receivables (as defined), certain other assets of the
Company and a first lien on two of its hospitals. Accordingly, the Credit
Facility is not an obligation of PHC. Borrowings under the Credit Facility bear
interest at prime plus 1.5% or LIBOR plus 3.75% per annum and are limited to the
hospitals' eligible patient receivables and certain operating measurements, as
defined. The Company is obligated to pay commitment fees of 0.375% based upon
amounts available for borrowing during the terms of the Credit Facility, subject
to certain conditions, as defined. The Company also is subject to certain
default provisions and a covenant on certain minimum levels of cash generated
from operations. The Company was not in compliance with certain covenants under
the Credit Facility for the month ending December 31, 2000. The Company
subsequently received waivers for all such violations. The weighted average
borrowing rate under the Credit Facility was 10.4% for the year ended December
31, 2000.

         The termination of the off-balance sheet commercial paper program
effectively resulted in the Company's reacquisition of $32.0 million in accounts
receivable previously sold to an unaffiliated trust on a non-recourse basis,
which was financed with borrowings under the Credit Facility (See Note 9). At
December 31, 2000, the Company had $30.0 million in outstanding borrowings under
the Credit Facility and $7.7 million in outstanding letters of credit, which are
fully secured by cash collateral held by a collateral agent for the benefit of
the lenders. The Company recorded deferred financing costs of $2.4 million in
connection with the Credit Facility.

         On October 12, 1999, the Company repaid all borrowings outstanding
under its senior credit facilities in conjunction with the sale of the Utah
Facilities, or $223.5 million. The senior credit facilities



                                       64
<PAGE>   65

were comprised of a revolving credit facility and two term loans (Tranches A and
B). The weighted average borrowing rates for the year ended December 31, 1999
were 8.02%, 7.94% and 8.10% under the Revolving Credit Facility, Tranche A and
Tranche B, respectively. The Company recorded an extraordinary charge of $4.2
million, no tax benefits, from the write-off of deferred financing costs due to
early extinguishment of debt under the senior credit facilities.

         During the first quarter ended March 31, 1998, the Company recognized
an extraordinary charge for the write-off of deferred financing costs of $1.2
million, net of tax benefits of $816,000, relating to the credit facility in
existence prior to March 30, 1998.

         SENIOR SUBORDINATED NOTES - On August 16, 1996, the Company completed a
$325.0 million registered offering of 10% Senior Subordinated Notes, which are
general unsecured senior subordinated obligations of the Company and are not
guaranteed by any of its subsidiaries. The Notes are subject to compromise as a
result of PHC's Chapter 11 bankruptcy filing on September 15, 2000. Accordingly,
the principal amount of the Notes ($325.0 million) and related accrued interest
($36.3 million) have been presented as "Liabilities Subject to Compromise" in
the Company's Consolidated Balance Sheet as of December 31, 2000. The Notes are
scheduled to mature on August 15, 2006. The Notes are not subject to any
mandatory redemption and may not be redeemed prior to August 15, 2001.

         6.51% SUBORDINATED NOTE - Pursuant to an agreement made in conjunction
with the Merger, the Former Majority Shareholder received the Park Note, a $7.2
million 6.51% subordinated unsecured note from the Company. Under the terms of a
settlement agreement executed in connection with the global settlement of
shareholder litigation, the Park Note and accrued interest thereon convert to
PHC's common stock in the event PHC files a voluntary petition in bankruptcy. No
shares of common stock have been issued to Park at this time. Under the Amended
Plan, (i) the Park Note will be deemed to have been converted to approximately
1.9 million shares of PHC's common stock upon the filing of the Bankruptcy, (ii)
the Park Note holder will be deemed to have been issued the common stock in
accordance with the terms of the settlement and (iii) the Park Note will be
cancelled. On the Effective Date, the 1.9 million shares of PHC common stock
will be deemed canceled and rendered null and void, and Park will neither
receive nor retain any property on account of such equity interests. As a result
of PHC's Chapter 11 bankruptcy filings (see Note 2), the principal amount of the
Park Note and related accrued interest ($0.5 million) have been presented as
"Liabilities Subject to Compromise" in the Company's Consolidated Balance Sheet
as of December 31, 2000.

         Due to cross default provisions, a hospital subsidiary's capital lease
obligation has been included in current liabilities in the Company's
consolidated balance sheet at December 31, 2000.

         OTHER DEBT - Other debt at December 31, 2000 and 1999 consisted
primarily of capital lease obligations. These obligations mature in various
installments through 2031 at interest rates ranging from 8.65% to 10.5% as of
December 31, 2000 and 1999, respectively.




                                       65
<PAGE>   66




         The following table summarizes maturities of long-term debt outstanding
as of December 31, 2000 for the next five years and thereafter, excluding
amounts in default classified as current liabilities or amounts classified as
liabilities subject to compromise as a result of PHC's Chapter 11 bankruptcy
filing.

<TABLE>

<S>                   <C>
2001 .............    $   471
2002 .............        410
2003 .............     30,375
2004 .............        107
2005 .............         27
Thereafter .......      2,618
                      -------
    Total ........    $34,008
                      =======
</TABLE>

         The Company paid interest of $ 4.1 million, $50.2 million and $51.7
 million during 2000, 1999 and 1998, respectively.

NOTE 8. LEASES

         The Company leases property and equipment under cancelable and
non-cancelable leases. Future minimum operating and capital lease payments as of
December 31, 2000, including amounts relating to leased hospitals, for the next
five years and thereafter were ($ in 000's):



<TABLE>
<CAPTION>

               YEARS ENDED DECEMBER 31,       OPERATING         CAPITAL
               ------------------------     ------------     ------------
<S>                                         <C>              <C>
2001 (a) ...............................    $      2,251     $        774
2002 ...................................           1,364              675
2003 ...................................             591              615
2004 ...................................             299              335
2005 ...................................             242              238
Thereafter .............................           1,536            6,158
                                            ------------     ------------
Total minimum future payments ..........    $      6,283            8,795
                                            ============
Less amount representing interest ......                           (4,787)
                                                             ------------
                                                                    4,008
Less current portions ..................                             (471)
                                                             ------------
Long-term capital lease obligations ....                     $      3,537
                                                             ============
</TABLE>

----------

(a) Excludes $4.8 million, including interest of $1.7 million, of future minimum
lease payments under a capital lease obligation in default.



         The following summarized amounts relate to assets leased by the Company
under capital leases ($ in 000's):

<TABLE>
<CAPTION>

                                           DECEMBER 31,
                                   ------------------------------
                                       2000              1999
                                   ------------      ------------
<S>                                <C>               <C>
Property & equipment .........     $      8,863      $     10,331
Accumulated depreciation .....           (3,314)           (3,406)
                                   ------------      ------------
    Net book value ...........     $      5,549      $      6,925
                                   ============      ============
</TABLE>

         Depreciation of assets under capital leases is included in depreciation
and amortization in the Consolidated Statements of Operations. Rental expense
was $5.5 million, $15.6 million and $23.2 million for 2000, 1999 and 1998,
respectively.




                                       66
<PAGE>   67




NOTE 9. SALE OF ACCOUNTS RECEIVABLE

         A subsidiary of the Company formerly had an agreement with an
unaffiliated trust (the "Trust") to sell the Company's hospital eligible
accounts receivable (the "Eligible Receivables") on a nonrecourse basis to the
Trust, hereafter referred to as the Commercial Paper program. The Commercial
Paper program was terminated on May 16, 2000, with amounts outstanding
thereunder refinanced with borrowings under the Credit Facility (See Note 7).
Consequently, the accompanying balance sheet as of December 31, 2000, reflects
offsetting increases in accounts receivable and long-term debt of $32.0 million.

         Eligible receivables sold at book value to the Trust at no gain or loss
at December 31, 1999 were $31.0 million. Interest expense charged to the Trust
related to the Commercial Paper program was passed through to the Company and
included as interest expense in the Company's Consolidated Statement of
Operations. Interest expense incurred by the Company related to this program was
$0.7 million, $2.2 million and $2.0 million for the years ended December 31,
2000, 1999 and 1998 respectively.

NOTE 10. CREDIT RISK AND FAIR VALUE OF FINANCIAL INSTRUMENTS

         CREDIT RISK - Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of accounts
receivable. Credit risk on accounts receivable is limited because a majority of
the receivables are due from governmental agencies, commercial insurance
companies and managed care organizations. The Company continually monitors and
adjusts its reserves and allowances associated with these receivables.

         FAIR VALUES OF FINANCIAL INSTRUMENTS - All financial instruments are
held for purposes other than trading. The estimated fair values of all financial
instruments, other than long-term debt, approximated their carrying amounts due
to the short-term maturity of these instruments. The carrying amount and fair
value of long-term debt are as follows ($ in 000's):

<TABLE>
<CAPTION>

                                                                   DECEMBER 31,
                                         ---------------------------------------------------------------
                                                     2000                              1999
                                         -----------------------------     -----------------------------
                                           CARRYING          FAIR            CARRYING           FAIR
                                            AMOUNT           VALUE            AMOUNT           VALUE
                                         ------------     ------------     ------------     ------------
<S>                                      <C>              <C>              <C>              <C>
Long-term Debt:
  Revolving Credit Facility ........     $     30,000     $     30,000     $         --     $         --
  10% Senior Subordinated Notes ....          325,000          113,750          325,000          188,500
  6.51% Subordinated Note ..........            7,185              (a)            7,185            4,400
</TABLE>

(a) See Note 2 for a discussion of the impact of PHC's bankruptcy filing on the
6.51% Subordinated Note.

         The fair values of the Credit Facility approximated the carrying
amounts since the interest rate was based on a current market rate. The fair
value of the Notes is based on the quoted market price. The fair value of the
remaining debt, where applicable, was estimated using discounted cash flow
analyses based on the Company's current incremental borrowing rate for similar
types of borrowing arrangements.

         As of May 16, 2001, the fair value of the Notes based on the quoted
market price was $107.3 million.



                                       67
<PAGE>   68





NOTE 11. STOCKHOLDERS' EQUITY

         COMMON AND PREFERRED STOCK - The Company has 150.0 million authorized
shares of common stock, no stated value per share. Each share is entitled to one
vote and does not have any cumulative voting rights. The Company is also
authorized to issue 25.0 million shares of preferred stock at $0.01 par value
per share, which may be issued in such series and have such rights, preferences
and other provisions as may be determined by the Board of Directors without
approval by the holders of common stock. No preferred shares are currently
outstanding.

         Under PHC's Amended Plan, all shares of common stock currently
outstanding will be canceled and rendered null and void upon the Effective Date,
and PHC's current equity holders will neither receive nor retain any property on
account of such equity interests. (See Note 2).

         In connection with the global settlement of Shareholder Litigation
effective September 2, 1999, the Company issued 1.5 million shares of common
stock for purposes of distribution to class members and 1.0 million shares of
common stock to the Former Chairman to terminate a service and advisory contract
with him. The Company recorded unusual charges of $3.0 million related to the
shares issued based upon the quoted market value of the Company's common stock
at the time the global settlement was executed.

         In March 2000 the Company made a restricted stock grant of 1.3 million
shares of common stock to its Chief Executive Officer pursuant to his employment
agreement. The grant vests over a four year period. Total deferred compensation
cost associated with the grant was $284,000, which will be amortized over the
vesting period of such grant to the extent applicable. Under PHC's Amended Plan,
all shares of PHC common stock underlying the restricted stock grant will be
canceled and rendered null and void upon the Effective Date, and the Chief
Executive Officer will neither receive nor retain any property on account of
such equity interests.

         STOCK OPTION PLANS - Under PHC's Amended Plan, all of the Company's
stock option plans and all options outstanding thereunder will be canceled and
rendered null and void upon the Effective Date, and the holders of such options
will neither receive nor retain any property on account of such interests.

         On July 15, 1996, the Company adopted the 1996 Stock Incentive Plan
(the "Incentive Plan") to provide stock-based incentive awards, including
incentive stock options, non-qualified stock options, restricted stock,
performance shares, stock appreciation rights and deferred stock, to directors,
key employees, consultants and advisors.

        In connection with the Merger, the Company granted 1.6 million Value
Options to certain directors and officers of the Company in addition to
aggregate cash payments of $20.7 million to terminate all phantom stock
appreciation rights and/or preferred stock units under a previously existing
stock incentive plan. Additionally, pursuant to the various employment
agreements, the Company also granted 1.2 million Value Options and 2.8 million
Market Options to certain senior executive officers. In connection with the
global settlement of Shareholder Litigation, 1.4 million Value Options and all
of the Market Options were cancelled (see Note 3). The issuance of the Value
Options was originally recorded as a merger expense in connection with the
Merger. Accordingly, the Company recorded a benefit of $10.2 million which was
included as a component of the $5.5 million net gain related to the settlement
of the Shareholder Litigation in unusual items, and a corresponding reduction in
common stock from the cancellation of the Value Options based upon the quoted
market value of the Company's common stock at the time the global settlement was
executed. The cancellation of the Market Options had no impact on the Company's
stockholders' equity or 1999 results of operations.




                                       68
<PAGE>   69

         As more fully discussed in Note 14, in connection the execution of the
Executive Agreement and subsequent resignation of the Senior Executives, 696,000
Value Options were cancelled.

         At December 31, 2000, there were 9.7 million shares of common stock
reserved for exercise of options. Except for the Value Options as noted above,
stock options were generally granted at an exercise price equal to or in excess
of the estimated fair market value of the shares on the date of grant and expire
ten years from the grant date. The Value Options and options granted to
directors were fully vested on the date of grant, with the remaining options
vesting generally over a period of 3 to 4 years from the date of grant. Options
generally expire upon certain events (such as termination of employment with the
Company), except for Value Options, which remain exercisable until the end of
the 10-year option term. The following table presents the number of shares
covered by options outstanding and the related number of options granted,
assumed, exercised and canceled for each period in the three years ended
December 31, 2000 (in 000's, except per share amounts):


<TABLE>
<CAPTION>
                                                                               WEIGHTED
                                            NUMBER           EXERCISE          AVERAGE
                                              OF              PRICE            EXERCISE
                                           OPTIONS          PER SHARE           PRICE
                                         -----------      --------------     -----------
<S>                                      <C>              <C>                <C>
Outstanding at January 1, 1998 .....           7,555      $0.01 to $9.00     $      4.90
  Granted ..........................              --                  --              --
  Exercised ........................             (17)     $         3.56     $      3.56
  Canceled .........................            (156)     $3.92 to $9.00     $      4.96
  Forfeited ........................            (696)     $         0.01     $      0.01
                                         -----------

Outstanding at December 31, 1998 ...           6,686      $0.01 to $9.00     $      5.41
  Granted ..........................           1,105      $0.63 to  2.20     $      2.11
  Canceled .........................          (5,127)     $0.01 to $9.00     $      5.66
                                         -----------

Outstanding at December 31, 1999 ...           2,664      $0.01 to $9.00     $      3.51
  Exercised ........................            (177)     $         0.01     $      0.01
  Canceled .........................          (1,070)     $1.00 to $9.00     $      4.23
                                         -----------

Outstanding at December 31, 2000 ...           1,417      $0.01 to $9.00     $      3.40
                                         ===========
</TABLE>


         The number of options exercisable at December 31, 2000, 1999 and 1998
were 1.1 million, 1.8 million and 4.1 million, respectively. The following table
summarizes information concerning currently outstanding and exercisable options
as of December 31, 2000 (in 000's, except per share and time period amounts):

<TABLE>
<CAPTION>

                                 OPTIONS OUTSTANDING                                OPTIONS EXERCISABLE
        ------------------------------------------------------------------     -----------------------------
                                              Weighted
                                               Average          Weighted                         Weighted
            Range of                          Remaining         Average                          Average
            Exercise           Number        Contractual        Exercise         Number          Exercise
             Price          Outstanding         Life             Price         Exercisable        Price
        ---------------     -----------    --------------    -------------     -----------     -------------
<S>                         <C>            <C>               <C>               <C>             <C>
        $0.01                    197          6.85 years          $0.01            197             $0.01
        $0.63-$9.00            1,220          7.14 years          $3.94            885             $4.39
</TABLE>


         The weighted average grant-date fair values were $0.78 for options
granted during 1999 and $3.66 for options granted during 1997, using the
Black-Scholes option pricing model with the following



                                       69
<PAGE>   70

weighted-average assumptions for 1999 and 1997 respectively: risk-free interest
rates of 5.97% and 5.60%; dividend yields of 0.0%; volatility factors of the
expected market price of the Company's stock of 96.4% and 97.4%; and a
weighted-average expected life of the options of 4 years.

         The Black-Scholes option pricing model was developed for use in
estimating the fair value of traded options which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. Because the Company's employee stock options have characteristics
significantly different from those of traded options, and because changes in the
subjective input assumptions can materially affect the fair value estimate, in
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock options.

         For purpose of pro forma disclosures, the estimated fair value of the
options is amortized to expense over the options' vesting period. The Company's
pro forma information for 2000, 1999 and 1998 is as follows and includes
compensation expense of $397,000 (no tax effect), $751,000 (no tax effect) and
$4.1 million ($2.4 million after-tax), respectively, ($ in 000's, except for
earnings per share data):

<TABLE>
<CAPTION>

                                              2000               1999               1998
                                          ------------       ------------       ------------

<S>                                       <C>                <C>                <C>
Pro forma net loss .................      $    (75,867)      $    (34,394)      $     (8,597)
Pro forma net loss per share:
   Basic and assuming dilution .....      $      (1.29)      $      (0.61)      $      (0.16)
</TABLE>

         WARRANTS AND CONVERTIBLE SECURITIES - As of December 31, 2000, the
Company had outstanding warrants to purchase 414,690 shares of Common Stock at
an exercise price of $9.00 per share expiring December 31, 2003. Under PHC's
Amended Plan, warrants currently outstanding will be canceled and rendered null
and void upon the Effective Date, and the holders of such warrants will neither
receive nor retain any property on account of such interests.

NOTE 12. EMPLOYEE BENEFIT PLANS

         The Company has a defined contribution 401(k) retirement plan covering
all eligible employees at its hospitals and the corporate office. Participants
may contribute up to 20% of pretax compensation, not exceeding a limit set
annually by the Internal Revenue Service. The Company matches $.25 for each
$1.00 of employee contributions up to 6% of employees' gross salary and may make
additional discretionary contributions. Total expense for employer contributions
to the plan for 2000, 1999 and 1998 was $1.2 million, $1.2 million and $2.0
million, respectively.

         The Company has a supplemental executive retirement plan ("SERP") to
provide additional post-termination benefits to a selected group of management
and highly compensated employees. All claims outstanding under the SERP are
subject to compromise as a result of PHC's Chapter 11 bankruptcy filing and have
been presented as such in the accompanying consolidated balance sheet (see Note
2). The Company's obligations under the SERP will be treated as allowed general
unsecured claims and will be discharged on the Effective Date in accordance with
the provisions of the Amended Plan.

         As a result of a change in control from the Merger, officers and
employees of the Company who were participants in the SERP prior to the Merger
became fully vested in all benefits thereunder. In April 1997, the Board of
Directors elected to terminate the provision of future benefits for certain
participants under the plan, which resulted in a plan curtailment. As a result,
the Company incurred minimal expenses in 2000 and 1999 related to the plan. In
connection with the execution of the Executive




                                       70
<PAGE>   71

Agreement and the global settlement of the Shareholder Litigation, the Company
was released from SERP obligations to certain former senior executives. The
effect of this release is included as a component of the $5.5 million net gain
related to the settlement of the Shareholder Litigation included in unusual
items for the year ended December 31, 1999.

NOTE 13. COMMITMENTS AND CONTINGENCIES

         LITIGATION - The Company is subject to claims and legal actions by
patients and others in the ordinary course of business. The Company believes
that all such claims and actions are either adequately covered by insurance or
will not have a material adverse effect on the Company's financial condition,
results of operations or liquidity.

         On September 15, 2000, PHC filed a voluntary petition for protection
under Chapter 11 of the Bankruptcy Code with the United States Bankruptcy Court
for the Southern District of Texas (Case no. 00-38590-H5-11). The bankruptcy
filing is limited to PHC, the parent company, and does not include any of PHC's
hospital subsidiaries. See Note 2 for a more comprehensive discussion of this
matter.

         On December 5, 2000, two proofs of claim aggregating approximately
$94.0 million were filed with the Bankruptcy Court by a Relator on behalf of the
United States and California for alleged violations by PHC under the Federal
False Claims Act and the California False Claims Act. The Company agreed that
the United States, California and the Relator would have allowed general
unsecured claims in the bankruptcy case in the aggregate amount of $5.5 million
and that the allowed claims would be entitled to share with other allowed
general unsecured claimants in a distribution of New Notes and common stock of
reorganized PHC and a cash payment to be issued under the Plan. The Company also
agreed to enter into a five year Corporate Integrity Agreement with the Office
of Inspector General of the U.S. Department of Health and Human Services. See
Note 2 for a more comprehensive discussion of this matter.

         A subsidiary of the Company is a defendant in two law suits alleging
certain violations of Federal and North Dakota wage and hour laws for the period
1994 through 1998 at the Fargo, North Dakota hospital. The actions currently
pending are Sister Colette Werlinger, et al., vs. Champion Healthcare
Corporation, et al., Civ. NO. 97-2466 (District Court, County of Cass, State of
North Dakota) and Sister Juliana Wisnewski, et al., vs. Champion Healthcare
Corporation, et al., Civil No. A3-96-72 in the United States District Court for
the District of North Dakota, Southeastern Division, on appeal as Shelly Reimer,
et al. vs. Champion Healthcare Corporation, et al., Case No. 00-2413 in the
United States 8th Circuit Court of Appeals. The federal case was certified as a
Fair Labor Standards Act collective action in 1999, and the state case was
granted class action status in 1998. In January 2000, the federal court granted
the Company's motion for summary judgment for all but one of the federal claims.
The federal issue not dismissed involved a computation error on the part of the
Company that had been voluntarily corrected. Related liquidated damages were
subsequently settled with the payment of an immaterial amount. The parties have
appealed the federal trail court's summary judgment rulings to the 8th Circuit
Court of Appeals. In November 2000, the state court issued a ruling that
increased the number of individuals covered under the class action and the scope
of the potential damages to which the Company might be subject in the event of
an adverse jury verdict. Attempts to settle this matter have been unsuccessful
to date, although discussions are ongoing. In the fourth quarter of 2000, the
Company recorded an unusual charge of $2.7 million to accrue for its estimated
liability with respect to this matter. The Company has also incurred an
additional $655,000 in legal fees related to this matter.

         On April 26, 2001, the Company learned that a private person acting on
behalf of the United States had filed a civil damages action under seal in
February 1996 against many defendants throughout the United States, including a
subsidiary of the Company, Paracelsus Fentress County General Hospital,



                                       71
<PAGE>   72

Inc. ("Fentress"), in the United States District Court for the Eastern District
of Pennsylvania. The complaint alleged that Fentress and the other defendants
committed violations of the federal civil False Claims Act by using inaccurate
codes to obtain higher reimbursement from Medicare for treating certain types of
pneumonia. The complaint seeks an unspecified amount of money damages,
penalties, costs and reasonable attorney's fees and other unspecified relief.

         The United States has not intervened in the case, and Fentress has not
been formally served with the complaint. Before learning of the complaint,
Fentress had been involved in discussions with the Federal government regarding
a review of pneumonia claims filed with the Medicare program by Fentress for
years 1992-1997 with a view to a possible settlement of the issue. Based on the
results of the Company's independent review, the Company has accrued $800,000
for potential settlement costs associated with this matter.

         Also on April 26, 2001, the Company learned that an unidentified
private person acting on behalf of the United States had filed a civil damages
action under seal in July 2000 against the Company and Fentress in the United
States District Court for the Middle District of Tennessee. The complaint
alleged that Fentress committed violations of the federal civil False Claims Act
by using inaccurate codes to obtain higher reimbursement from Medicare for
treating certain medical conditions and that the Company assisted Fentress. The
complaint seeks money damages of not less than $5 million, treble the amount of
damages, penalties and other unspecified relief. The Company is in the
preliminary stages of its review of this matter and is unable to predict at this
time what impact, if any, this action will have on the Company's financial
condition, results of operations or liquidity.

         REGULATORY INVESTIGATION - On March 9, 1998, the U.S. Securities and
Exchange Commission (the "SEC") entered a formal order authorizing a private
investigation, In re Paracelsus Healthcare Corp., FW-2067. Pursuant to the
formal order, the staff of the SEC's Fort Worth District Office is investigating
the accounting and financial reporting issues that were the subject of the
internal inquiry described in the Company's 1996 Form 10-K filed in April 1997.
The Company is cooperating with the staff of the SEC.

         PROFESSIONAL AND LIABILITY RISKS - The Company is subject to claims and
suits in the ordinary course of business, including those arising from care and
treatment provided at its facilities. The Company maintains insurance and, where
appropriate, reserves with respect to the possible liability arising from such
claims. The Company is self-insured for the first $1.0 million per occurrence of
general and professional liability claims. Excess insurance amounts up to $50.0
million are covered by third party insurance carriers. The Company accrues an
estimated liability for its uninsured exposure and self-insured retention based
on historical loss patterns and actuarial projections.

         The Company believes that its insurance and loss reserves are adequate
to cover potential claims that may be asserted and that the outcome of such
claims will not have a material effect on the Company's financial position,
results of operations or liquidity.

         MEDICARE AND MEDICAID - Within the statutory framework of the Medicare
and Medicaid programs, there are substantial areas subject to administrative
rulings, interpretations and discretion that may affect payments made under
these programs. Funds received from these programs are subject to audit. These
audits can result in retroactive adjustments of such payments. It often takes
many years to make a final determination about the amounts earned under the
programs because of audits by the program representatives, providers' rights of
appeal and the application of numerous technical reimbursement provisions.
Management believes that adequate provision has been made for such adjustments.
There can be no assurance that future audits will not result in material
retroactive adjustments.





                                       72
<PAGE>   73




NOTE 14. CERTAIN RELATED PARTY TRANSACTIONS

         THE EXECUTIVE AGREEMENT - On November 25, 1998, the Company and its
then senior executives, Mr. Charles R. Miller, Mr. James G. VanDevender and Mr.
Ronald R. Patterson, collectively the Senior Executives, executed the Executive
Agreement superseding their existing employment contracts and certain other
stock option and retirement agreements with the Company. Under the Executive
Agreement, as amended, Messrs. Miller and Patterson remained in their management
positions with the Company until their resignation on June 30, 1999. Mr.
VanDevender entered into a separate employment agreement with the Company and
served as interim Chief Executive Officer effective July 1, 1999 until his
resignation from the Company on February 29, 2000.

         Pursuant to the Executive Agreement, the Company paid the Senior
Executives $501,000 in 1998 for amounts due under the SERP, and the Senior
Executives released the Company from any obligations under the SERP or any
similar retirement plan. In April 1999, the Company also paid the Senior
Executives $4.6 million, of which approximately $4.0 million was recorded
ratably to expense through June 30, 1999, the required-stay period. The
remaining amount of $645,000, which is associated with a non-compete arrangement
provided for in the Executive Agreement, was recorded as other assets and
amortized to expense over the non-compete period (one year) upon the Senior
Executives' separation of service. The Company and the Senior Executives
provided each other with mutual releases of any and all obligations either party
may have under the respective employment agreements or otherwise arising out of
the Senior Executives' employment.

         Pursuant to the Executive Agreement, the Senior Executives gave up all
rights to exercise or dispose of 696,000 Value Options that they received at the
time of the Merger. The Value Options were cancelled upon the Senior Executives'
resignation from the Company. The quoted market value of the Value Options upon
the execution of the Executive Agreement was approximately $1.6 million and was
recorded as a reduction to common stock. A corresponding liability of $1.6
million was amortized ratably to income over the required-stay period ended June
30, 1999.

         The Company recorded approximately $2.2 million and $352,000 of net
expenses related to the Executive Agreement, which was included in unusual
items, for the years ended December 31, 1999 and 1998, respectively.

         6.51% SUBORDINATED NOTE - The Former Majority Shareholder received the
 Park Note, a $7.2 million 6.51% subordinated note, from the Company in
 conjunction with the Merger, which is currently subject to compromise as a
 result of PHC's Chapter 11 bankruptcy filing on September 15, 2000 (See Note
 2). The Company did not pay interest on such note in 2000 and paid interest of
 $467,000 in 1999 and 1998, respectively.

         CONSULTING AGREEMENT - Effective August 1996, the Company was a party
to an agreement with the Former Chairman, pursuant to which he provided
management and strategic advisory services to the Company for an annual
consulting fee for a term not to exceed ten years. The Company paid the Former
Chairman consulting fees of $187,500 in 1999 and 1998. In connection with the
global settlement of the Shareholder Litigation, the Company paid the Former
Chairman $1.0 million in cash and issued to him 1.0 million shares of common
stock to terminate the agreement. The Company recorded unusual charges of $2.2
million relating therewith based on the value of the cash payment and the quoted
market value of the Company's common stock at the time the global settlement was
executed.

         INSURANCE AGREEMENT - The Company is also a party to an insurance
agreement that provides insurance benefits to the Former Chairman in the event
of his death or permanent disability benefits of $1.0 million per year during
the 10-year term of such agreement, which expires 2006. As a result of




                                       73
<PAGE>   74

PHC's Chapter 11 bankruptcy filing, the Company's obligation under this
agreement will be discharged as of the Effective Date in accordance with the
provisions of PHC's Amended Plan.

NOTE 15. QUARTERLY DATA (UNAUDITED)

         The following table summarizes the Company's quarterly financial data
for the years ended December 31, 2000 and 1999 ($ in 000's, except per share
data):

<TABLE>
<CAPTION>


                                                                                                     LOSS PER SHARE
                                       LOSS FROM                                       -------------------------------------------
                           NET        CONTINUING      DISCONTINUED        NET          CONTINUING     DISCONTINUED          NET
       QUARTERS          REVENUE      OPERATIONS       OPERATIONS         LOSS         OPERATIONS      OPERATIONS          LOSS
-------------------     ---------     ----------      ------------     ---------       ----------     ------------     -----------
<S>                     <C>           <C>             <C>              <C>             <C>            <C>              <C>
First Quarter -
 2000 (a) ........      $  95,084      $  (8,503)      $      --       $  (8,503)      $   (0.15)      $      --       $   (0.15)
 1999 (b) ........        150,944         (1,586)             --          (1,586)          (0.03)             --           (0.03)
Second Quarter -
 2000 (c) ........         91,039         (9,164)             --          (9,164)          (0.16)             --           (0.16)
 1999 (d)(e) .....        143,267         (7,609)             --          (7,609)          (0.14)             --           (0.14)
Third Quarter -
 2000 (f) ........         93,207        (11,485)             --         (11,485)          (0.20)             --           (0.20)
 1999 (g) ........        138,161         (3,376)           (601)         (3,977)          (0.06)          (0.01)          (0.07)
Fourth Quarter -
 2000 (h) ........         89,821        (46,318)             --         (46,318)          (0.78)             --           (0.78)
 1999(i) (j) .....         84,165        (15,885)           (418)        (20,471)          (0.28)          (0.01)          (0.36)
</TABLE>



----------

      a)    Includes reorganization costs of $2.5 million.

      b)    Includes an unusual charge of $1.1 million resulting from the
            execution of the Executive Agreement.

      c)    Includes reorganization costs of $1.8 million.

      d)    Includes a loss of $2.4 million on the sale of hospitals.

      e)    Includes unusual costs of (i) $1.1 million resulting from the
            execution of the Executive Agreement and (ii) $5.5 million relating
            to corporate restructuring charges.

      f)    Includes reorganization costs of $1.5 million.

      g)    Includes (i) an unusual gain of $5.5 million resulting from the
            settlement of the Shareholder Litigation and (ii) a gain of $2.0
            million on the sale of a hospital.

      h)    Includes (i) impairment charges of $29.7 million to write-down
            long-lived assets to fair value at certain facilities, (ii) $8.2
            million in unusual charges related to the Allowed Qui Tam Claims, a
            class action suit at one facility and a gain on insurance proceeds
            as a result of flood damage at one facility, (iii) a $3.0 million
            net gain on the sale of facilities and (iv) reorganization costs of
            $1.9 million.

      i)    Includes a gain of $77.8 million on the sale of the Utah Facilities
            and an increase in income tax provision of $26.8 million from the
            recording of a valuation allowance, which offsets the Company's net
            deferred tax assets. Of the $26.8 million, $24.7 million was
            reflected as an increase in the income tax provision on income from
            continuing operations and $2.1 million was applied to eliminate
            income tax benefits on losses from discontinued operations and an
            extraordinary loss.

      j)    Includes extraordinary loss from the early extinguishment of debt,
            (no tax effect) of $4.2 million.

         Quarterly operating results are not necessarily representative of
operations for a full year for various reasons including levels of occupancy,
fluctuations in interest rates, acquisitions and divestitures.



                                       74
<PAGE>   75

ITEM 9.     CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
                      ACCOUNTING AND FINANCIAL DISCLOSURE


         On March 15, 2001, the accounting firm, Ernst & Young LLP ("EY"),
resigned as the auditor of the financial statements of the Company. EY resigned
because statements made by a representative of the Creditors Committee in the
PHC bankruptcy hearings could in the future create the appearance that EY lacked
the necessary independence to remain as the auditors for the Company.

         During the two most recent fiscal years and through March 15, 2001 (the
"Reporting Period"), none of EY's reports on the Company's financial statements
contained an adverse opinion or a disclaimer of opinion, or were qualified or
modified as to uncertainty, audit scope or accounting principles except that the
report for the 1999 fiscal year included a paragraph expressing substantial
doubt about the Company's ability to continue as a going concern. During the
Reporting Period, there were no matters of disagreement with EY on any matters
of accounting principles or practices, financial statement disclosure, or
auditing scope or procedures that, if not resolved to the satisfaction of EY,
would have caused EY to make a reference to the matter in its reports on the
financial statements. In addition, during the Reporting Period there were no
"reportable events" as described in Item 304 (a)(1)(v) of Regulation S-K.

         The Company requested EY to furnish it with a letter addressed to the
Securities and Exchange Commission stating whether it agrees with the above
statements. A copy of EY's letter, dated March 16, 2001, was filed as an exhibit
to the Company's Form 8-K dated March 15, 2001

         On March 15, 2001, the Company engaged PricewaterhouseCoopers LLP as
its new accounting firm to audit the Company's financial statements. The
decision to engage PricewaterhouseCoopers LLP was approved by the Company's
Board of Directors and the Bankruptcy Court. During the Reporting Period,
PricewaterhouseCoopers LLP has not been engaged as either the principal
accountant of the Company to audit its financial statements or of any
significant subsidiary. During the Reporting Period, the Company has not
consulted with PricewaterhouseCoopers LLP about any of the matters listed in
Regulation S-K Item 304(a)(2)(i) or (ii).



                                       75
<PAGE>   76




                                    PART III

ITEM 10.     DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

         The information required by this Item regarding the Company's executive
officers is set forth under "Executive Officers of the Registrant" in Part I of
this Report.

         The Amended Plan provides that on the Effective date, the management
control and operation of the reorganized debtor shall become the general
responsibility of the board of directors of reorganized PHC. The initial board
of directors shall consist of five individuals to be designated prior to the
confirmation date. Directors so designated will serve until the first annual
meeting of stockholders of reorganized PHC and otherwise pursuant to the terms
of the certificate of incorporation and/or bylaws of reorganized PHC.

         The directors of the Company, their positions and offices, their
respective terms of office as directors, their respective ages and background
are as follows:

         LAWRENCE P. ENGLISH, age 60, a director since 1999 and Chairman of the
Board since February 2000. Mr. English's term expires at the 2001 annual meeting
of stockholders. Since June 2000, Mr. English has been Chairman and Chief
Executive Officer of Quadramed Corporation, a healthcare information and
technology company. Prior to assuming this position, Mr. English was President
of Lawrence P. English, Inc., a consulting and turnaround management firm. He
was the founder, Chairman and Chief Executive Officer ("CEO") of Aesthetics
Medical Management, Inc., a physician management company from 1997 to 1998. From
1992 to 1996, he was the president of Cigna Healthcare, a healthcare management
organization and a division of Cigna Corporation. Mr. English currently serves
as a director of Spacefitters, Inc., a Windsor, Connecticut based technology
company and Curative Health Services Inc., a Hauppauge, New York disease
management company. Mr. English has over 37 years of experience in the insurance
and health care industries.

         JOAN S. FORTUNE, age 53, a director since 1999 whose term expires at
the 2002 annual meeting of stockholders. From 1995 until 1999, she was retired
with no other position. Ms. Fortune was General Partner of Frontenac Company, a
venture capital firm from 1987 until her retirement in 1995. At Frontenac, Ms.
Fortune specialized in investments in healthcare products and services. Prior to
her time at Frontenac, she was a management consultant with Hayes/Hill, Inc. and
worked for more than 10 years in the healthcare industry at American Hospital
Supply Corporation, G.D. Searle & Co. and a research facility associated with
the University of Wisconsin.

         NOLAN LEHMANN, age 57, a director since 1998 whose term was to expire
at the 2000 annual meeting of stockholders. Mr. Lehmann is the President and
director of Equus Capital Management Corporation, an investment advisor firm
located in Houston, Texas, since 1983. Mr. Lehmann is also President and a
director of Equus II Incorporated, a registered investment company traded on the
New York Stock Exchange. Mr. Lehmann also serves as a director of Allied Waste
Industries, Inc. Mr. Lehmann holds graduate and undergraduate degrees in
accounting and economics from Rice University and is a Certified Public
Accountant.

         ROBERT W. MILLER, age 59, a director since 1999 whose term was to
expire at the 2000 annual meeting of stockholders. Mr. Miller was a partner with
the law firm of King & Spalding from 1985 until his retirement at the end of
1997. He currently serves as non-executive Chairman of the Board of Magellan
Health Services, Inc., a behavioral managed care company listed on the New York
Stock Exchange, and is a past president of the American Academy of Healthcare
Attorneys.



                                       76
<PAGE>   77

         HEINER MEYER ZU LOSEBECK, age 48, a director since 1998 whose term
expires at the 2001 annual meeting of stockholders. Dr. Meyer zu Losebeck is the
Managing Director of Paracelsus-Kliniken-Deutschland GmbH ("PKD"), Park, and
other affiliates of PKD. PKD owns and operates 26 hospitals ranging in size from
42 to 350 beds in Germany and Switzerland. Park owns approximately 34.5 percent
of the shares of the Company, and PKD owns all the shares of Park. From 1989
through August 1997, Dr. Meyer zu Losebeck was a tax consultant, auditor, and
chartered accountant at Dr. Mertens and Partners, Osnabruck, Germany.

         PETER SCHNITZLER , age 33, a director since 1999 whose term was to
expire at the 2000 annual meeting of stockholders. Mr. Schnitzler is the
Corporate Accountant of PKD. He has been employed by PKD (and its respective
legal predecessor) since 1993. Mr. Schnitzler has a graduate degree in finance,
auditing and hospital administration.


COMPLIANCE WITH SECTION 16(a) OF THE SECURITIES EXCHANGE ACT OF 1934

         During the year ended December 31, 2000, Dr. Meyer zu Losebeck did not
file on a timely basis Form 4 "Statement of Changes in Beneficial Ownership of
Securities" in connection with the termination of his executorship of Professor
Krukemeyer's estate, pursuant to which Dr. Meyer zu Losebeck formerly had voting
and dispositive power with respect to the shares of the Company's common stock
owned by Park-Hospital GmbH. In May 2001, Dr. Meyer zu Losebeck filed a Form 5
"Annual Statement of Changes in Beneficial Ownership" reporting the termination
of his executorship of Professor Krukemeyer's estate. Based solely upon
confirmations provided by the directors and executive officers of the Company
reporting transactions involving the Company's securities during the most recent
fiscal year, the Company believes that all other transactions by reporting
persons were reported on a timely basis. Based on shareholder filings, the
Company does not believe any other shareholders are subject to Section 16(a)
filing requirements.




                                       77
<PAGE>   78
ITEM 11.     EXECUTIVE COMPENSATION

         The following table summarizes the compensation with respect to all
services rendered to the Company during the calendar years indicated for its
Chief Executive Officer, its four most highly compensated executive officers and
Mr. VanDevender, the Company's former interim Chief Executive Officer, who
resigned from the Company effective February 29, 2000 (collectively the "Named
Executives").

                           SUMMARY COMPENSATION TABLE

<TABLE>
<CAPTION>
                                                                                   LONG-TERM
                                                                                  COMPENSATION
                                                      ANNUAL COMPENSATION            AWARDS
                                                  -------------------------       ------------
                                                                                                       ALL
                                                                                    SECURITIES        OTHER
                                                                                    UNDERLYING        COMPEN-
   NAME AND PRINCIPAL                                 SALARY          BONUS          OPTIONS          SATION
      POSITION                         YEAR            ($)             ($)             (#)            ($)(d)
------------------------------      ----------      ----------      ----------      ----------      ----------
<S>                                 <C>             <C>             <C>             <C>             <C>
Robert L. Smith (a)                       2000      $  333,896      $       --                      $   20,605
  Chief Executive Officer &
  Director

Lawrence A. Humphrey                      2000      $  280,000      $   70,000              --      $    2,987
  Executive Vice President &              1999         276,898         160,900         100,000           3,989
  Chief Financial Officer                 1998         268,427              --              --           2,375

Deborah H. Frankovich                     2000      $  206,667      $   44,810              --      $    3,381
  Senior Vice President &                 1999         197,428          75,998          75,000           2,883
  Treasurer                               1998         190,396              --              --           2,375

Steven D. Porter (b)                      2000      $  240,000      $   40,000              --      $    2,087
  Senior Vice President of                1999         200,000              --              --             787
  Operations

Robert M. Starling                        2000      $  206,667      $   29,810              --      $    2,670
  Senior Vice President &                 1999         195,987          75,998          75,000           3,329
  Controller                              1998         190,105              --              --           2,165

James G. VanDevender (c)                  2000      $   90,000      $       --              --      $   22,148(e)
  Former Senior Executive Vice            1999         457,500         125,000              --       1,324,466
  President & interim Chief               1998         370,313              --              --         108,005
  Executive Officer
</TABLE>



----------

(a)      Mr. Smith joined the Company as Chief Executive Officer and director
         effective March 27, 2000.

(b)      Mr. Porter resigned from the Company effective February 28, 2001. He
         had been employed by the Company since July 1, 1999.

(c)      Mr. VanDevender resigned from the Company effective February 29, 2000.

(d)      Represents relocation reimbursements, life insurance premiums and
         matching contributions paid by the Company under its Employee
         Retirement Savings 401(k) Plan and includes payments in 1998 for vested
         benefits under the supplemental executive retirement plan to Mr.
         VanDevender of $104,969 respectively.



                                       78
<PAGE>   79

(e)      1999 included payments of $1.3 million to Mr. VanDevender in connection
         with the Executive Agreement.

         OPTION GRANTS IN THE LAST FISCAL YEAR. The Company did not make any
stock option grants in 2000. The exercise prices on stock options previously
granted were not amended or adjusted. The Company has no outstanding stock
appreciation rights.


AGGREGATED OPTIONS EXERCISED IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION
VALUES

         No options were exercised by the Named Executives during 2000. The
following table sets forth the number of options held by the Named Executives
and their value at December 31, 2000. Under PHC's Amended Plan, all of the
Company's stock option plans and all options outstanding thereunder will be
canceled and rendered null and void upon the Effective Date, and the holders of
such options will neither receive nor retain any property on account of such
interests.

<TABLE>
<CAPTION>

                                              NUMBER OF SECURITIES                              VALUE OF UNEXERCISED
                                             UNDERLYING UNEXERCISED                                 IN-THE-MONEY
                                              OPTIONS AT FY-END (#)                            OPTIONS AT FY-END($)(a)
                                     --------------------------------------------    ----------------------------------------
               NAME                    EXERCISABLE            UNEXERCISABLE              EXERCISABLE         UNEXERCISABLE
------------------------------      -----------------   ------------------------     ------------------   -------------------
<S>                                 <C>                 <C>                          <C>                  <C>

Robert L. Smith                               --                     --                       --                    --
Lawrence A. Humphrey                     167,500                 62,500                       --                    --
Deborah H. Frankovich                    123,125                 46,875                       --                    --
Robert M. Starling                       123,125                 46,875                       --                    --
</TABLE>

----------
(a)  Market value of underlying securities at December 31, 2000 was below the
     option exercise price for all options outstanding.

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN

         The Company has a supplemental executive retirement plan ("SERP") to
provide additional post-termination benefits to selected members of management
and certain highly compensated employees.

         All claims outstanding under the SERP are subject to compromise as a
result of PHC's Chapter 11 bankruptcy filing and have been presented as such in
the accompanying consolidated balance sheet (see Note 2). The Company's
obligations under the SERP will be treated as an allowed general unsecured
claims and will be discharged on the Effective Date in accordance with the
provisions of the Plan.

         As a result of a change in control from the Merger, officers and
employees of the Company who were participants in the SERP prior to the Merger
became fully vested in all benefits thereunder. Pursuant to their respective
employment agreements, certain Champion executives became participants in the
SERP and received retroactive benefits for their years of service with Champion.
In April 1997, the Board of Directors elected to terminate the provision of
future benefits for certain participants under the plan.

         Pursuant to the Executive Agreement, the Company was released from SERP
obligations to Mr. VanDevender. In turn, the Company paid Mr. VanDevender
$104,969 during 1998 (as reported in footnote (e) to the Summary Compensation
Table), which represented amounts due for vested benefits under the SERP. In
connection with the global settlement of the Shareholder Litigation, the Company



                                       79
<PAGE>   80

was also released from certain existing contractual obligations under the SERP
to certain former officers when the settlement became effective. No officers of
the Company participate in the SERP.

ANNUAL BONUS PLAN

         The 2000 Bonus Plan (the "Bonus Plan") is designed to reward certain
employees of the Company for achieving corporate and/or individual market
performance objectives. The Bonus Plan is intended to provide an incentive for
superior work and to motivate participating employees toward higher achievement
and business results, to link their goals and interests more closely with those
of the Company and its shareholders, and to enable the Company to attract and
retain highly qualified employees. With respect to hospital chief executive
officers and those officers holding the title of executive officer and above,
the Bonus Plan is administered and approved by the Compensation and Stock Option
Committee each year. Upon achievement by the Company of certain targeted
operating results or other performance goals such as operating income and
quality standards, the Company will pay performance bonuses, the aggregate
amounts of which will be determined annually based upon an objective formula.

EMPLOYEE RETIREMENT SAVINGS 401(K) PLAN

         The Company has a defined contribution 401(k) retirement plan covering
all eligible employees at its hospitals and the corporate office. Participants
may contribute up to 20% of pretax compensation, not to exceed a limit set
annually by the Internal Revenue Service. The Company matches $.25 for each
$1.00 of employee contributions up to 6% of employees' gross pay. The Company
may make additional discretionary contributions. In 2000, the Company
contributed $1.2 million to the plan.

EMPLOYMENT, SERVICES AND OTHER AGREEMENTS

         On March 27, 2000, the Company entered into an employment agreement
with Mr. Smith. Mr. Smith's compensation includes (i) a base salary of $35,420
per month, (ii) a bonus equal to 50% of Mr. Smith's base pay based upon the
Company achieving certain performance goals, as defined, subject to a guaranteed
bonus equal to 25% of base pay for the first year of the employment agreement
(iii) certain benefits, including, but not limited to, life insurance and
long-term disability and (iv) a restricted stock grant of 1,300,000 shares of
Company common stock, which is to vest in 25% increments each year beginning
January 1, 2001. Under PHC's Amended Plan, all shares of PHC common stock
underlying the restricted stock grant will be canceled and rendered null and
void upon the Effective Date, and Mr. Smith will neither receive nor retain any
property on account of such equity interests.

         The Company entered into Indemnity and Insurance Coverage Agreements,
effective August 16, 1996, with the certain Named Executives, members of the
Board of Directors and certain other officers of the Company, to advance
reasonable defense costs in connection with litigation, investigations and other
proceedings, subject to their undertakings to repay such costs in certain
circumstances. Pursuant to these agreements, the Company incurred defense costs
of approximately $205,000 in 1999 on behalf of Mr. VanDevender and certain other
former Senior Executives.

COMPENSATION OF DIRECTORS

         Each non-employee director of the Company receives an annual fee of
$25,000, a fee of $2,500 for each meeting (or $1,000 for each telephonic
conference) of the Board or $1,000 for any committee thereof attended and annual
grant of fully-vested stock options at each annual meeting of stockholders after
which the director continues to serve. Directors of the Company who are also
employees of the




                                       80
<PAGE>   81

Company will not receive any additional compensation for their service as
directors. All directors will be reimbursed for reasonable expenses incurred in
the performance of their duties.

         Directors are also eligible to receive options to purchase shares of
Common Stock under the 1996 Stock Incentive Plan (the "Incentive Plan"). The
Company did not grant any stock options in 2000.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

         The following table sets forth information concerning the shares of
Common Stock beneficially owned as of May 25, 2001 by (i) each stockholder known
by the Company to be a beneficial owner of more than five percent of Common
Stock, (ii) each director of the Company, (iii) Mr. James G. VanDevender, the
Company's former interim chief executive officer, and five of the most highly
compensated executive officers and (iv) all directors and executive officers of
the Company as a group.

         The table below does not reflect the aggregate shares of common stock
held by the former Champion shareholders. If these shareholders were treated as
a group under Section 13(d) of the Securities Exchange Act of 1934 for the
purposes of holding their shares, the group would hold in excess of five percent
of the issued and outstanding shares of common stock, and the shareholdings of
each of the Champion shareholders would need to be disclosed in the table.
Although the former Champion shareholders could be deemed to be a group for
purposes of holding shares of the Company's common stock, they have not filed an
ownership report that disclosures that they are members of a group.




                                       81
<PAGE>   82

         Under PHC's Amended Plan, all shares of the Company's common stock held
by existing equity holders will be canceled and rendered null and void, and
PHC's current equity holders will neither receive nor retain any property on
account of such equity interests.

<TABLE>
<CAPTION>

                                                 AMOUNT AND NATURE OF          PERCENTAGE OF
 NAME AND ADDRESS OF BENEFICIAL OWNER(1)       BENEFICIAL OWNERSHIP(2)(3)         CLASS(3)
 ----------------------------------------      ---------------------------     --------------
<S>                                            <C>                             <C>
Park-Hospital GmbH(4,5)                                 19,906,742                33.7%
Paracelsus-Kliniken-Deutschland GmbH(4,5)               19,906,742                33.7%
Dr. Heiner Meyer zu Losebeck(4,5)                       19,916,000(6)             33.7%
Peter Schnitzler(4)                                         10,000(6)                *
Robert L. Smith                                            325,000                   *
Nolan Lehmann(7,8,9)                                     2,411,658                 4.1%
Equus II Incorporated(7,8)                               1,844,345                 3.1%
Equus Capital Partners, L.P.(7,8)                          540,481                   *
Joan S. Fortune                                             10,000(6)                *
Robert W. Miller                                            15,000(6)                *
Lawrence P. English                                         10,000(6)                *
Olympus Private Placement, L.P.(10, 11)                  3,319,261                 5.6%
Robert S. Morris(10, 11)                                 3,335,239                 5.6%
James A. Conroy(10, 11)                                  3,335,239                 5.6%
Lawrence A. Humphrey                                       243,018(12)               *
Deborah  H. Frankovich                                     295,391(13)               *
Robert M. Starling                                         174,902(14)               *
James G. VanDevender                                       100,000(15)               *
Steven D. Porter                                            90,634(15)               *
All directors and officers as a group (17 persons)      23,645,755(16)            39.4%
</TABLE>


----------
* Percentage is less than 1% of the total outstanding shares of the Company.

(1)      The address of each named director and officer, unless otherwise
         indicated, is c/o Paracelsus Healthcare Corporation, 515 W. Greens
         Road, Suite 500, Houston, Texas 77067.

(2)      Unless otherwise indicated, such shares of Common Stock are owned
         directly with sole voting and investment power.

(3)      Includes shares issuable upon exercise of stock options or warrants
         that are exercisable as of, or exercisable 60 days after May 16, 2001.
         Such shares, for the purpose of computing the percentage of outstanding
         Common Stock, are deemed owned by each named individual and by the
         group, but are not deemed to be outstanding for the purpose of
         computing the percentage ownership of any other person.

(4)      The address is Sedanstrasse 109, D-49076 Osnabruck, Federal Republic of
         Germany.

(5)      Park is the record owner of such shares. PKD, as the owner of all of
         Park shares, may be deemed to beneficially own the shares of the
         Company's common stock owned by Park. Pursuant to the Schedule 13D
         (Amendment No. 3) filed by Park, the executorship of the Dr. Heiner
         Meyer zu Losebeck under the wills with regard to Professor Krukemeyer's
         estate terminated on December 31, 2000. As a result, as of January 1,
         2001, the Dr. Heiner Meyer zu Losebeck no longer has voting and
         dispositive power with respect to the shares of common stock of the
         Company owned by Park.

(6)      Includes 10,000 shares issuable upon exercise of options that are
         currently exercisable.

(7)      Mr. Lehmann is President of Equus Capital Management Corporation, the
         financial advisor and manager of Equus II Incorporated and Equus
         Capital Partners, L.P. Mr. Lehmann is also President and Director of
         Equus II Incorporated.

(8)      Address is 2929 Allen Parkway, Suite 2500, Houston, TX 77019.



                                       82
<PAGE>   83

(9)      By reason of his status as President of Equus Capital Management
         Corporation and as President and Director of Equus II Incorporated, Mr.
         Lehmann may be deemed to be the beneficial owner of the common shares
         owned by Equus II Incorporated and Equus Capital Partners, L.P. In
         addition, Mr. Lehmann owns directly 16,832 shares and 10,000 shares
         issuable upon exercise of options that are currently exercisable.
         Accordingly, Mr. Lehmann may be deemed to be the beneficial owner of
         2,411,658 shares of Common Stock. Mr. Lehmann disclaims beneficial
         ownership of Common Stock owned by Equus II Incorporated and Equus
         Capital Partners, L.P. Both Equus II Incorporated and Equus Capital
         Partners, L.P. (as well as other entities with which Mr. Lehmann is
         associated) are former Champion shareholders. The number of shares
         beneficially owned by Mr. Lehmann does not include any shares owned by
         other former Champion shareholders.

(10)     Address of principal business office for each reporting person is c/o
         Olympus Partners, Metro Center, One Station Place, Stamford,
         Connecticut 06902.

(11)     Pursuant to the Schedule 13D filed on September 17, 1999, by the
         indicated reporting persons, Messrs. Morris and Conroy share control
         and may be deemed beneficial owners of the 3,319,261 shares owned by
         Olympus Private Placement, L.P. and 15,978 shares owned by Olympus
         Executive Fund, L.P. by virtue of their positions as general partners
         or officers of general partners of these entities or other entities
         that control these entities. Olympus Private Placement, L. P. and
         Olympus Executive Fund, L.P. are former Champion shareholders and may
         be part of a group of former Champion shareholders. The number of
         shares beneficially owned by Olympus Private Placement, L. P. and
         Olympus Executive Fund, L.P. does not include any shares owned by other
         former Champion shareholders.

(12)     Includes 205,000 shares issuable upon exercise of options that are
         currently exercisable, or exercisable within 60 days.

(13)     Includes 151,250 shares issuable upon exercise of options that are
         currently exercisable, or exercisable within 60 days.

(14)     Includes 151,250 shares issuable upon exercise of options that are
         currently exercisable, or exercisable within 60 days.

(15)     Mr. VanDevender resigned from the Company on February 29, 2000. Mr.
         Porter resigned from the Company on February 28, 2001.

(16)     Includes 795,403 shares issuable upon exercise of options that are
         currently exercisable, or exercisable within 60 days.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

         6.51% SUBORDINATED NOTE - The Former Majority Shareholder received a
$7.2 million 6.51% subordinated note from the Company (See Note 7), which is
currently subject to compromise as a result of PHC's Chapter 11 bankruptcy
filing on September 15, 2000 (See Note 2). The Company did not pay interest on
the note in 2000 and paid interest of $467,000 in 1999 and 1998.

         INSURANCE AGREEMENT - The Company is also a party to an insurance
agreement, which provides insurance benefits to the Former Chairman in the event
of his death or permanent disability in an amount equal to $1.0 million per year
during the 10-year term of such agreement, which expires 2006. As a result of
PHC's Chapter 11 bankruptcy filing, the Company's obligation under this
agreement will be discharged as of the Effective Date in accordance with the
provisions of the Plan.





                                       83
<PAGE>   84




                                     PART IV

ITEM 14.   EXHIBITS, FINANCIAL STATEMENT SCHEDULE AND REPORTS ON FORM 8-K

(a)(1) FINANCIAL STATEMENTS

         See Part II. Item 8 of this Report.

(a)(2) FINANCIAL STATEMENT SCHEDULE

                        PARACELSUS HEALTHCARE CORPORATION
                              DEBTOR-IN-POSSESSION
                 SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
                                  ($ in 000's)

<TABLE>
<CAPTION>

                                          BALANCE AT     CHARGED TO
                                          BEGINNING       COSTS AND                                         BALANCE AT
               DESCRIPTION                 OF YEAR        EXPENSES       WRITE-OFFS            OTHER        END OF YEAR
               -----------                ----------     ----------      ----------            -----        -----------
<S>                                       <C>            <C>             <C>                   <C>          <C>

 Year ended December 31, 2000
    Allowance for doubtful accounts         $27,553          36,030         (34,302)             --           $29,281

 Year ended December 31, 1999
    Allowance for doubtful accounts         $40,551          41,692         (54,690)             --           $27,553

 Year ended December 31, 1998
    Allowance for doubtful accounts         $54,442          42,659         (56,550)             --           $40,551
</TABLE>

----------

         All other schedules for which provision is made in the applicable
accounting regulations of the Securities and Exchange Commission are not
required under the related instructions, are inapplicable or have been disclosed
in the consolidated financial statements and notes thereto and therefore have
been omitted.


(a)(3)  EXHIBITS

            3.1(s)      Amended and Restated Bylaws of Paracelsus Healthcare
                        Corporation dated March 24, 1999.

            3.4(a)      Amended and Restated Articles of Incorporation of
                        Paracelsus.

            4.1(a)      Indenture, dated August 16, 1996 between Paracelsus
                        and Bank of New York (as successor to AmSouth Bank of
                        Alabama) as Trustee (including the form of certificate
                        representing the 10% Senior Subordinated Notes due
                        2006).

            4.2(b)      Shareholder Protection Rights Agreement between
                        Paracelsus and ChaseMellon Shareholder Services, L.L.C,
                        as Rights Agent.




                                       84
<PAGE>   85

            4.5(c)      Form of Warrant issued pursuant to Champion Series E
                        Note Purchase Agreement, dated May 1, 1995, as amended.

            4.6(d)      Form of Warrant issued pursuant to Champion Series D
                        Note and Stock Purchase Agreement dated December 31,
                        1993, as amended.

            4.9(e)      Certificate representing Common Stock.

            10.1(e)     Pooling Agreement, dated as of April 16, 1993 among
                        PHC Funding Corp. II ("PFC II"), Sheffield Receivables
                        Corporation and Bankers Trust Company, as trustee (the
                        "Trustee").

            10.2(e)     Servicing Agreement, dated as of April 16, 1993,
                        among PFC II, Paracelsus and the Trustee.

            10.3(e)     Guarantee, dated as of April 16, 1993, by Paracelsus
                        in favor of PFC II.

            10.4(e)     Sale and Servicing Agreement between subsidiaries of
                        Paracelsus and PFC II.

            10.5(e)     Subordinate Note by PFC II in favor of Hospitals.

            10.12(q)    Stock Purchase Agreement for Bledsoe County General
                        Hospital, dated March 12, 1999, among Paracelsus
                        Healthcare Corporation, Paracelsus Bledsoe County
                        General Hospital, Inc., and Associates Capital Group,
                        LLC.

            10.13(q)    First Amendment to Stock Purchase Agreement for
                        Bledsoe County General Hospital, dated March 31, 1999,
                        among Paracelsus Healthcare Corporation, Paracelsus
                        Bledsoe County General Hospital, Inc., and Associates
                        Capital Group, LLC.

            10.16(f)    The Restated Paracelsus Healthcare Corporation
                        Supplemental Executive Retirement Plan.

            10.17(a)    Amendment No. 1 to the Supplemental Executive Retirement
                        Plan.

            10.19(e)    Paracelsus Healthcare Corporation Annual Incentive Plan
                        (10.17).

            10.20(r)    Asset Purchase Agreement dated March 15, 1999, by and
                        among Paracelsus Convalescent Hospitals, Inc.,
                        Paracelsus Real Estate Corporation and Sunland
                        Associates, Inc.

            10.21(r)    Amendment One to Asset Purchase Agreement, dated April
                        14, 1999, by and among Paracelsus Convalescent
                        Hospitals, Inc., Paracelsus Real Estate Corporation and
                        Sunland Associates, Inc.

            10.22(r)    Rheem Valley Asset Purchase Agreement, dated March 15,
                        1999, by and among Paracelsus Convalescent Hospitals,
                        Inc., Paracelsus Real Estate Corporation and Sunland
                        Associates, Inc.




                                       85
<PAGE>   86

            10.23(r)    Amendment One to Rheem Valley Asset Purchase Agreement,
                        dated April 14, 1999, by and among Paracelsus
                        Convalescent Hospitals, Inc., Paracelsus Real Estate
                        Corporation and Sunland Associates, Inc.

            10.24(s)    Stock Purchase Agreement dated September 14, 1999, by
                        and among Paracelsus Healthcare Corporation, Paracelsus
                        Senatobia Community Hospital, Inc. and Associates
                        Capital Group, LLC.

            10.26(t)    Recapitalization Agreement, dated August 16, 1999, by
                        and among Paracelsus Healthcare Corporation, PHC/CHC
                        Holdings, Inc., as parents, and PHC/Psychiatric
                        Healthcare Corporation, PHC-Salt Lake City, Inc.,
                        Paracelsus Pioneer Valley Hospital, Inc., Pioneer Valley
                        Health Plan, Inc., PHC-Jordan Valley, Inc., Paracelsus
                        PHC Regional Medical Center, Inc., Paracelsus Davis
                        Hospital, Inc., PHC Utah, Inc., and Clinicare of Utah,
                        Inc., as sellers, and JLL Hospital, LLC, as buyer.

            10.33(f)    Restated Champion Healthcare Corporation Founders' Stock
                        Option Plan.

            10.34(a)    License Agreement between Dr. Manfred George Krukemeyer
                        and Paracelsus.

            10.36(a)    Registration Rights Agreement between Paracelsus and
                        Park-Hospital GmbH.

            10.39(a)    Insurance Agreement between Paracelsus and Dr. Manfred
                        G. Krukemeyer.

            10.40(a)    Non-Compete Agreement between Paracelsus and Dr. Manfred
                        G. Krukemeyer.

            10.42(a)    Dividend and Note Agreement between Paracelsus and
                        Park-Hospital GmbH.

            10.48(a)    Paracelsus 1996 Stock Incentive Plan.

            10.49(a)    Paracelsus Healthcare Corporation Executive Officer
                        Performance Bonus Plan.

            10.54(a)    Registration Rights Agreement among Paracelsus and
                        certain Champion Investors.

            10.56(a)    Indemnity and Insurance Coverage Agreement between
                        Paracelsus and certain Champion and Paracelsus executive
                        officers.

            10.57(m)    AmeriHealth Amended and Restated 1988 Non-Qualified
                        Stock Option Plan.

            10.58(k)    Champion Employee Stock Option Plan dated December 31,
                        1991, as amended (10.14).

            10.59(k)    Champion Employee Stock Option Plan No. 2 dated May 29,
                        1992, as amended (10.15).

            10.60(k)    Champion Employee Stock Option Plan No. 3 dated
                        September 1992, as amended (10.16).

            10.61(k)    Champion Employee Stock Option Plan No. 4, dated January
                        5, 1994, as amended (10.17).

            10.62(n)    Champion Healthcare Corporation Physicians Stock Option
                        Plan (4.2).



                                       86
<PAGE>   87

            10.63(k)    Champion Selected Executive Stock Option Plan No. 5,
                        dated May 25, 1995 (4.12).

            10.64(k)    Champion Directors' Stock Option Plan, dated 1992.

            10.65(a)    Paracelsus' 6.51% Subordinated Notes Due 2006 (10.64).

            10.67(g)    The Second Amended and First Restated Asset Purchase
                        Agreement for Chico Community Hospital, dated December
                        15, 1997, and as amended on June 12, 1998.

            10.68(g)    Asset Purchase Agreement for Chico Community
                        Rehabilitation Hospital, dated December 15, 1997, and as
                        amended on June 10, 1998.

            10.69(g)    Agreement for Purchase and Sale of Partnership Interest,
                        dated June 1, 1998, by and between Dakota Medical
                        Foundation and Paracelsus Healthcare Corporation of
                        North Dakota, Inc.

            10.70(h)    Asset Purchase Agreement, dated September 30, 1998, by
                        and among Alta Healthcare System LLC, and Paracelsus
                        Healthcare Corporation.

            10.71(i)    Settlement Agreement between the (a) United States of
                        America, acting through the United States Department of
                        Justice and on behalf of the Office of Inspector General
                        of the Department of Health and Human Services; (b)
                        Timothy Hill and Alan Leavitt; (c) Paracelsus Healthcare
                        Corporation; and (d) individual defendant Joseph Sharp.

            10.72(j)    $180 Million Reducing Revolving Credit Facility and $75
                        Million Term Loan Facilities dated as of March 30, 1998,
                        among Paracelsus, Banque Paribas, as agent, and other
                        lenders named therein.

            10.73(k)    The First Amendment to Amended and Restated Credit
                        Agreement, effective June 15, 1998, by and among
                        Paracelsus Healthcare Corporation, Paribas, Toronto
                        Dominion (Texas), Inc. and Bank Montreal (10.74).

            10.74(o)    Memorandum of Understanding among Paracelsus Healthcare
                        Corporation, Charles R. Miller, James G. VanDevender,
                        Ronald R. Patterson, Park-Hospital GmbH, and the members
                        of the Ad Hoc Committee of Former Shareholders of
                        Champion Healthcare Corporation (10.75).

            10.75(x)    Employment agreement effective July 1, 1999 between
                        James G. VanDevender and Paracelsus Healthcare
                        Corporation (10.76).*

            10.76(p)    Third Amendment to Amended and Restated Credit Agreement
                        and Approval of Asset Dispositions effective June 30,
                        1999 (10.77).

            10.77(p)    Shareholder Agreement dated March 19, 1999, between
                        Park-Hospital GmbH and Paracelsus Healthcare Corporation
                        (10.78).

            10.78(p)    Settlement Agreement dated March 24, 1999, by and among
                        the former shareholders of Champion Healthcare
                        Corporation, Park-Hospital GmbH, Dr. Manfred Georg
                        Krukemeyer, and Paracelsus Healthcare Corporation
                        (10.79).



                                       87
<PAGE>   88

            10.79(p)    Stipulation of Settlement dated May 11, 1999, by and
                        among plaintiffs, individually and as representatives of
                        the Class, as defined, Paracelsus Healthcare
                        Corporation, Manfred G. Krukemeyer, R.J. Messenger,
                        James T. Rush, Charles R. Miller, James G. VanDevender,
                        the Champion Shareholders, as defined, Park-Hospital
                        GmbH, Donaldson Lufkin & Jenrette Securities
                        Corporation, Bear Stearns & Co., Inc., Smith Barney,
                        Inc., and ABN AMRO Chicago Corporation in connection
                        with the litigation captioned In re Paracelsus Corp.
                        Securities Litigation, Master File No. H-96-3464 (EW)
                        filed with the United States District Court for the
                        Southern District of Texas (10.78).

            10.80(p)    Settlement Agreement dated March 17, 1999, by and
                        between James G. Caven and Robert Orovitz, derivatively
                        on behalf of Champion Healthcare Corporation and double
                        derivatively on behalf of Paracelsus Healthcare
                        Corporation; Paracelsus Healthcare Corporation; the
                        former shareholders of Champion Healthcare Corporation;
                        Park-Hospital GmbH; Donaldson Lufkin & Jenrette
                        Securities Corporation; Bears Stearns & Co.; Smith
                        Barney, Inc.; and ABN AMRO Chicago Corporation; Manfred
                        Georg Krukemeyer; Charles R. Miller; James G.
                        VanDevender; Ronald R. Patterson; R.J. Messenger; James
                        T. Rush; Robert C. Joyner; Michael D. Hofmann; Christian
                        A. Lange; and Scott K. Barton (10.80).

            10.81(v)    Amendment No. 1 to Employment agreement effective
                        July 1, 1999 between James G. VanDevender and Paracelsus
                        Healthcare Corporation (10.82).

            10.82(w)    Employment Agreement effective March 27, 2000 between
                        Robert L. Smith and Paracelsus Healthcare Corporation
                        (10.83).

            10.83       Stay-On Bonus Agreement dated 3/3/2000 between Lawrence
                        A. Humphrey and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            10.84       Stay-On Bonus Agreement dated 3/3/2000 between Deborah
                        H. Frankovich and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            10.85       Stay-On Bonus Agreement dated 3/3/2000 between Rob
                        Starling and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            10.86       Stay-On Bonus Agreement dated 3/3/2000 between Steve
                        Porter and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            21.1        List of subsidiaries of Paracelsus.

            23.1        Consent of Ernst & Young LLP.

            27          Financial Data Schedule.

            ----------

            * Portions of the indicated exhibit have been omitted pursuant to a
            request for confidentiality treatment, which was filed separately
            with the Securities and Exchange Commission on March 30, 2000.


                                       88
<PAGE>   89

(a)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Quarterly Report) to the Company's
         Quarterly Report on Form 10-Q for quarter ended September 30, 1996.

(b)      Incorporated by reference from Exhibit of the same number to the
         Company's Registration Statement on Form 8-A, filed on August 12, 1996.

(c)      Incorporated by reference from Exhibit 10.23(g) to Champion's Annual
         Report on Form 10-K for the year ended December 31, 1995.

(d)      Incorporated by reference from Exhibit 10.23(f) to Champion's Annual
         Report on Form 10-K for the year ended December 31, 1995.

(e)      Incorporated by reference from Exhibit of the same number to the
         Company's Quarterly Report on Form 10-Q for the quarter ended September
         30, 1997.

(f)      Incorporated by reference from Exhibit of the same number to the
         Company's Registration Statement on Form S-4, Registration No.
         333-08521, filed on July 19, 1996.

(g)      Incorporated by reference from Exhibits of the same numbers to the
         Company's Current Report on Form 8-K, dated June 30, 1998.

(h)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated June 30, 1998.

(i)      Incorporated by reference from Exhibit of the same number to the
         Company's Quarterly Report on Form 10-Q for the quarter ended September
         30, 1998.

(j)      Incorporated by reference from Exhibits 10.6 and 10.15 to the Company's
         Quarterly Report on Form 10-Q for the quarter ended March 31, 1998.

(k)      Incorporated by reference from Exhibit 10.7 to the Company's Quarterly
         Report on Form 10-Q for the quarter ended June 30, 1998.

(l)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Annual Report) to Champion's Annual
         Report for the year ended December 31, 1994.

(m)      Incorporated by reference from Exhibit 10.06 to AmeriHealth's Annual
         Report on Form 10-K for the year ended December 31, 1992.

(n)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Registration Statement) to Champion's
         Registration Statement on Form S-8, filed on August 3, 1995.

(o)      Incorporated by reference from Exhibit of the same number to the
         Company's Annual Report on Form 10-K, dated December 31, 1998.

(p)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Annual Report) to the Company's Quarterly
         Report on Form 10-Q for the quarter ended September 30, 1999.



                                       89
<PAGE>   90

(q)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated April 15, 1999.

(r)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated July 2, 1999.

(s)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated September 30, 1999.

(t)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated October 8, 1999.

(u)      Incorporated by reference from Exhibit of the same number to the
         Company's Quarterly Report on Form 10-Q for the quarter dated June 30,
         1999.

(v)      Incorporated by reference from Exhibit 10.82 to the Company's Annual
         Report on Form 10-K, dated December 31, 1999.

(w)      Incorporated by reference from Exhibit 10.83 to the Company's Quarterly
         Report on Form 10-Q for the quarter ended March 31, 2000.

(x)      Incorporated by reference from Exhibit 10.76 to the Company's Annual
         Report on Form 10-K, dated December 31, 2000.

(a)  REPORTS ON FORM 8-K

     None.




                                       90
<PAGE>   91




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                               PARACELSUS HEALTHCARE CORPORATION
                                                          (Registrant)



Date: June 5, 2001                             By: /s/ ROBERT L. SMITH
                                                   -----------------------------
                                                   Robert L. Smith
                                                   Chief Executive Officer &
                                                   Director

         Pursuant to the requirement of the Securities Act of 1934, this report
has been signed below by the following persons on behalf of the Registrant and
in the capacities and on the dates indicated.

<TABLE>
<CAPTION>

                    SIGNATURE                                         TITLE                              DATE
---------------------------------------               -------------------------------------     --------------------

<S>                                                   <C>                                       <C>
/s/ LAWRENCE P. ENGLISH                               Chairman of the Board                     June 5, 2001
---------------------------------------
Lawrence P. English

/s/ ROBERT L. SMITH                                   Chief Executive Officer &                 June 5, 2001
---------------------------------------               Director
Robert L. Smith

/s/ LAWRENCE A. HUMPHREY                              Executive Vice President, Chief           June 5, 2001
---------------------------------------               Financial Officer
Lawrence A. Humphrey

/s/ ROBERT M. STARLING                                Senior Vice President and                 June 5, 2001
---------------------------------------               Controller
Robert M. Starling

/s/ HEINER MEYER ZU LOSEBECK                          Director                                  May 23, 2001
---------------------------------------
Dr. Heiner Meyer Zu Losebeck

/s/ NOLAN LEHMANN                                     Director                                  June 5, 2001
---------------------------------------
Nolan Lehmann

/s/ PETER SCHNITZLER                                  Director                                  May 28, 2001
---------------------------------------
Peter Schnitzler

/s/ JOAN S. FORTUNE                                   Director                                  May 21, 2001
---------------------------------------
Joan S. Fortune

/s/ ROBERT W. MILLER                                  Director                                  May 29, 2001
---------------------------------------
Robert W. Miller
</TABLE>


                                       91
<PAGE>   92
                                 EXHIBIT INDEX

<TABLE>
<CAPTION>

EXHIBIT
NUMBER      DESCRIPTION
------      -----------
<S>         <C>
3.1(s)      Amended and Restated Bylaws of Paracelsus Healthcare Corporation
            dated March 24, 1999.

3.4(a)      Amended and Restated Articles of Incorporation of Paracelsus.

4.1(a)      Indenture, dated August 16, 1996 between Paracelsus and Bank of
            New York (as successor to AmSouth Bank of Alabama) as Trustee
            (including the form of certificate representing the 10% Senior
            Subordinated Notes due 2006).

4.2(b)      Shareholder Protection Rights Agreement between Paracelsus and
            ChaseMellon Shareholder Services, L.L.C., as Rights Agent.
</TABLE>





<PAGE>   93
<TABLE>
<S>                     <C>
            4.5(c)      Form of Warrant issued pursuant to Champion Series E
                        Note Purchase Agreement, dated May 1, 1995, as amended.

            4.6(d)      Form of Warrant issued pursuant to Champion Series D
                        Note and Stock Purchase Agreement dated December 31,
                        1993, as amended.

            4.9(e)      Certificate representing Common Stock.

            10.1(e)     Pooling Agreement, dated as of April 16, 1993 among
                        PHC Funding Corp. II ("PFC II"), Sheffield Receivables
                        Corporation and Bankers Trust Company, as trustee (the
                        "Trustee").

            10.2(e)     Servicing Agreement, dated as of April 16, 1993,
                        among PFC II, Paracelsus and the Trustee.

            10.3(e)     Guarantee, dated as of April 16, 1993, by Paracelsus
                        in favor of PFC II.

            10.4(e)     Sale and Servicing Agreement between subsidiaries of
                        Paracelsus and PFC II.

            10.5(e)     Subordinate Note by PFC II in favor of Hospitals.

            10.12(q)    Stock Purchase Agreement for Bledsoe County General
                        Hospital, dated March 12, 1999, among Paracelsus
                        Healthcare Corporation, Paracelsus Bledsoe County
                        General Hospital, Inc., and Associates Capital Group,
                        LLC.

            10.13(q)    First Amendment to Stock Purchase Agreement for
                        Bledsoe County General Hospital, dated March 31, 1999,
                        among Paracelsus Healthcare Corporation, Paracelsus
                        Bledsoe County General Hospital, Inc., and Associates
                        Capital Group, LLC.

            10.16(f)    The Restated Paracelsus Healthcare Corporation
                        Supplemental Executive Retirement Plan.

            10.17(a)    Amendment No. 1 to the Supplemental Executive Retirement
                        Plan.

            10.19(e)    Paracelsus Healthcare Corporation Annual Incentive Plan
                        (10.17).

            10.20(r)    Asset Purchase Agreement dated March 15, 1999, by and
                        among Paracelsus Convalescent Hospitals, Inc.,
                        Paracelsus Real Estate Corporation and Sunland
                        Associates, Inc.

            10.21(r)    Amendment One to Asset Purchase Agreement, dated April
                        14, 1999, by and among Paracelsus Convalescent
                        Hospitals, Inc., Paracelsus Real Estate Corporation and
                        Sunland Associates, Inc.

            10.22(r)    Rheem Valley Asset Purchase Agreement, dated March 15,
                        1999, by and among Paracelsus Convalescent Hospitals,
                        Inc., Paracelsus Real Estate Corporation and Sunland
                        Associates, Inc.
</TABLE>




<PAGE>   94
<TABLE>
<S>                     <C>
            10.23(r)    Amendment One to Rheem Valley Asset Purchase Agreement,
                        dated April 14, 1999, by and among Paracelsus
                        Convalescent Hospitals, Inc., Paracelsus Real Estate
                        Corporation and Sunland Associates, Inc.

            10.24(s)    Stock Purchase Agreement dated September 14, 1999, by
                        and among Paracelsus Healthcare Corporation, Paracelsus
                        Senatobia Community Hospital, Inc. and Associates
                        Capital Group, LLC.

            10.26(t)    Recapitalization Agreement, dated August 16, 1999, by
                        and among Paracelsus Healthcare Corporation, PHC/CHC
                        Holdings, Inc., as parents, and PHC/Psychiatric
                        Healthcare Corporation, PHC-Salt Lake City, Inc.,
                        Paracelsus Pioneer Valley Hospital, Inc., Pioneer Valley
                        Health Plan, Inc., PHC-Jordan Valley, Inc., Paracelsus
                        PHC Regional Medical Center, Inc., Paracelsus Davis
                        Hospital, Inc., PHC Utah, Inc., and Clinicare of Utah,
                        Inc., as sellers, and JLL Hospital, LLC, as buyer.

            10.33(f)    Restated Champion Healthcare Corporation Founders' Stock
                        Option Plan.

            10.34(a)    License Agreement between Dr. Manfred George Krukemeyer
                        and Paracelsus.

            10.36(a)    Registration Rights Agreement between Paracelsus and
                        Park-Hospital GmbH.

            10.39(a)    Insurance Agreement between Paracelsus and Dr. Manfred
                        G. Krukemeyer.

            10.40(a)    Non-Compete Agreement between Paracelsus and Dr. Manfred
                        G. Krukemeyer.

            10.42(a)    Dividend and Note Agreement between Paracelsus and
                        Park-Hospital GmbH.

            10.48(a)    Paracelsus 1996 Stock Incentive Plan.

            10.49(a)    Paracelsus Healthcare Corporation Executive Officer
                        Performance Bonus Plan.

            10.54(a)    Registration Rights Agreement among Paracelsus and
                        certain Champion Investors.

            10.56(a)    Indemnity and Insurance Coverage Agreement between
                        Paracelsus and certain Champion and Paracelsus executive
                        officers.

            10.57(m)    AmeriHealth Amended and Restated 1988 Non-Qualified
                        Stock Option Plan.

            10.58(k)    Champion Employee Stock Option Plan dated December 31,
                        1991, as amended (10.14).

            10.59(k)    Champion Employee Stock Option Plan No. 2 dated May 29,
                        1992, as amended (10.15).

            10.60(k)    Champion Employee Stock Option Plan No. 3 dated
                        September 1992, as amended (10.16).

            10.61(k)    Champion Employee Stock Option Plan No. 4, dated January
                        5, 1994, as amended (10.17).

            10.62(n)    Champion Healthcare Corporation Physicians Stock Option
                        Plan (4.2).
</TABLE>



<PAGE>   95
<TABLE>
<S>                     <C>
            10.63(k)    Champion Selected Executive Stock Option Plan No. 5,
                        dated May 25, 1995 (4.12).

            10.64(k)    Champion Directors' Stock Option Plan, dated 1992.

            10.65(a)    Paracelsus' 6.51% Subordinated Notes Due 2006 (10.64).

            10.67(g)    The Second Amended and First Restated Asset Purchase
                        Agreement for Chico Community Hospital, dated December
                        15, 1997, and as amended on June 12, 1998.

            10.68(g)    Asset Purchase Agreement for Chico Community
                        Rehabilitation Hospital, dated December 15, 1997, and as
                        amended on June 10, 1998.

            10.69(g)    Agreement for Purchase and Sale of Partnership Interest,
                        dated June 1, 1998, by and between Dakota Medical
                        Foundation and Paracelsus Healthcare Corporation of
                        North Dakota, Inc.

            10.70(h)    Asset Purchase Agreement, dated September 30, 1998, by
                        and among Alta Healthcare System LLC, and Paracelsus
                        Healthcare Corporation.

            10.71(i)    Settlement Agreement between the (a) United States of
                        America, acting through the United States Department of
                        Justice and on behalf of the Office of Inspector General
                        of the Department of Health and Human Services; (b)
                        Timothy Hill and Alan Leavitt; (c) Paracelsus Healthcare
                        Corporation; and (d) individual defendant Joseph Sharp.

            10.72(j)    $180 Million Reducing Revolving Credit Facility and $75
                        Million Term Loan Facilities dated as of March 30, 1998,
                        among Paracelsus, Banque Paribas, as agent, and other
                        lenders named therein.

            10.73(k)    The First Amendment to Amended and Restated Credit
                        Agreement, effective June 15, 1998, by and among
                        Paracelsus Healthcare Corporation, Paribas, Toronto
                        Dominion (Texas), Inc. and Bank Montreal (10.74).

            10.74(o)    Memorandum of Understanding among Paracelsus Healthcare
                        Corporation, Charles R. Miller, James G. VanDevender,
                        Ronald R. Patterson, Park-Hospital GmbH, and the members
                        of the Ad Hoc Committee of Former Shareholders of
                        Champion Healthcare Corporation (10.75).

            10.75(x)    Employment agreement effective July 1, 1999 between
                        James G. VanDevender and Paracelsus Healthcare
                        Corporation (10.76).*

            10.76(p)    Third Amendment to Amended and Restated Credit Agreement
                        and Approval of Asset Dispositions effective June 30,
                        1999 (10.77).

            10.77(p)    Shareholder Agreement dated March 19, 1999, between
                        Park-Hospital GmbH and Paracelsus Healthcare Corporation
                        (10.78).

            10.78(p)    Settlement Agreement dated March 24, 1999, by and among
                        the former shareholders of Champion Healthcare
                        Corporation, Park-Hospital GmbH, Dr. Manfred Georg
                        Krukemeyer, and Paracelsus Healthcare Corporation
                        (10.79).
</TABLE>



<PAGE>   96
<TABLE>
<S>                     <C>

            10.79(p)    Stipulation of Settlement dated May 11, 1999, by and
                        among plaintiffs, individually and as representatives of
                        the Class, as defined, Paracelsus Healthcare
                        Corporation, Manfred G. Krukemeyer, R.J. Messenger,
                        James T. Rush, Charles R. Miller, James G. VanDevender,
                        the Champion Shareholders, as defined, Park-Hospital
                        GmbH, Donaldson Lufkin & Jenrette Securities
                        Corporation, Bear Stearns & Co., Inc., Smith Barney,
                        Inc., and ABN AMRO Chicago Corporation in connection
                        with the litigation captioned In re Paracelsus Corp.
                        Securities Litigation, Master File No. H-96-3464 (EW)
                        filed with the United States District Court for the
                        Southern District of Texas (10.78).

            10.80(p)    Settlement Agreement dated March 17, 1999, by and
                        between James G. Caven and Robert Orovitz, derivatively
                        on behalf of Champion Healthcare Corporation and double
                        derivatively on behalf of Paracelsus Healthcare
                        Corporation; Paracelsus Healthcare Corporation; the
                        former shareholders of Champion Healthcare Corporation;
                        Park-Hospital GmbH; Donaldson Lufkin & Jenrette
                        Securities Corporation; Bears Stearns & Co.; Smith
                        Barney, Inc.; and ABN AMRO Chicago Corporation; Manfred
                        Georg Krukemeyer; Charles R. Miller; James G.
                        VanDevender; Ronald R. Patterson; R.J. Messenger; James
                        T. Rush; Robert C. Joyner; Michael D. Hofmann; Christian
                        A. Lange; and Scott K. Barton (10.80).

            10.81(v)    Amendment No. 1 to Employment agreement effective
                        July 1, 1999 between James G. VanDevender and Paracelsus
                        Healthcare Corporation (10.82).

            10.82(w)    Employment Agreement effective March 27, 2000 between
                        Robert L. Smith and Paracelsus Healthcare Corporation
                        (10.83).

            10.83       Stay-On Bonus Agreement dated 3/3/2000 between Lawrence
                        A. Humphrey and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            10.84       Stay-On Bonus Agreement dated 3/3/2000 between Deborah
                        H. Frankovich and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            10.85       Stay-On Bonus Agreement dated 3/3/2000 between Rob
                        Starling and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            10.86       Stay-On Bonus Agreement dated 3/3/2000 between Steve
                        Porter and PHC/CHC Holdings, Inc. and Paracelsus
                        Healthcare Corporation.

            21.1        List of subsidiaries of Paracelsus.

            23.1        Consent of Ernst & Young LLP.

            27          Financial Data Schedule.
</TABLE>

            ----------

            * Portions of the indicated exhibit have been omitted pursuant to a
            request for confidentiality treatment, which was filed separately
            with the Securities and Exchange Commission on March 30, 2000.



<PAGE>   97

(a)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Quarterly Report) to the Company's
         Quarterly Report on Form 10-Q for quarter ended September 30, 1996.

(b)      Incorporated by reference from Exhibit of the same number to the
         Company's Registration Statement on Form 8-A, filed on August 12, 1996.

(c)      Incorporated by reference from Exhibit 10.23(g) to Champion's Annual
         Report on Form 10-K for the year ended December 31, 1995.

(d)      Incorporated by reference from Exhibit 10.23(f) to Champion's Annual
         Report on Form 10-K for the year ended December 31, 1995.

(e)      Incorporated by reference from Exhibit of the same number to the
         Company's Quarterly Report on Form 10-Q for the quarter ended September
         30, 1997.

(f)      Incorporated by reference from Exhibit of the same number to the
         Company's Registration Statement on Form S-4, Registration No.
         333-08521, filed on July 19, 1996.

(g)      Incorporated by reference from Exhibits of the same numbers to the
         Company's Current Report on Form 8-K, dated June 30, 1998.

(h)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated June 30, 1998.

(i)      Incorporated by reference from Exhibit of the same number to the
         Company's Quarterly Report on Form 10-Q for the quarter ended September
         30, 1998.

(j)      Incorporated by reference from Exhibits 10.6 and 10.15 to the Company's
         Quarterly Report on Form 10-Q for the quarter ended March 31, 1998.

(k)      Incorporated by reference from Exhibit 10.7 to the Company's Quarterly
         Report on Form 10-Q for the quarter ended June 30, 1998.

(l)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Annual Report) to Champion's Annual
         Report for the year ended December 31, 1994.

(m)      Incorporated by reference from Exhibit 10.06 to AmeriHealth's Annual
         Report on Form 10-K for the year ended December 31, 1992.

(n)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Registration Statement) to Champion's
         Registration Statement on Form S-8, filed on August 3, 1995.

(o)      Incorporated by reference from Exhibit of the same number to the
         Company's Annual Report on Form 10-K, dated December 31, 1998.

(p)      Incorporated by reference from Exhibit of the same number (or if
         otherwise noted, Exhibit number contained in parenthesis which refers
         to the exhibit number in such Annual Report) to the Company's
         Quarterly Report on Form 10-Q for the quarter ended September 30, 1999.


<PAGE>   98

(q)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated April 15, 1999.

(r)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated July 2, 1999.

(s)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated September 30, 1999.

(t)      Incorporated by reference from Exhibit of the same number to the
         Company's Current Report on Form 8-K, dated October 8, 1999.

(u)      Incorporated by reference from Exhibit of the same number to the
         Company's Quarterly Report on Form 10-Q for the quarter dated June 30,
         1999.

(v)      Incorporated by reference from Exhibit 10.82 to the Company's Annual
         Report on Form 10-K, dated December 31, 1999.

(w)      Incorporated by reference from Exhibit 10.83 to the Company's Quarterly
         Report on Form 10-Q for the quarter ended March 31, 2000.

(x)      Incorporated by reference from Exhibit 10.76 to the Company's Annual
         Report on Form 10-K, dated December 31, 2000.